Robust approaches for performing meta-analysis of genome-wide association studies to identify single nucleotide polymorphisms and copy number variations associated with complex traits by Charoen, Pimphen
Robust approaches for performing meta-analysis of genome-wide 
association studies to identify single nucleotide polymorphisms and 
copy number variations associated with complex traits 
 
 
Pimphen Charoen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Epidemiology and Biostatistics 
 
Imperial College London 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
2013 
1 
 
Declaration 
 
All the work contained in this thesis is my own, unless otherwise stated. 
 
 
Pimphen Charoen 
 
 
 
 
 
We confirm that this thesis is an accurate presentation of this work: 
 
 
 
Name of supervisor: Dr Lachlan Coin 
 
 
Name of supervisor: Dr Paul O’Reilly 
 
 
Name of supervisor: Prof Marjo-Riitta Jarvelin 
 
2 
 
Copy right Declaration 
 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. 
Researchers are free to copy, distribute or transmit the thesis on the condition 
that they attribute it, that they do not use it for commercial purposes and that 
they do not alter, transform or build upon it. For any reuse or redistribution,  
researchers must make clear to others the licence terms of this work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
 
From 2007, there has been a huge proliferation in the discovery of genetic variants affecting 
human traits and diseases, achieved largely by the integration of multiple genome-wide 
association studies (GWAS) via meta-analysis. The principal objective of this thesis is to 
develop robust approaches for meta-analysis GWAS in order to reduce false positive 
findings and optimise statistical power. I consider both Single Nucleotide Polymorphism 
(SNP) and Copy Number Variant (CNV) GWAS. First, to gain background knowledge in GWAS 
and meta-analysis, I was involved in a large-scale meta-analysis GWAS to identify genetic 
variants associated with alcohol consumption, as the main statistical analyst. This study 
provided me with the opportunity to investigate ways of reducing the probability of false 
positive findings, via quality control procedures. The main discovery from the study was the 
identification of the Autism susceptibility candidate 2 gene (AUTS2) as associated with 
alcohol consumption at genome-wide significance. In the alcohol study, different phenotype 
transformations were applied to the data according to the inclusion or exclusion of non-
drinkers, which led to questioning which transformation of skewed continuous phenotypes 
optimises statistical power in GWAS in general, forming the second major investigation in 
my thesis. It was shown that while the inverse normal transformation (INT) may not be the 
preferable choice of transformation in many epidemiological studies where effect sizes are 
large, its application to non-normal phenotypes in GWAS, where effect sizes are small and 
the priority is discovery over interpretability, may lead to an increase in the discovery of 
genetic variants affecting continuous traits.  Finally, as knowledge about CNVs has 
accumulated in recent years, the meta-analysis of GWAS on CNVs has become a natural next 
step forward in the field. Therefore, I investigated and developed an approach to enable 
CNV meta-analysis to proceed in a similar way as SNP meta-analyses. This approach was 
developed into a software package, cnvPipe, which was applied to investigate CNVs 
associated with height and weight in the meta-analysis setting. 
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Aims, scope, and outline of thesis 
 
Aims and objectives 
 
The overall aim of this project is to develop more robust meta-analysis approaches, via 
reducing false positive findings and optimising the statistical power of discovering causal 
variants, for both Single Nucleotide Polymorphism (SNP) and Copy Number Variant (CNV) 
genome-wide association studies (GWAS). The new approaches developed are tested on 
simulated and real data in order to assess their robustness. This is achieved by meeting the 
following objectives: 
 
1) Gain knowledge in GWAS and meta-analysis by involvement in one of the large-scale 
European Network for Genetic and Genomic Epidemiology (ENGAGE) meta-analysis 
GWAS projects as the main statistical analyst. My role is to identify the common 
genetic variants associated with alcohol consumption in the general population by 
performing quality control (QC) and meta-analysis across a large number of GWAS 
results from the ENGAGE consortium.  
2) Investigate a variety of standard and non-standard quality control measures to 
increase the reliability of GWAS results. 
3) Investigate which phenotype transformation optimises statistical power under 
skewed continuous phenotypes, across a range of different modelling scenarios, in 
the context of linear regression performed in GWAS. 
4) Extend the use of meta-analysis of SNP GWAS results to CNV GWAS results. 
5) Perform real data analyses using the developed approaches. 
6) Produce software to support the developed meta-analysis approaches. 
 
Scope of thesis 
The scope of this thesis covers the development of any approaches that reduce false 
positive findings and optimise statistical power in GWAS, in particular in the meta-analysis 
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setting. The thesis includes consideration of meta-analysis models using fixed-effect inverse 
variance and weighted-Z, and the phenotype transformations using the log and inverse 
normal transformations. Dr Lachlan Coin, my supervisor, and myself developed the software 
packages included in this thesis. In addition to providing functions in these software 
packages relating to meta-analysis models and data quality controls, I tested, debugged, and 
verified the software. Providing the details of these software packages is outside the scope 
of this thesis. Functional studies that were performed by our collaborators at King’s College 
London for the alcohol consumption study are briefly described in Chapter 2 to provide 
supportive evidence, but the details of these functional studies do not fall within the scope 
of this thesis.  
 
 
Outline of thesis 
Chapter 1 gives an overview of the main concepts important to GWAS, which will be 
referred to throughout subsequent chapters. The chapter first describes approaches 
commonly used in SNP GWAS and later describes an extension of SNP data GWAS to 
support GWAS for CNVs. The main discoveries from SNP and CNV GWAS in the past decade 
are briefly summarised in the literature review. 
 
The primary objective at the start of the project was to gain knowledge of GWAS and meta-
analysis studies that use SNP data. Based on this knowledge, I was in a better position to 
address the technical and methodological issues that required further work in the field, such 
as how to perform GWAS QC in such a way to limit false discoveries, which phenotype 
transformation of continuous data optimises statistical power in the subsequent GWAS 
analyses in different scenarios, and how to extend the meta-analysis approach used for SNP 
data GWAS to CNV data GWAS. 
 
To gain knowledge of GWAS and meta-analysis studies, I was involved in an alcohol 
consumption project as the main analyst. I describe, in Chapter 2, an alcohol consumption 
12 
 
project whose aim is to identify the common genetic variants associated with alcohol 
consumption. This project was initiated during the early stage of the GWAS meta-analysis 
era as part of the ENGAGE. A standard meta-analysis GWAS approach is applied but with in-
depth investigations in terms of the quality control measures to apply and which type of 
analysis to perform, in an attempt to reduce false positive findings in particular. This chapter 
describes investigations performed throughout the process, which lead to debate among 
the study leaders and influence the decisions that are made, and thus impact the final 
results in the discovery and replication stages. In addition, since the study took place at the 
beginning of the meta-analysis GWAS era, there was no software to systematically perform 
meta-analysis. Therefore, I contributed to the development of an in-house software, called 
Metamapper, to facilitate GWAS meta-analyses. The main finding from the alcohol 
consumption meta-analysis GWAS was our reporting of rs6943555 in AUTS2 as attaining 
genome-wide significance, with its functional role subsequently confirmed by our 
collaborator Prof Gunter Schumann’s team. To our knowledge, this is the first and the 
largest SNP meta-analysis study conducted so far on alcohol consumption. The work 
contained in this chapter corresponds closely to the paper published in PNAS on the topic 
[Schumann, et al. 2011]. 
 
In the alcohol study, different phenotype transformations were applied to the data 
according to the inclusion or exclusion of non-drinkers, which led to questioning which 
phenotype transformation of skewed continuous phenotypes optimises statistical power in 
GWAS in general, forming the second major investigation in my thesis. The most commonly 
applied transformations in GWAS are standardisation, the log transformation (LT), and the 
inverse normal transformation (INT). However, to date there has been little investigation 
into their effect on statistical power in the context of GWAS. Furthermore, there appear to 
be no rules-of-thumb in use by the field; indeed different transformations have been 
applied to the same phenotype in different studies, for example in height and BMI GWAS 
studies [Cho, et al. 2009, Gudbjartsson, et al. 2008, Sanna, et al. 2008, Speliotes, et al. 2010, 
Loos, et al. 2008, Cris, et al. 2009]. Therefore, in Chapter 3, I test the statistical power to 
detect genotype-phenotype associations under no transformation (equivalent to 
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standardisation in terms of power), the LT, and the INT using both simulated data as well as 
re-analysis of reported associations in the Northern Finland Birth Cohort 1966 (NFBC1966). 
We also test the sensitivity of the inverse variance (IV) and weighted-Z (WZ) methods of 
meta-analysis to the transformations performed. I find that the application of the INT to 
non-normal phenotypes in GWAS, where effect sizes are small and the priority is discovery 
over interpretability, may lead to an increase in the discovery of genetic variants affecting 
continuous traits. The work in this chapter closely reflects a manuscript on the topic that is 
currently under review with Genetic Epidemiology.  
 
In Chapter 4, I extend the investigation of meta-analysis GWAS from that performed on SNP 
data GWAS results to those conducted on the more recently available CNV data. In contrast 
to mutations altering one single nucleotide base that can give rise to SNPs, CNVs often cover 
extensive regions, ranging from 1 kb to several Mbs in length. As a result of their substantial 
size, they may have a substantial impact on large parts of genes, with potential functional 
roles influencing the risk of disease. It has been shown that there are a number of rare CNVs 
associated with human phenotypes. However, detecting rare CNVs via association testing is 
challenging due to the limited statistical power resulting from by the small number of 
counts of the minor allele. However, rare CNVs may be detected if a sufficiently large 
sample size is used. Therefore, as with SNP GWAS, a practical and cost effective approach to 
increase sample size is to perform meta-analysis across a number of studies. There are, to 
our knowledge, no publications of a CNV meta-analysis performed on a genome-wide scale. 
Therefore, the aim of this chapter is to develop an approach to enable CNV meta-analyses 
to proceed in a similar way as SNP meta-analyses, to determine an appropriate significance 
threshold for CNV GWAS based on defined CNV regions, and to produce a pipeline and 
software to be publicly available for all users. Our pipeline and software, called cnvPipe, was 
first implemented to combine CNV data across studies in the ENGAGE Consortium to search 
for CNVs associated with height and weight. While the results do not reveal strong evidence 
of CNV associations, a promising association signal is shown in the deletion in PTPN20A. This 
gene was not previously reported in SNP GWAS on height and thus this deletion may 
contribute to explaining some of the missing heritability in height variation. 
14 
 
 
Chapter 5 summarises the main findings of this thesis, and describes potential extensions to 
some of the topics considered. 
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Chapter 1 Introduction 
 
1.1 Background 
 
A decade ago, the first map of human genome was published and this event became a 
stepping stone for further investigations in the underlying genetics influencing phenotype 
variance or disease risk. The most common forms of genetic variants are known as Single 
Nucleotide Polymorphisms (SNPs) and Copy Number Variants (CNVs).  Advanced statistical 
methods and software tools have been developed and these opened the door for genome-
wide association study (GWAS) to effectively seek the underlying genetic variants in the 
complex human phenotypes. 
 
A major advance in GWAS was provided by the technique of ‘imputation’, where millions of 
SNPs, additional to those on the genotype chip, can be inferred using reference map.  As a 
consequence of imputation based on the same reference map, results contributing to 
phenotype-genotype association at the same SNPs in multiple studies can be combined on 
genome-wide scale using meta-analysis and this hugely accelerates genetic discoveries.  
 
As the extensive usage of meta-analysis in GWAS, the aim of this thesis is to develop the 
approach to be more robust by reducing false positive finding and optimising statistical 
power for both SNPs and CNVs and at the same time identify underlying genetic variations 
of phenotypes using these approaches. 
 
In this chapter, we first give an overview of the main concepts important to GWAS, which 
will be referred to throughout subsequent chapters. It describes approaches commonly 
used in SNP GWAS and later describes an extension of SNP data GWAS to support GWAS for 
CNVs. The main discoveries of from SNP and CNV GWAS in the past decade are briefly 
summarised in the literature review. 
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1.2 Genetic variation 
 
The human genome comprises around 3.3 billion nucleotides in sequence across 22 
autosomal chromosomes, which exist in homologous pairs, and the sex-determining 
chromosomes X and Y (the latter in males only). Adenine (A), thymine (T), cytosine (C) and 
guanine (G) are the nucleotides that form DNA sequence. The main forms of genetic 
variation in the human genome are Single Nucleotide Polymorphisms (SNPs) and Copy 
Number Variants (CNVs). An important feature of genetic variation data is the correlation 
between genetic variants that are nearby to each other across the genome, a phenomenon 
known as Linkage Disequilibrium (LD).  
 
1.2.1 Single nucleotide polymorphisms 
 
A single nucleotide polymorphism (SNP) is a DNA sequence variation between individuals 
occurring in the genome at a single nucleotide. For example, two fragments of DNA from 
different individuals may be: A-A-G-C-C-T-A and A-A-G-C-T-T-A, which contain a difference in 
a single nucleotide. In this case, we say that there are two alleles, allele C and allele T, at the 
fifth nucleotide position. For a variation to be called a SNP, the less frequent allele – the 
‘minor allele’ - must occur in greater than 1% of the population. On average, a SNP occurs 
once in every ~300 nucleotides. It is known that SNPs can affect the function of genes or 
regulatory sequence, which can cause a major impact on how humans develop through life 
and their susceptibility to diseases. 
 
1.2.2 Copy number variants 
 
Copy number variation (CNV) is another type of genetic variation. In contrast to SNPs, which 
affect only one nucleotide base pair, CNVs may range up to several megabases (106 
nucleotide bases) in size. This variation can be a consequence of a genome region that has 
been deleted (a ‘deletion’) or duplicated a number of times (a ‘duplication’). For example, a 
chromosome sequence that was originally A-A-G-C-C-T-A may have the second, third and 
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fourth bases duplicated so that it becomes A-A-G-C-A-G-C-C-T-A or deleted so that it 
becomes A-C-T-A. Since CNVs often correspond to relatively large genomic regions, they 
may have a major effect on function by deleting or duplicating parts of, or entire, genes. 
Therefore, it is hypothesised that CNVs may have a substantial contribution to human trait 
variation and to the risk of disease. 
 
1.2.3 Linkage disequilibrium 
 
Linkage disequilibrium (LD) is the term used in genetics to describe the correlation between 
the alleles of genetic variants in a sample of individuals. LD is usually measured between 
pairs of genetic variants either by D’ or, most often in the field of genetic epidemiology, by 
r2. For the LD between alleles at two genetic variants, say alleles A and B, which have allele 
frequencies of pA and pB, D’ can be calculated as 
 
,
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LD between nearby SNPs and/or CNVs tends to be high due to the ‘linkage’ (co-segregation 
of nearby sequence through generations) between them, whereas it tends to zero for 
distant variants (e.g. > 100 kb) due to the comparatively high recombination rate over such 
distances in the genome. The LD structure is in fact critical to the design of genome-wide 
association studies, since it is only possible to genotype a fraction of genetic variants, yet 
the LD between causal variants and those on a genotyping chip allows a signal of association 
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to be observed. Thus if we make the assumption that causal variants are not on the 
genotyping chip, then the purpose of genome-wide association studies is to detect the 
indirect associations between phenotype and the variants that are in strong LD with the 
causal variants along the genome (Figure 1.1).  
 
 
Figure 1.1. Indirection associations between causal variant and phenotype in GWAS 
 
1.3 GWAS of SNP data 
 
The aim of GWAS is to find associations between genetic variants and phenotypes of 
interest. Once found, these associated variants are used as markers to specify the causal 
genetic regions on the genome. As an advantage of rapid advances in genotyping 
techniques, genotyping platforms that assay between 100,000 and 1,000,000 SNPs have 
been applied to genotype a large number of samples at an affordable cost. Therefore, GWAS 
can search for causal variants throughout the genome using this dense set of SNPs and via 
the LD between them. Based on the continuing success of GWAS, it was shown that there 
have been more than 800 human GWAS, which have found more than 2000 associated SNPs 
[Prescott 2002]. In this section, we will describe the main important steps of the GWAS 
approach. 
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1.3.1 Quality control  
 
Quality control is a crucial step in obtaining high quality genotype data, which should 
subsequently lead to reliable results. Genotype data generally contains a large number of 
systematic errors, so there must be a way to filter these out. Below I describe some of the 
main filters used as part of genotype quality control.  
 
To make a genotype ‘call’ at a SNP, where its two alleles are referred to as allele A and  
allele B, all samples are first visualised on two dimensions corresponding to the normalised 
intensity values of their A and B alleles (Figure 1.2a). Those samples that are clustered due 
to the high intensity of the allele A and low intensity of allele B are ‘called’ as homozygous 
AA. Similarly, samples clustered due to the high intensity of allele B and low intensity of 
allele A are called as homozygous BB. The samples with a similar intensity of both A and B 
alleles are called as heterozygous AB. However, for samples that have an unclear intensity 
clustering, their genotypes are considered unreliable and thus filtered out rather than 
called. For example, the samples that have allele intensities between the homozygous and 
heterozygous clusters would be filtered out and thus their genotypes cannot be called (grey 
points in Figure 1.2b).   
 
After genotype calling, the rate at which genotypes were not called due to ambiguous allele 
intensities, known as the missingness rate, for each SNP and individual is then used as a 
filter for considering a particular SNP or individual as having unreliable genotype data. As an 
example, a missingness rate of 5% can be used as a filter threshold for removal of both SNPs 
and individuals. A low minor allele frequency (MAF) at a variant can indicate not only that 
the variant genuinely has a small frequency of a particular allele but may also indicate 
difficulties in genotype calling. Moreover, since SNPs with very low MAF have limited 
statistical power to detect phenotype-genotype association, they are usually excluded 
below 1% MAF. Hardy–Weinberg equilibrium (HWE) testing is also used as an important 
filter. The Hardy-Weinberg principle states that the genotype proportions in the population 
are as expected according to the allele frequencies and independent mating and that those 
proportions remain constant in time. Deviations from HWE can be a consequence of 
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inbreeding, selection, or migration. Nevertheless, in genotype data, a significant deviation 
from HWE is most likely due to genotyping error [Consortium 2007]. Thus, HWE testing is 
usually performed as a data quality check, and in controls only since deviation in cases could 
be due to selection at causal variants, and SNPs showing deviation from HWE are normally 
excluded. 
 
 
Figure 1.2. An example of intensity cluster plots: a) a SNP with a cluster plot where all 
samples can be easily called and b) a SNP where calling is challenging for some samples, 
which are excluded in the genotype calling process (grey points). 
 
1.3.2 Multiple testing 
 
An advantage of dense association genome scans is that they provide good coverage across 
the genome, meaning that the causal SNP is likely to be in LD with one of the genotyped 
SNPs. The simplest and most widely used analysis strategy is to carry out a test of 
association between SNP and the phenotype one SNP at a time. However, when tests are 
conducted across the large number of SNPs across the genome, this leads to a high risk of 
false positive findings. Therefore, tight standards for statistical significance are required. To 
prevent false positive findings, the problem of multiple testing in SNP data is usually tackled 
by controlling the family-wise error rate (FWER). To ensure the level of stringency is 
maintained when testing multiple SNPs, the per-SNP significance level corresponding to a 
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given FWER is calculated. For the FWER of ,  the per-SNP significance level  can be 
calculated as   where n is the number of independent SNPs to be tested 
*Sidak 1968+. As an approximate way to produce a per-SNP significance level, the Bonferroni 
correction, which corresponds to testing at a significance threshold of  , is commonly 
used. For example, we would apply  of 5e-8 (the per-SNP significance level) if we want to 
obtain the FWER of 0.05 (the overall P-value) over 1 million independent SNPs. The number 
of SNPs actually used to calculate the corrected P-value, known as the ‘effective’ number of 
SNPs, is far fewer than the total number of SNPs genotyped because all genotyped SNPs are 
not independent due to LD between them. 
 
As an alternative to the FWER approach, which has been criticized for producing overly 
conservative significance thresholds [WTCCC consortium 2008], the False Discovery Rate 
(FDR) is a well-established method for addressing the multiple testing problem. Rather than 
controlling the probability of making even one false discovery, as in FWER, the FDR controls 
the proportion of false positives out of the total number of positives, increasing power at 
the cost of allowing some false discoveries. Thus, the FDR provides a less stringent 
significance threshold in multiple testing. The Bayesian approach to multiple testing has also 
been taken because rather than relating only to the number of tests performed, it, perhaps 
more intuitively, considers the proportion of true findings expected among the tests 
performed. The observed association of each SNP is weighted against its prior probability of 
causal association to obtain the posterior probability of association for each SNP, and the 
number of SNPs tested is not considered. It has been shown that both Frequentist and 
Bayesian approaches provide similar genome-wide significance thresholds of [WTCCC 
consortium 2008]. Since the field has adopted the FWER approach with adjustment for the 
correlation structure between SNPs, and have produced a genome-wide significance 
threshold of 5e-8, then this thesis uses this threshold and the FWER approach throughout.  
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1.3.3 Population stratification 
 
The presence of population stratification can result in systematic differences in allele 
frequencies between subpopulations, which can lead to false positive associations when a 
GWAS is performed on samples from the overall population. For example, subpopulation 1 
has an A allele frequency of 0.9, and subpopulation 2 has an A allele frequency of 0.1. 
Assuming that cases and controls are equally distributed in both populations, this implies no 
association between the A alleles and the disease. However, if cases were collected mostly 
from subpopulation 1 and controls are collected mostly from population 2 (Figure 1.3), then 
an association is observed between cases-control status and SNP even when there is no 
causal association present. This problem is an inherent consequence of non-random mating 
in natural populations. The detected association is a consequence of the underlying 
structure of the population rather than a disease associated locus. Therefore, ideally this 
would be accounted for at the data collection stage by sampling cases and controls 
randomly throughout the population. However, this is often not possible, for instance when 
the data has already been collected, and therefore there has been an attempt to 
understand the effect of population structure on GWAS results to enable better approaches 
to dealing with this problem at the analysis stage. 
 
It has been shown that population structure leads to overdispersion of the test statistic in 
association studies. As a consequence, false positives can exceed the nominal level. 
Nevertheless, this overdispersion is approximately constant across the genome and thus the 
test statistic resulting from this overdispersion can be corrected with a uniform correction 
[Balding 2006]. Devlin and Roeder proposed such an approach, known as ‘genomic control’, 
which has been shown to correct the test statistic for overdispersion [Devlin and Roeder 
1999]. The idea of genomic control is to down-weight the test statistic by a fixed amount. 
The variance inflation factor, , is calculated as the median of test statistics divided by its 
expectation under the  distribution (~0.456). The  statistics are then down-weighted 
by multiplying them by a factor, .  

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In addition to genomic control [Devlin and Roeder 1999], another approach that has been 
widely used to account for population stratification is the application of Principal 
Component Analysis (PCA). PCA has been widely used as a tool to understand the internal 
structure of high dimensional data that is difficult to visualize. PCA transforms a set of 
observations of correlated variables into a set of uncorrelated variables called principal 
components (PCs). The first PC reflects the largest variability in the data. Then, similarly, 
each succeeding component accounts for as much of the remaining variability as possible. 
As a result of much of the variation in a set of correlated variables being explained by the 
top principal components, high dimensional data can be observed by inspecting a much 
smaller number of dimensions and thus the main structure under this reduced dimension 
can be easily observed. By applying PCA to hundreds of thousands of SNPs across the 
genome, the top PCs have been shown to contain information about the relatedness 
between samples, which can associate with the outcome and cause confounding, usually via 
the association between relatedness and geographic location [Novembre, et al. 2008] and 
thus other risk factors. Therefore, including these top PCs as covariates in the downstream 
association analyses can correct for the potential confounding effects of population 
stratification by adjusting for the variation in allele frequencies across ancestral sub-
populations. 
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Figure 1.3. False positive association due to population structure 
 
1.3.4 Imputation 
 
Even though affordable genotyping platforms provide data on a large number of SNPs, there 
are even larger numbers of SNPs that are not directly genotyped. Therefore, imputation 
provides a cost effective way to predict unobserved genotype SNPs that can be used in the 
analysis as if they were genotyped. By using a fine-scale reference genotype map, from 
resources such as the HapMap panel, in conjunction with genotyped data of the study, the 
unobserved genotypes that are present on the reference panel can be imputed. Two main 
software packages have been widely used for such imputation: IMPUTE [Marchini, et al. 
2007] and MACH [Y.Li, et al. 2006]. This imputation technique allows GWAS to be performed 
at a finer scale, with both genotyped and imputed SNPs tested for their association with the 
phenotype under study. Nevertheless, because there is uncertainty in the imputation of 
unobserved genotypes, the quality of imputation at each SNP needs to be checked and is 
usually used as a post-analysis QC criterion.  
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1.3.5  Association analysis 
 
The simplest and most widely used association analysis strategy is to carry out a test of 
association between genotypes and a phenotype of interest one SNP at a time across the 
genome. For complex traits, an additive effect is usually assumed for the individual SNP risk 
[Balding 2006]. The additive effect assumes carriers of two risk alleles have twice the risk of 
carriers with one risk allele. The assumption of an additive effect will result in higher power 
if the genotype risks are close to additive risks and lower power if the disease takes a 
dominant or recessive form. However, dominant effects are often well captured by an 
additive model because the rare homozygote is generally infrequent and so the relative 
impact of the models on results can be minimal. For quantitative phenotypes, the method 
usually employed is linear regression. Linear regression assumes a linear relationship 
between the mean value of the phenotype and the genotype. The test assumes that the 
phenotype is normally distributed conditional on genotype. If this is not the case, a 
transformation of the phenotype data, such as log or inverse normal transformation, is 
usually performed in order to obtain approximate normality. The null hypothesis is that the 
expected regression line that minimises the residuals between the genotypes and 
phenotype values has a gradient of zero. The corresponding linear regression model is 
written as: 
 
           , 
 
where yi is the phenotype of individual i and the xi is the genotype, coded assuming an 
additive effect as xi = 0 (AA), 1 (AB), or 2 (BB). 
 
The regression model can also be used for case-control association tests, by implementing 
logistic regression. The logistic regression, in this context, models the log odds of disease as 
a linear function of the genotypes for each SNP. The null hypothesis is that the regression 
line that minimises the residuals between the genotypes and the log odds of the phenotype 
has a gradient of zero. This logistic model of the probability of disease, pi, is written as 
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1.3.6 Meta-analysis 
 
As the ultimate goal of GWAS is to identify all associated genetic variants, all genetic 
variants with large, modest, and small effect sizes are searched for. However, to detect 
modest or small effect sizes, a large number of samples are required. Therefore, the concept 
of combining results from a number of studies in a meta-analysis became a priority in the 
field as GWAS results began emerging and indicating that larger sample sizes still were 
required to detect many of the genetic effects. As imputation provides information about 
the same SNPs across different platforms, combining results across a consistent set of SNPs 
became feasible. Therefore, collaboration was formed between large numbers of studies 
with GWAS data to combine together all available results for a phenotype of interest using 
meta-analysis. Genetic discovery has been hugely accelerated in this meta-analysis era. 
 
Meta-analysis has been widely used to combine results from a number of GWAS studies by 
using common result measures, such as the effect sizes and P-values. It increases the power 
to detect estimates of the true effect size over those derived using only one of the studies. 
There are a number of meta-analysis models that have been used to combine evidence of 
associations.  
 
1.3.6.1 Fisher’s method 
 
A simple way to combine results from independent studies without using weights can be 
achieved using Fisher’s method. This method directly combines P-values from independent 
studies. For the i=1, .., k independent studies to be combined, 
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where  is the P-value at a given SNP from study i. Without using weights, the combined P-
value under Fisher’s method averages all P-values across studies equally regardless of their 
relative reliability.  
 
1.3.6.2 Weighted Z-statistic 
 
Another approach that has been used to combine results from independent studies is the 
weighted Z-statistic. The sample sizes in individual studies are used to calculate their 
weights in the statistic, such that large studies are given greater weight than small studies 
due to their greater reliability. The effect direction is also taken into account. For the i=1, .., 
k independent studies to be combined, let  be the test Z-statistic and the sample size 
for the ith study.  The weighted Z-statistic can be calculated as  
 
, 
 
where  is the relative weight of the ith study. The sign of indicates the 
direction of the observed effect size of the ith study (  > 0 for effect estimate > 0 and  < 0 
for effect estimate < 0). 
  
1.3.6.3 Inverse variance method 
 
Another approach frequently used in meta-analyses is known as the inverse variance 
method. The weighted effect sizes across all studies are combined. The weight is calculated 
from the inverse variance of the effect of each study. Studies with smaller effect variance 
are given a greater weight than studies with larger effect variance. There are two inverse 
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variance models used for meta-analysis, the fixed-effect model and the random effects 
model. 
 
Fixed-effect model 
Fixed-effects models assume that the true effect size is the same in all studies. For the i = 
1,.., k independent studies to be combined, let  be the observed effect size with variance 
 for the ith study where the underlying population effect size. For a fixed effect model, 
all population effect sizes are assumed equal, that is , where  is the true 
common underlying effect size. Thus, an estimate of the treatment effect is given by  
  
where the weights are inversely proportional to  variance,  
 
 
Random-effect model 
While fixed-effect models assume that the true effect size is the same in all studies, random 
effects models allow the true effect to vary in different studies. It takes into account the 
extra variation, the between study variance of the studies effect sizes, . Adjusted weights 
for each of the studies may now be calculated as  
 
   
 
where the between study variance of the study effect sizes is 
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and the heterogeneity test statistic is given by 
 
. 
 
In meta-analysis GWAS setting, the inverse variance under the fixed effect model is most 
commonly used and therefore this model is generally applied throughout this thesis. In 
addition, the weighted-Z is occasionally used in parallel with the fixed effect model in order 
to confirm results and investigate if any other interesting results can be detected by this 
method. Nevertheless, if both models are used formally for detection then the multiple 
testing incurred should be accounted for.  
 
                 
1.4 GWAS of CNV data 
 
GWAS results based on SNP data so far only explain a small proportion of phenotypic 
variance for the vast majority of phenotypes, therefore CNVs have been investigated as a 
possible source of variation that may explain this “missing heritability” underlying the 
genetics of complex diseases and phenotypes [Manolio, et al. 2009]. There have been 
several techniques developed to directly genotype CNVs including comparative genomic 
hybridization and tiling oligonucleotide microarrays [Conrad, et al. 2010; Redon, et al. 2006]. 
However, because direct CNV genotyping comes with high cost, indirect CNV inference via 
SNP data is commonly performed in practice. Genome-wide SNP data are widely available in 
many epidemiology data sets, so this allows CNVs to be called (see below) and genome-wide 
associations between CNVs and phenotypes to be investigated. Copy number states (CN) 
can be categorised into 5 genotypes, that are, two copies of a deletion (CN = 0), one copy of 
a deletion (CN = 1), normal number of copies or diploid state (CN = 2), one copy of a 
,
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duplication (CN = 3), and two copies of a duplication (CN = 4). This section first describes the 
process of CNV calling via SNP data and then describes the quality control usually taken 
after CNVs are called. 
 
1.4.1 CNV detection and genotyping from SNP data 
 
Due to the high cost of applying direct CNV detection methods on a genome-wide scale, 
several software packages to indirectly detect and genotype CNVs via SNP data have been 
developed [Coin, et al. 2010; Glessner, et al. 2013; Wang, et al. 2007]. At each SNP, where 
its two alleles are referred to as allele A and allele B, CNVs are called based on two 
measurements, the Log R Ratio (LRR) and the B Allele Frequency (BAF). The LRR represents 
the measure of the total allelic intensity from allele A and allele B, 
, where #A is the total intensity of allele A and #B is the total intensity of allele B. The BAF is 
the proportion of the total intensity (#A + #B) explained by the B allele intensity (#B), 
  
Table 1.1 shows an example of BAF and LRR values calculated for CNVs 
indicating 3 different copy number states. The combinations of LRR and BAF can be 
visualised (Figure 1.4) and both their values used to infer the CNV genotype. By comparing to 
a diploid state (CN = 2), the presence of a single copy of a deletion (CN = 1) can be observed 
when there is a decrease in the LRR value and a lack of heterozygotes is shown by the BAF. 
The presence of a single copy of a duplication (CN = 3) is observed as an increase in the LRR 
and a separation into two clusters of the heterozygous genotypes. 
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Table 1.1. BAF and LRR value in different states of CNV 
Genotype CN BAF LRR 
AA, AB, BB 2 
(diploid state) 
0, 0.5, 1 0 
 A, B 
 
1 
(single copy of a deletion) 
0, 1 -0.7 
AAA, AAB, ABB, BBB 
 
3 
(single copy of a duplication) 
0, 0.33, 
0.66, 1 
0.4 
 
 
 
Figure 1.4. Visualisation of CNV states in terms of the BAF and LRR. 
 
The most commonly applied software package for inferring CNVs from SNP data so far is 
PennCNV. PennCNV has been used in a number of large CNV studies [Elia, et al. 2012; 
Glessner, et al. 2010a; Glessner, et al. 2010b; Glessner, et al. 2009; Wang, et al. 2010]. Its 
algorithm is based on a hidden Markov model (HMM) that accounts for the correlation 
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between the copy number states at adjacent SNPs. The HMM assumes that the CN at each 
SNP depends only on the CN of the preceding SNP. To account for the information from the 
preceding SNP, the ‘transition probabilities’ of CNs between those two SNPs are included in 
the model. For example, the transition probability from one-copy of a deletion to the 
normal state is more likely than the transition probability from one-copy of a deletion to 
one-copy of a duplication. Since the copy number state cannot be directly observed, hence 
use of a hidden model, other observed information including LRR, BAF, the distance 
between SNPs, and the allele frequency of the SNP are exploited. By using these observed 
information and the CN of the preceding SNP, copy numbers at each SNP can be predicted. 
By applying PennCNV to genotyped data from 112 HapMap individuals, approximately 27 
CNVs are detected for each individual with a median size of approximately 12 kb [Wang, et 
al. 2007]. 
 
1.4.2 Quality control in CNV genotyping 
 
Multiple factors can bias the detection of CNV calls, therefore it is important to apply 
several quality control checks. These include ethnicity clustering using principal component 
analysis, normalisation of BAF and LRR intensities, GC-content model adjustment, which are 
implemented before and during CNV calling. However, since this thesis focuses on analyses 
of called CNVs, this section briefly describes how samples can be further QC-ed after the 
CNVs are called. 
 
In this section, we focus on the QC of the PennCNV output as PennCNV is used as the main 
software to call CNVs in this thesis. PennCNV takes in LRR and BAF values at each SNP. For 
each CNV call, PennCNV outputs the start and end locations of the CNV, the number of SNPs 
within the CNV, the CN state, and confidence scores for the call. Given that the LRR and BAF 
values are calculated from allelic intensity values, any ‘statistical noise’ that affects the 
intensity can lead to unreliable CNV calling. The noise is observed as intensity fluctuation 
and if CNV calls across the genome contain a lot of noise, this may reflect an unacceptably 
high deviation in total intensity. Therefore, samples with a high deviation of total intensity 
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should be treated as low-quality samples. To detect and define high intensity fluctuation, 
three measurements are used: the standard deviation of the LRR (SD_LRR), the total signal 
fluctuation of the signal intensity file (WF), and the GC-content-caused fluctuation of the 
signal intensity file (GCWF). 
 
It has been recommended that individual laboratories and sample sources determine 
appropriate QC thresholds for their data depending on factors such as the platform used. As 
an example, appropriate thresholds for Illumina 550k data are recommended as: call rate > 
98%, SD_LRR < 0.3, |GCWF| < 0.05, and CNV count < 100, and for Affymatrix 6.0 data: call 
rate > 96%, SD_LRR < 0.35, |GCWF| < 0.02 and count CNV < 80 [Glessner, et al. 2013]. 
 
1.5 Literature review 
 
1.5.1 SNP GWAS review 
 
One of the earliest discoveries that applied the GWAS approach was the study on the 
association between Age-related Macular Degeneration (AMD) and variants in the 
complement factor H gene (CFH) [Klein, et al. 2005]. The genome-wide screen of 96 cases 
and 50 controls was performed on 116,204 directly genotyped SNPs. There were 103,611 
SNPs that passed quality control and a P-value of 4.8x10-7 (0.05/103,611) was used for the 
significant threshold after accounting for multiple corrections using the Bonferroni 
correction. Two SNPs, rs380390 and rs10272438, were found to be significantly associated 
with AMD (Boferroni corrected P-value = 0.0043 and 0.008, respectively). However, 
rs10272438 has a significant deviation from HWE, which indicates possible genotyping 
errors, and after re-genotyping individuals with a missing genotype call at rs10272438 and 
repeating the analysis, the association was no longer significant after Bonferroni correction. 
The CFH gene, which harbours rs380390, was then sequenced in the sample. A total of 50 
SNPs were identified and 17 of these SNPs are nonsynonymous SNPs. One of the 
nonsynonymous SNPs, rs1061170, showed the strongest association with AMD. With 
convincing biological evidence that CFH causes the accumulation of drusen, which deposits 
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in and around macula and is the primary feature of AMD, the CFH gene was proposed to be 
associated with AMD. 
 
The first large-scale collaborative GWAS, in terms of sample size and the analysis of 
numerous phenotypes, was conducted by the Wellcome Trust Case Control Consortium 
(WTCCC). In 2007, the WTCCC published GWAS results on seven common diseases: type 1 
diabetes, type 2 diabetes, coronary heart disease, hypertension, bipolar disorder, 
rheumatoid arthritis and Crohn's disease [Consortium 2007]. Approximately 2,000 cases and 
a shared set of approximately 3,000 controls were examined in each disease. All 17,000 
samples were genotyped using the Affymetrix 500K genotyping chip. At the significance 
level determined by the authors of P < 5x10-7, 7 SNPs were discovered for type 1 diabetes, 3 
SNPs for type 2 diabetes, 1 SNP in coronary heart disease, none in hypertension, 1 SNP in 
bipolar disorder, 3 SNPs in rheumatoid arthritis and 9 SNPs in Crohn's disease.  
 
However, GWAS meta-analyses offered new hope of performing studies on sample sizes 
large enough to detect a larger number of genotype-phenotype associations. Twelve novel 
T2D association signals were identified at P < 5 × 10−8 by conducting a meta-analysis of eight 
T2D GWAS comprising 8,130 T2D cases and 38,987 controls [Voight, et al. 2010]. Previously, 
in the single study setting, the WTCCC reported only 3 associated SNPs in type 2 diabetes at 
the significance level of P < 5x10-7 using 2,000 cases and 3,000 controls [Consortium 2007]. 
Therefore, these additional 12 association signals were a consequence of the power 
increase gained by applying the meta-analysis approach (Figure 1.5). In addition, one of the 
meta-analyses that I contributed to as a co-author is on identifying genetic variants 
associated with birth weight [Freathy, et al. 2010]. Given a known association between 
extreme birth weight and perinatal morbidity and mortality, and the association between 
lower birth weight and later-life chronic disease, it is important to understand the common 
genetic variants associated with birth weight. Six GWAS with ~2.5 million genotyped and 
imputed SNPs on a total of 10,623 individuals were meta-analysed in the first stage. Birth 
weight was standardised and adjusted for sex and gestational age. SNP rs900400, which lies 
between LEKR1 and CCN1, and rs9883204 in ADCY5, were associated with birth weight with 
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P-values of 2x10-35 and 7x10-15, respectively. To verify that these two SNPs are not false 
positives, the association was tested in a further 13 studies, with a total 27,591 individuals, 
in the replication stage. The SNPs were replicated with P-values of 3x10-26 and 3x10-9, 
respectively, which confirms the validity of the association signal. Each C allele of rs900400 
and rs9883204 lower the birth weight by an average of 40g and 30g, respectively, per allele. 
 
  
Figure 1.5. Reported associated genes in type 2 diabetes based on a) a single study in 
WTCCC in 2007 [Consortium 2007] and b) combined multiple studies using meta-analysis in 
2010 [Voight, et al. 2010]. 
 
In 2011, it was shown that there had been more than 800 human GWASs, which discovered 
more than 2000 associated SNPs [Prescott 2002]. These GWAS discoveries are 
systematically catalogued and the key characteristics of the observed associations 
characterised in the website www.genome.gov/gwastudies. There was also an exponential 
increase in the number of meta-analysis GWAS publications between 2005 and 2010 
(Figure1.6). These publications ranged across a number of different types of meta-analyses, 
paper type, meta-analysis method and software package employed (Figure 1.7).   
 
 
36 
 
 
 
 
 
Figure 1.6. Number of meta-analysis GWAS studies by year of publication. These study 
numbers are based on the PubMed search under ‘meta-analysis’(Title/Abstract) and 
‘genome-wide association’(Title/Abstract) [Begum, et al. 2012]. 
 
 
  
Figure 1.7. Summary of GWAS meta-analysis review: (A) type of meta-analysis, (B) type of 
paper; (C) type of meta-analysis method, (D) software used [Begum, et al. 2012]. 
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1.5.2 CNV GWAS review 
 
In 2006, the first generation CNV map of the human genome was compiled based on 270 
individuals from the HapMap project, comprising 90 individuals with ancestries from each of 
Europe, Africa, and Asia [Redon, et al. 2006]. This first CNV map provides an understanding 
of the basic characteristics of CNVs in the human genome. The map showed that CNVs cover 
approximately 12% of genome in terms of sequence length, and thus take up a larger 
cumulative sequence than SNPs. SNPs were shown to be enriched within CNVs across the 
genome, a finding which led to an investigation on how well SNPs ‘tag’ CNVs across the 
genome via their correlation (r2 > 0.8). If there are SNPs in high LD with CNVs, this implies 
that CNVs can be tagged by SNPs and thus SNPs can indirectly provide information about 
CNVs even when they are not genotyped. By checking the correlation between SNPs and 
CNVs, it was reported that 51% of CNVs are tagged by SNPs in Europeans. Therefore, with 
the first CNV map, there is evidence that CNVs can be indirectly investigated via SNPs. 
 
A more thorough CNV map was compiled in 2010 based on a larger number of samples, 
using 450 individuals from the HapMap project and smaller CNVs were searched for 
(minimum length 443 bp) [Conrad, et al. 2010]. To further investigate common CNVs in 
particular, those with a MAF > 5% we selected for more focussed study. It was reported that 
77% of these common CNVs are well tagged by SNPs, which suggests that SNP GWAS have 
already indirectly captured the potential effect of common CNVs reasonably effectively. To 
further explore this, association analysis on common CNVs were performed in 8 phenotypes 
for which SNP GWAS had already been published [Craddock, et al. 2010]. The CNVs found to 
have significant associations in this study are located in the same regions previously found 
by the SNP GWAS, implying that common CNVs are unlikely to contribute much more to 
disease susceptibility than that estimated from SNP GWAS already. 
 
Even though the study of common CNVs has so far has not filled in the gap of missing 
heritability, many studies have reported a major role for rare CNVs in diseases. For example, 
several rare CNVs have been found to be associated with an increased risk in obesity related 
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phenotypes and a number of psychiatric disorders [Elia, et al. 2012; Glessner, et al. 2010a; 
Glessner, et al. 2010b; Glessner, et al. 2009; Walters, et al. 2010]. 
 
While numerous SNPs have been found to be associated with obesity related phenotypes 
[Prescott 2002], they explain only a small proportion of the phenotypic variation. Therefore, 
there have been further investigations into the role of CNVs. Several studies have shown 
that rare CNVs associate with obesity related phenotypes. By performing a genome-wide 
CNV GWAS scan on 11,856 individuals, evidence for association with severe obesity was 
found at deletions at the 16p11.2 locus (P = 5.8 × 10−7; odds ratio =30) [Walters, et al. 2010]. 
This deletion of approximately 600 kb in length, with MAF estimated as 0.4-0.6%, contains 
the TBX6 gene. The very high estimated odds ratio of 30 provides evidence that rare CNVs 
can be highly penetrant. Another study also found rare CNVs associated with obesity [Wang, 
et al. 2010]. Rare and large CNVs (MAF < 1%, length > 1 Mb) were found to be 
overrepresented among 430 cases who had moderate to extreme obesity compared to 379 
controls who had never been obese (odd ratio = 1.5). In another study, rare CNVs were 
discovered among 1,080 obese American children of European descent compared to 2,500 
lean controls [Glessner, et al. 2010a]. 
 
Rare CNVs have also been found to have a major role in the risk of a number of psychiatric 
disorders. Autism spectrum disorders (ASDs), which are a neurodevelopmental disorder that 
develop in childhood, were shown to be associated with enrichment of rare CNVs in the 
NLGN1 and ASTN2 genes [Glessner, et al. 2009]. In addition, a CNV GWAS was performed on 
Schizophrenia. This study investigated 977 Schizophrenia cases and 2,000 healthy adults of 
European ancestry [Glessner, et al. 2010b]. It was shown that rare CNVs are significantly 
enriched in the cases (P = 1.5 x 10-7). A CNV GWAS on Attention Deficit Hyperactivity 
Disorder (ADHD) observed an enrichment of CNVs in 1 013 ADHD cases compared to 4,105 
healthy children of European ancestry (P=2.1 x 10-9) [Elia, et al. 2012]. 
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Chapter 2 The GWAS analysis of alcohol consumption 
 
2.1 Introduction  
 
In the past decades, GWAS has been successful in identifying genetic variants associated 
with diseases. By 2011, it was shown that there are more than 800 human GWASs and 
found more than 2,000 associated SNPs [Prescott 2002]. Since then, there has still been a 
high increase in published GWAS reports. 
 
In the early time, GWAS was done in a single study which contains small-moderate sample 
size. When imputation was developed in 2007 [Marchini, et al. 2007; Y.Li, et al. 2006], this 
allows unobserved genotypes to be estimated with high accuracy and a uniform set of 
genotypes can be obtained from different genotyping platforms. This leads to the start in 
combining multiple GWAS results performed on different genotyping platforms via meta-
analysis. By increasing sample size, meta-analysis improves statistical power to detect 
phenotype-genotype associations which is crucial especially when the observed effect size 
in GWAS has moderate-to-small size. 
 
In 2008, our project which aims to identify the common genetic variants associated with 
alcohol intake was initiated under the European Network for Genetic and Genomic 
Epidemiology (ENGAGE). Being part of ENGAGE, a number of collaborations were involved in 
this project. Under an agreement, our team from Northern Finnish Birth Cohort (NFBC) data 
has taken the leading role. To gain the knowledge in GWAS and meta-analysis, I was 
involved in this project as the main statistical analyst and contact person. Even though some 
GWAS meta-analysis studies were conducted by 2008 when our project started, the 
systematic and robust meta-analysis pipeline was later published [Zeggini and P.A.loannidis 
2009]. In addition to the meta-analysis pipeline, many issues specific to each data set are 
needed to be considered case by case. Therefore, this chapter provides in depth 
investigations through the process that lead to discussion and decisions in the project. As a 
result of this project, we found autism susceptibility candidate 2 gene (AUTS2) attained 
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genome-wide significance when results from discovery and replication stage are combined. 
In addition, AUTS2 shows supporting evidences from functional studies. This work was 
published in PNAS [Schumann, et al. 2011] where this chapter reflects those results with 
more in depth investigations through the process. 
 
2.2 Background of genetics studies in alcohol consumption 
 
Alcohol drinking is highly prevalent in many countries. The top ten countries of alcohol 
consumption are all in Europe. These top ranks include Luxembourg, Hungary, Czech 
Republic, and Ireland with the consumption of pure alcohol ranged from 10.8 litres to 12.6 
litres per year. Alcohol use causes many problems to society, e.g. car accidents, criminal 
damage, and suicide, as well as harms personal health as it links to a number of diseases, 
e.g. cancers, obesity, and cardiovascular diseases. 
 
Drinking alcohol is a type of ethyl alcohol or ethanol. Once alcohol enters the body, it is 
absorbed almost immediately into the bloodstream and later metabolised mainly in the 
liver. Alcohol is first converted into acetaldehyde by the enzyme alcohol dehydrogenase 
(ADH) and then acetaldehyde is converted to acetate by the enzyme aldehyde 
dehydrogenase (ALDH). If acetaldehyde is not converted to acetate, the acetaldehyde is 
accumulated and this causes increasing blood flow to the skin e.g. face, neck, and chest, 
rapid heartbeat, headache, and drowsiness. 
 
There have been a number of studies investigating genetics of alcoholism. In family studies, 
it has been shown that there is 3-4 fold prevalence of alcohol dependence among first-
degree relatives compared to the general population. To further explore whether the effect 
found in family studies is mainly genetic or through the shared environment, several studies 
further used the twin and twin adoption data. Moderate or high genetic influences on being 
alcoholic have been shown in twin studies. In addition, this was further explored in adoptive 
studies. The incidence of being alcoholic in twins whose biological fathers were alcoholic is 
shown to be much higher, regardless of the presence of alcoholism in their adoptive families 
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[Matt McGue 1999, Sher et al. 2005, Messas & Vallada Filho 2004]. This further supports the 
genetic evidence of alcoholism. 
 
It has been shown that the risk of being alcoholic is associated with genes involved in 
ethanol metabolism and genes related to central nervous system functioning. The mutation 
at ALDH2 which results in inactivate ALDH2 was found as the protective gene in Asian ethic 
origin [Messas and Vallada Filho 2004] through unpleasant symptoms from drinking. As this 
genetic variation is rare in Europeans, they mostly do not have this protective effect. 
Disulfiram is a drug that has been used to prevent alcoholism. It inactivates the ALDH gene, 
therefore the effects of alcohol occur rapidly and thus prevent the further drinking. The 
variations in ADH2 and ADH3 were also shown to affect the risk of developing alcoholism 
[Sher, et al. 2005]. On a different pathway, the genes related to central nervous system 
functioning, were also in an interest as they could reflect the structured patterns of 
behaviour to alcohol consumption. The variations in the genes involving dopamine 
receptors have been shown to be associated with alcohol dependence [Messas and Vallada 
Filho 2004]. The dopamine receptors are the receptors found in the central nervous system. 
The dopamine receptors are known to have possible roles in impulsive behaviours, brain 
rewarding system, regulation of emotions, attention/hyperactive disorder, craving, and 
novelty searching personality. 
 
In contrast to alcohol dependence, little is known about the underlying genetics of alcohol 
consumption in general population although it has been reported that the heritability of 
alcohol consumption is estimated to be approximately 40% [Kaprio, et al. 1987]. Due to the 
alcohol consumption available in a large number of studies in the ENGAGE, we conducted 
the first and, so far, the largest GWAS study to investigate this underlying genetic in alcohol 
consumption. In addition, the known gene families of ADH and ALDH in alcohol dependence 
will be further checked to see whether these genes also have some effects to the alcohol 
consumption. 
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2.3 Data 
 
Being part of ENGAGE, twelve cohorts which have the measurement of alcohol consumption 
and genome-wide data were participated in this study. The total number of 26,316 
individuals was included with the genome-wide data of approximately 2.5 million directly 
genotyped or imputed SNPs for each individual. Seven additional cohorts with the total 
number of 21,185 individuals later provided the data for the replication stage.  
 
The amount of alcohol consumption was collected based on the study-specific 
questionnaires. The amount of alcohol consumption was converted into g/day intake 
divided by body weight (kg), to obtain the same unit of measurement in g/day/kg. Table 2.1 
summarises the data for all cohorts and  Figure 2.1 shows the project outline for the GWAS 
discovery stage, replication stage, clinical and functional studies.  
 
Quality control is used as a process to ensure the reliable results. Generally, quality controls 
are first applied within study to prevent systematic errors from poor quality samples or 
SNPs. As a regular routine, the quality control was generally done right after genotyping and 
imputation process therefore the level of QC stringency is down to cohort individual choice 
at the beginning stage. This includes the thresholds of missing rate of genotype calling at 
each SNP/at each individual, minor allele frequency, and Hardy-Weinberg Equilibrium (see 
Chapter1 for more details). For our alcohol consumption study, the reported QCs from all 
cohorts are similar where some thresholds are slightly different. This includes the Caucasian 
ancestry, imputation call rate between 0.9-0.95, minor allele frequency of 1%, the 
significant threshold of Hardy-Weinberg Equilibrium between 10-7 and 10-4.   
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Table 2.1. Sample size, country of origin and phenotypic characteristics of genome-wide 
association studies (GWAS) and replication samples 
Study (origin) 
 
N (% Women, % 
drinkers of all) 
 
Age, year (SD) Geometric mean of alcohol 
intake among drinkers 
g/day/kg 
  male female male  female 
GWAS (n=26,316)      
COLAUS (Switzerland) 4402 (48.6, 84.8) 53.1 (10.8)  54.0 (10.7) 0.15  0.10 
DESIR (France) 730 (74.8, 65.9) 53.1 (5.6) 49.3 (8.7) 0.24  0.10  
EPIC-Norfolk (UK) 2354 (53.4, 80.5) 59.9 (9.0) 58.7 (9.0) 0.09  0.06  
ERF (The Netherlands) 709 (46.4,83.2) 47.2 (14.4) 44.0 (13.9) 0.13  0.07  
ERGO (The Netherlands) 4606 (58.5, 79.5) 67.1 (7.2) 67.9 (8.0) 0.11  0.04  
KORA (Germany) 1633 (50.6, 70.8) 62.9 (10.1) 62.1 (10.0) 0.23  0.11  
LOLIPOP (UK) 1601 (23.2, 75.6) 53.8 (10.3) 51.3 (10.4) 0.24  0.16  
NFBC 1966 (Finland) 4445 (51.2, 90.6) 31.2(0.4) 31.2 (0.4) 0.10  0.04  
NTRNESDA
 
(The 
Netherlands) 
3711 (65.3, 90.6) 45.4 (13.6) 41.8 (13.4) 0.11 0.06 
SSAGA (Australia) 652 (100, 92.9) - 45.5 (12.1) - 0.02  
FTC (Finland)  110 (100, 100) - 50.6 (11.3) - 0.04  
TwinsUK (UK) 2086 (100,72) - 48.1 (11.8) - 0.09  
      
Replication (n=21,185)      
ARYA (The Netherlands) 747 (53.1, 100) 28.4 (0.9) 28.4 (0.9) 0.28  0.25  
EGPUT (Estonia) 1019 (49.4, 62.0) 44.2 (16.8) 45.4 (16.0) 0.09  0.03  
Prospect-EPIC (The 
Netherlands) 
1669 (100, 99.6) - 57.2 (6.1) - 0.02  
Fenland (UK) 1099 (55.5, 86.3) 44.4 (7.5) 44.9 (7.3) 0.10  0.08  
DESIR (France) 4084 (46.2, 76.9) 46.7 (10.2) 46.9 (10.3) 0.22 0.08 
UHP (The Netherlands) 2812 (52.5, 86.5) 40.8 (12.5) 39.3 (12.4) 0.13  0.08  
EPIC-Turin (Italy) 9755 (42.8, 91.5) 49.4 (7.7) 48.8 (7.3) 0.20  0.06  
      
_____________________________________________________________________________ 
Abbreviations: ARYA (The Atherosclerosis Risk in Young Adults), COLAUS (the Caucasian population of 
Lausanne, Switzerland), DESIR (Data from an Epidemiological Study on the Insulin Resistance syndrome), 
EGPUT (Estonian Genome Project of University of Tartu), EPIC: Norfolk, Prospect, and Turin (The European 
Prospective Investigation Into Cancer and Nutrition: in Norfolk region (UK), The Netherlands, and Turin region 
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(Italy)), ERF (Erasmus Rucphen Family), ERGO (The Rotterdam Study), Fenland (Regional study on population 
from Cambridgeshire in UK), FTC (Finnish Twin Cohort (FTC), KORA (Kooperative Gesundheitsforschung in der 
Region Augsburg), LOLIPOP (The London Life Sciences Population Study), NFBC1966  (Northern Finland Birth 
Cohort 1966), NTRNESDA (The Netherlands Twin Registry (NTR) and the Netherlands Study of Depression and 
Anxiety (NESDA)), SSAGA (the Semi-Structured Assessment for Genetics of Alcoholism), UHP (Utrecht Health 
Project).  
 
 
 
Figure 2.1. The alcohol project outline 
 
In addition to 19 cohorts which have continuous alcohol consumption after unit conversion, 
3 additional cohorts, that are Decode, Prevend, and Sorbs, have their questionnaires 
regarding alcohol consumption classified in categories (Table 2.2). To avoid any 
inconsistency with other cohorts with continuous phenotype, it was decided that these 3 
cohorts with categorical data are to be investigated separately. Results obtained from 
categorical data will only be used to observe the evidence of association of the replicated 
SNPs at the final stage. To allow results from categorical data to be compared with results 
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from continuous data, we convert these categorical data to continuous data such that the 
most possible consistency with the other 19 continuous data sets can be induced. 
 
More details for all cohorts can be found in an appendix, including information on 
genotyping platform, calling algorithm, genotype based exclusions, criteria to filter SNPs for 
imputation (e.g. thresholds of call rate, HWE, and MAF), the number of SNPs for imputation, 
imputation software, NCBI reference sequence, Hapmap reference, strand, and genotype-
phenotype association software. Questionnaires used in each cohort are listed however not 
all cohorts provide us this detail.  
 
Table 2.2. Sample size, country of origin and phenotypic characteristics of population-based 
samples with categorical data 
Study (origin) 
 
N (% Women, % 
drinkers of all ) 
 
Age, year (SD) 
 
male female 
 
Population based samples with categorical data 
  
DeCODE (Iceland) 10834 (66.9, 44.5) 58.9 (16.9) 52.2 (17.3) 
PREVEND (The Netherlands) 6308 (50.0, 74.6) 49.7 (12.8) 46.9 (11.6) 
Sorbs (Germany) 481 (59.2, 53.7) 48.0 (16.0) 45.6 (14.4) 
    
DeCODE (DeCODE Genetics), PREVEND (The Prevention of REnal and Vascular ENd stage Disease), the Sorbs 
study (Sorbs) 
 
2.4 Discovery stage 
 
Analyses of the genome-wide data were done using available software which is down to the 
cohort individual choice, which are SNPTEST [Marchini, et al. 2007], PLINK [Purcell, et al. 
2007] and GENABEL [Aulchenko, et al. 2007]. These software packages perform a 
quantitative trait association analysis on a single SNP as well as taking into account the 
imputation information at the imputed SNP. Each single SNP was regressed with 
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quantitative phenotype under an additive genetic model which assumes carriers of 2 risk 
alleles have twice the risk compared to carriers of 1 risk allele. The analyses were stratified 
by cohort and gender. The analysis was stratified by gender because adoption studies have 
provided evidence of possible sex differences in the heritability of alcoholism [Prescott 
2002]. Therefore, there may be the case that, for some genetic variants there are different 
effects between genders, that is, genetic effects calculated from males alone and females 
alone may be significantly different from each other and thus also from genetic effects 
calculated from males and females combined. Therefore, as well as performing analyses in 
the combined male and female data, we also perform analyses stratified by gender. 
Subsequently, we observed evidence of heterogeneity in the true genetic effects between 
genders in our most associated SNPs, which may be explained by interactions between SNPs 
and gender (see section 2.7.3).  In addition, our data includes both drinkers and non-
drinkers, so we decided to investigate this based on two groups of data, with the first group 
including only drinkers and the other group including both drinkers and non-drinkers. The 
reason that non-drinkers are included/excluded to make 2 groups of data is because it is 
possible that there are non-genetic reasons for people deciding not to drink, e.g. cultural, 
religious, health or social reasons. If this is the case, there is less noise to investigate an 
underlying genetic when non-drinkers are excluded, whereas if this is not the case, we will 
lose power due to the decrease of sample size. Therefore, both cases are considered and 
thus each cohort performed 4 association analyses in total for 1) male drinkers, 2) female 
drinkers, 3) male drinkers and male non-drinkers, and 4) female drinkers and female non-
drinkers. Note that, in our analysis where a large number of non-drinkers are included, it 
might be argued that linear regression might not be the best model to use due to the 
potential deviation of residual normality. Instead, it might be more appropriate to 
investigate this data by comparing non-drinkers with drinkers where logistic regression 
analysis can be applied. However, due to our original objective to investigate the genetics 
effect for the continuous amount of alcohol consumption in g/day, we applied linear 
regression, and if genetics play a role in non-drinking behaviour then analysing drinkers and 
non-drinkers together makes sense. Therefore, to reduce the potential deviation of residual 
normality when including non-drinkers, we apply what we consider the most powerful 
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strategy by using an INT (see 2.4.1.3 for how INT is performed). Nevertheless, to further 
investigate under the genetic determinants of alcohol consumption in a case-control setting, 
we have also been collaborating with CHARGE consortium (Cohorts for Heart and Aging 
Research in Genomic Epidemiology) to explore genetics influencing low and high alcohol 
consumption (not included in this thesis).  Next, I will describe further investigations that 
have been done at the discovery stage. These investigations are described as before and 
after association analysis stage. 
 
2.4.1 Investigations before association analysis stage 
 
For the investigations before association analysis stage, first phenotype distributions across 
cohorts are visually checked to detect any obvious inconsistency between studies’ 
distribution. The second investigation is to investigate an approach to convert alcohol intake 
shown as categorical data into continuous data but yet maintain the most possible 
consistency with the other continuous alcohol intake data. Lastly, an investigation is on the 
choice of phenotype transformations for right-skewed distribution observed under alcohol 
intake to induce the normality before applying linear regression.  
 
2.4.1.1 Checking phenotype distributions between studies 
 
The first systematic checking was embedded in the R-script which was distributed to 
collaborators at the same time as the analysis plan. The R-script is used to transform 
phenotypes based on all models requested (see Phenotype transformation section below) 
which can directly corporate into an input file for association analysis software. In addition, 
it outputs histograms of non-transformed and log-transformed phenotype as well as reports 
the summary of statistics for the purpose of systematic checking. These summary of 
statistics (Table 2.1) and histograms were used as a rough check for the similarity and 
dissimilarity between cohorts. Across all 19 cohorts, we did not observe notably inconsistent 
histograms. All cohorts have right-skewed distributions due to the fact that there are less 
people at the higher drinking levels.  After log-transformation, the normality is induced to all 
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phenotype distributions where log of alcohol intake greater than -1 is observed in all 
cohorts. 
 
The best example of identification of such problems via comparison of phenotype 
distribution in fact comes from a follow-up study to the one described in this chapter, 
involving additional data sets including the ‘Young Finn’ and ‘HBC’ sets (both from Finland). 
These two studies show negative values of up to -3 under logarithmic scale (Figure 2.2). This 
implies that those studies’ questionnaires allow the alcohol intake measurement in a fine 
scale, that is, as low as 0.001 g/day. We later check and found that those individuals were 
reported to have only chocolate liquor therefore the very small amount of alcohol 
consumption can be detected. However, in other studies whose questionnaire is focused on 
a standard unit of alcohol intake, e.g. a glass unit, individuals consumed this very small 
amount of alcohol are instead treated as non-drinkers. This could later add an inconsistency 
in the analyses, for example these small drinkers are included in the analyses which concern 
only drinkers whereas they should be excluded based on the other studies’ criteria. 
 
 
Figure 2.2. Histograms of alcohol consumption (g/day) in Helsinki Birth Cohort (HBC) and 
Young Finns Study (YFS) 
 
49 
 
2.4.1.2 Categorical data 
 
A simple approach to convert alcohol intake shown as categorical data to continuous data is 
to take the mid-point of each category as individual’s drink [Key, et al. 2006]. However, the 
mid-point estimation might not be an appropriate value to use because alcohol 
consumption is not uniformly distributed. Instead of using the mid-point in each category, 
an appropriate point which is more closely reflected the actual mean of each category 
should be identified. This was investigated using the alcohol consumption distribution from 
NFBC1966 which is an ‘in-house’ data set only available to us. 
 
Figure 2.3 shows a diagram of the proposed approach to identify an appropriate mean 
values within categories. First, the cohort with categorical data is used as a reference 
categorical data. Alcohol consumption in NFBC1966 is then classified by the same number of 
reference categories. Firstly, non-drinkers are excluded from both reference and NFBC1966 
data. Then, to identify the breakpoints of categories in NFBC, the percentage of samples fall 
into ith reference category is calculated (Ci %). Next, the alcohol consumption in NFBC1966 is 
classified under these percentages to obtain the breakpoints of its ith category, i.e. [mini, 
maxi]. Now that the NFBC1966 alcohol consumption is classified into the same number of 
categories, this is then used to investigate where the actual mean value, , lies within each 
category. The actual mean value can be calculated in terms of the fraction of from mini 
(i.e. – mini) to the total distance (maxi – mini) as below. 
 
fi = ( – mini)/(maxi – mini). 
 
For the last category which has no upper bound, the width of the previous category is used, 
 
fi = ( – mini )/(maxi-1 – mini-1).   
 
i
x
i
x
i
x
i
x
i
x
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Based on the assumption that the shapes of alcohol intake distributions under the same 
percentage range in reference categories and NFBC1966 categories are the same, these 
fractions of total distance from the lower bound in each NFBC1966 category can be used as 
an appropriate point to calculate the mean value within reference categories instead of the 
mid-point approach.  
 
 
Figure 2.3. An approach to identify average values within categories. 
 
An example is shown using data from Prevend. In Prevend’s questionnaire, alcohol 
consumption is classified into 5 categories as shown in Table 2.3. By using the percentages 
of samples in each of 5 reference categories, the breakpoints of ith category in NFBC1966 
can be calculated. These breakpoints in NFBC1966 are shown to have similar range of 
alcohol consumption in Prevend (Table 2.4). The fraction of total distance, fi, are 0.44, 0.40, 
0.35, and 1.2 (all), 0.48, 0.44, 0.39, 1.46 (male), and 0.43, 0.39, 0.26, 0.73 (female). Thus, 
instead of the mid-point estimate, the estimates for each category in Prevend based on 
NFBC1966 distribution are shown in Table 2.5. 
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Table 2.3. Alcohol consumption in Prevend  
Questionnaire : 
alcohol 
consumption 
Samples in each 
category  
(ci %) 
Average age (years) 
all male female 
No, almost never 25% 18% 33% 51 
1 to 4 drinks per 
month 
15% 12% 19% 48 
2 to 7 drinks per 
week 
35% 37% 31% 47 
1 to 3 drinks per day 20% 25% 15% 50 
>= 4 drinks per day 5% 8% 2% 50 
 
 
Table 2.4. Similar range shown in NFBC1966 identified breakpoints compared to Prevend 
Category breakpoints in 
NFBC1966 in g/day ( ) 
PREVEND  
(10g alcohol/drink) 
all male female  
0.1-1.3 (0.6) 0.1-2.1 (1.1) 0.1-1.2 (0.6) 0.3-1.3 
1.3-8.6 (4.2) 2.1-11.6 (6.2) 1.2-6.4 (3.2) 2.9-10 
8.6-30.9 (16.4) 11.6-32.9 (19.9) 6.4-27.2 (11.8) 10-30 
> 30.9 (57.4) >32.9 (64.1) >27.2 (42.5) >40 
 
 
 
 
 
 
 
i
x
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Table 2.5. Comparison between mid-point estimates and estimates based on NFBC1966 
distribution for Prevend categorical data 
Questionnaire : 
alcohol 
consumption 
Mid-point 
estimates 
g/day 
Estimates based on NFBC 
all male female 
1 to 4 drinks per 
month 
0.82 0.77 0.8 0.76 
2 to 7 drinks per 
week 
6.45 5.7 6 5.63 
1 to 3 drinks per 
day 
20 16.9 17.8 15.1 
>= 4 drinks per 
day 
- 63.5 69.7 53.3 
 
2.4.1.3 Phenotype transformation 
 
An alcohol intake phenotype is a quantitative trait including zero values from non-drinkers. 
It has right-skewed distribution as there are less people at the higher drinking levels. Due to 
the skewness in alcohol consumption distribution, phenotype normalisation is required 
before applying linear regression in association analyses to induce normality. Logarithm is 
generally used in phenotype transformation because it allows interpretable results in linear 
regression, that is, the percentage change of outcome per unit change of predictor. In the 
data including drinkers only, LT improves normality in NFBC1966 (Figure 2.4), therefore it 
was applied to all other cohorts for drinkers-only data.  
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Figure 2.4. The histograms of alcohol consumption (g/day/kg) and log-transformed alcohol 
consumption. Note that the unit used in this figure (g/day/kg) is different from the unit 
shown in Figure 2.2 (g/day). 
 
If log was to be used to transform data where non-drinkers are included, a small positive 
number can also be added to shift the distribution and avoid taking log of zero. However, 
the choice of numbers to be added and the effect of transformation after this shifted 
distribution are not clear from the literature. Therefore, inverse normal transformation (INT) 
which has been previously used in GWAS as an alternative transformation [Gudbjartsson, et 
al. 2008; Sanna, et al. 2008] was applied. In our study, LT and INT were applied as the main 
transformations in the analyses when LT is applied to data including drinkers and INT is 
applied to data including both drinkers and non-drinkers. To apply INT, we ranked 
individuals according to intake (grams per day per kilogram) and performed the data 
analyses using the resultant study-specific quantiles. Individuals were ranked 1, 2, ... , 
N within each population sample according to intake. We calculated, for each percentage 
rank, the quantile value under a unit normal distribution, which was then treated as a 
quantitative variable in subsequent analyses. Where intake was tied, each individual was 
randomly assigned a relative rank, and the mean of their quantile-transformed values was 
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used. For example, if there were M non-drinkers in the cohort, the ranks 1, 2, ... , M were 
randomly assigned (without replacement) to each of the non-drinkers.  
 
The lack of guidance in the literature on which transformation optimises subsequent 
statistical power in association testing, in particular in the GWAS setting, motivated a 
detailed investigation comparing the statistical power of different transformations, which 
later forms Chapter 3. 
 
 
2.4.2 Investigation after association analysis stage  
 
When results from all cohorts are sent to us, we further look into investigations after 
association analysis stage. Firstly, results from all cohorts are systematically accessed. By 
accessing results across cohorts, we expect to spot, if there is any, the cohort which has 
overall results notably different from the others. This evidence could reflect some 
underlying problems within the cohort and thus its results should be revisited or excluded 
before meta-analysis stage. As an example of an extreme case, if there is one study 
accidentally incorrectly convert the unit to g/week/kg or g/day/g instead of the defined unit 
of g/day/kg, we would expect this cohort to produce different sized effect estimates 
(regression coefficients) compared to others. However, there are no systematic approaches 
for detecting all results between studies and therefore, in this section, this issue was 
investigated. The second investigation after association analysis stage is to explore how to 
systematically perform meta-analysis for GWAS data because, at the beginning of the 
project, there was no such software available. Therefore, I involved in developing a 
software, called Metamapper, to systematically perform meta-analysis for GWAS data and 
in addition integrated with visualisation tools which can provide better data interpretation. 
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2.4.2.1 Principal Component Analysis on z-statistics in all SNPs across studies 
 
The Principal Component Analysis (PCA) has been widely used as a tool to understand the 
internal structure of the high dimension data which is difficult to visualize.  As a result of 
much of the variation in a set of correlated variables being explained by the top principal 
components, high dimensional data can be observed by inspecting a much smaller number 
of dimensions and thus the main structure under the reduced dimension can be easily 
observed. (see Section 1.3.3).  
 
Each of reported association analysis results, including effect sizes (Beta), standard errors 
(SEbeta) of effect sizes, z-score, and P-values, in approximately 3 million genotyped and 
imputed SNPs from all cohorts are accessed using PCA. By doing this, cohorts with similar 
overall result are expected to cluster together while those with markedly different result 
can be seen as outliers. For the outlier cohort which contains markedly different result, it 
should be carefully investigated what causes its extreme result and whether it should be 
revisited/excluded before the meta-analysis.   
 
Before applying PCA, the same set of SNPs across studies is required. The set of QCed SNPs 
can be different between studies because imputation quality at the same SNP can be 
different. Therefore, to have the same set of SNPs across studies, only the QCed SNPs 
available in all cohorts are selected. In addition, if there are a large number of highly 
correlated SNPs which reflect in unusually long stretches of LD, this can highly influenced 
the PCs such that they are no longer well captured the structure from overall results that we 
are interested in. Therefore, to minimize the impact of LD, one SNP in every 100kb is only 
used to perform PCA. 
 
By applying PCA on SEbeta, it is likely that sample size can have a large contribution to the 
variation of SEbeta between cohorts across SNPs, that is, the larger cohorts are likely to have 
overall smaller variation of SEbeta compared to smaller cohorts. Therefore, under PCA of 
SEbeta, it is likely that the reduced dimensions can group cohorts together based on their 
sample sizes. As the variation of Beta is shown by SEbeta
 value, the variation of Beta between 
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cohorts across SNPs should be highly reflected by SEbeta. The larger cohorts, which are likely 
to have smaller SEbeta
 value, should reflect in an overall smaller variation of Beta compared 
to smaller cohorts. Thus, similarly, under PCA of Beta, it is likely that cohorts are grouping 
together based on the sample size. If instead there is a cohort with similar sample size lying 
outside the group, this may highlight that this cohort has an incorrect phenotype unit which 
reflect in the deviation of overall Beta and SEbeta and thus should be carefully investigated. 
As expected when applying PCA on SEbeta (Figure 2.6), most studies are clustered together, 
but there are four outlier studies, which are FTC (n=110), LOLIPOP_EW_A (n=439), 
LOLIPOP_EW_P (n=517) and DESIR (n=730). However, these are among the studies with the 
smallest sample sizes and this therefore most likely explains their departure from the main 
cluster. On the first inspection of Figure 2.5, LOLIPOP_EW_P might be the only cohort that is 
visually distinguished from the other cohorts because of PC3, however, under PC1 and PC2,  
FTC, LOLIPOP_EW_A, and DESIR are distinguished from the main cluster. This structure 
based on sample size can be clearly observed using PCA on SEbeta. Similarly, the same studies 
also lie out of the main cluster when PCA was applied to Beta (Figure 2.6).  
 
The reported P-values and z-scores are expected to give clearer insight to any outlier results 
across studies because they are not affected by sample size. Though, applying PCA on P-
value and z-score is not expected to detect incorrect units for the phenotype because they 
have no unit. Due to the fact that most SNPs are not associated with the phenotype, P-value 
is expected to be uniformly distributed and z-statistics is expected to be normally 
distributed. Any deviation from these expected distributions of P-values or z-statistics across 
studies was hoped to be spotted under PCA. Nevertheless, no outlier can be observed under 
reported P-values (Figure 2.7) and z-scores (Figure 2.8). This may imply that the reported 
results from all studies are adequately consistent.  
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Figure 2.5. 3D-score plot of PCA on effect-size standard deviations 
 
 
Figure 2.6. 3D-score plot of PCA on effect sizes 
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Figure 2.7. 3D-score plot of PCA on P-values 
 
 
Figure 2.8. 3D-score plot of PCA on z-scores 
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2.5 Discovery meta-analysis 
 
Daily alcohol intake in genome-wide data from 26,316 individuals in 12 populations, with 
and without exclusion of 4,814 non-drinkers, was then meta-analysed. The result from each 
cohort was adjusted for inflation due to population stratification using genomic control. An 
inverse variance weighted fixed effects model was used in the meta-analysis. Six meta-
analyses were performed, i.e. 1) male drinkers, 2) female drinkers, 3) male and female 
drinkers (sex-stratified), 4) male drinkers and non-drinkers, 5) female drinkers and non-
drinkers, 6) male and female drinkers and non-drinkers (sex-stratified). At the time, there 
was no software to systematically perform meta-analysis therefore we developed an in-
house developing program, called Metamapper, to combine these data. 
 
Meta-analysis software (Metamapper) 
At the early stage of GWAS meta-analysis, there was a supporting built-in function, called 
metagen in R, to perform meta-analysis at a single SNP 
(http://rss.acs.unt.edu/Rdoc/library/meta/html/metagen.html). However, this built-in 
function might not be an efficient approach to perform meta-analysis in GWAS data because 
additional R commands are required to corporate metagen function to perform meta-
analysis across all SNPs in genome-wide scale. In addition, to perform meta-analysis analysis 
on a large number of SNPs, R can be very time consuming.  
 
One of critical steps after obtaining results is the accurate annotation of the potential 
functional effects at associated SNPs. There is a wealth of accumulated information in 
publicly available databases, however accessing this information can be time consuming. In 
addition to the functional effect annotation at associated SNPs, this annotation from nearby 
SNPs within the same LD should also be investigated. This may further reveal potential 
interesting SNPs within LD with the functional role (e.g. non-synonymous, upstream, and 
downstream) to the causal variant due to an indirect association. 
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Due to the lack of software to systematically perform meta-analysis for GWAS data, my 
supervisor and I developed Metamapper to simplify GWAS meta-analyses together with 
integrated visualisation tools to automatically annotate meta-analysis results. In 
Metamapper, I included two meta-analysis models into Metamapper, that is, an inverse 
variance meta-analysis (IV) and weighted-Z meta-analysis (WZ), as well as testing the 
software on the real data. In the IV meta-analysis, both fixed and random effects models are 
included. Metamapper was used in our alcohol intake project as well as in two published 
papers [Freathy, et al. 2010; Pillas, et al. 2010]. 
 
To test the software, Metamapper was applied with a subset of CRP data [Elliott, et al. 2009] 
which were allowed to assess in the department. There are 11,768 individuals from 3 
cohorts which are directly genotyped and imputed to give 2,500,000 SNPs. When 
considering fixed and random effect models obtained using Metamapper and metagen in R, 
the same P-value was found. Moreover, I have a closer look to the CRP result by comparing 
with the result previously reported [M.Ridker, et al. 2008].  After adjusting for genomic 
control within each cohort using a fixed effect model, P-values of reported hit SNPs vs ours 
are both highly significant; rs1205 in CRP, 5.47x10-20 vs 7.33x10-30; rs3091244 in LEPR, 
1.53x10-15 vs 3.17x10-12; rs4129267 in IL6R, 9.33x10-6 vs 1.14x10-10; rs7310409 in HNF1A, 
4.63x10-8 vs 3.90x10-22.  In Figure 2.9, although the most associated SNP is intronic to IL6R 
(rs4129267: top blue right-triangle), the second most associated SNP (rs8192284: top red 
square), which has r2 greater than 0.8 to the top SNP, is non-synonymous coding and hence 
it has the potential to be the causative SNP. Thus, this SNP should be further explored. This 
example shows an advantage of data visualization built-in Metamapper which can provide 
better data interpretation. 
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Figure 2.9. Regional manhattan plot for rs4129267 in IL6R gene. SNPs are plotted by 
chromosomal position (NCBI build36) against association with CRP (-log10 P-value). SNP 
location in the gene are shown in symbols: non-synonymous, square; intronic, right triangle; 
left triangle, stop gained or stop lost; upside-down triangle, intergenic; horizontal rectangle, 
upstream or downstream; vertical rectangle, three prime UTR or five prime UTR. SNPs 
surrounding the most significant SNP, rs4129267, are colour coded (taken from pairwise R2 
values from the Hapmap CEU database): >0.99, blue; 0.8-0.99, red; 0.5-0.8 orange; 0.2-0.5, 
pink; 0.1-0.2, yellow; 0-0.1, white. 
 
2.6 Replication stage 
 
The candidate SNPs were selected based on top SNP from each analysis as well as nearby 
intragenic SNPs to further search for genes of potential interest. These candidate SNPs from 
the discovery stage were carried out to further investigate in 7 independent studies of 
21,186 individuals that had continuous data on alcohol consumption. Four studies, i.e. 
ARYA, UHP, TURIN, and D.E.S.I.R, are directly genotyped at these candidate SNPs, and the 
other studies provide in silico replication. Having raw data from three replication studies, I 
have done association analyses in these replication cohorts. All results from candidate SNPs 
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were meta-analysed using an inverse variance weighted fixed effect model in Metamapper. 
These meta-analysis results at the replication stage were later combined with results from 
the discovery stage to investigate the overall association results at these candidate SNPs. 
 
2.7 Results 
2.7.1 Discovery stage 
 
After combining all association results which were adjusted for genomic controls (Table 2.6) 
under 6 models, we did not observe an evidence of association signals that reach the GWAS 
P-value threshold of 5x10-8 (Figure 2.10).  This could be because an inaccurate alcohol 
measurement which leads to “noisy data”, and modest/low genetic effect which are less 
likely for associated SNPs to achieve the stringent GWAS threshold. We decided to select 
SNPs for replication due to either being the top ranked SNP from the GWAS for each of the 6 
models or being the second or third ranked independent SNP (> 200kb away) close to a gene 
with strong biological support. In details, to identify the second or third ranked independent 
SNP, we removed all SNPs within 200 kb of the top-ranked SNP in each analysis and then 
identified the most significant remaining association as the second-ranked SNP. We 
reapplied this procedure to further identify the third-ranked associated SNP. Based on this 
process 6 top ranked SNPs were selected (amongst drinkers: males, females and overall: 
rs26907 in RASGRF2, rs16823039 near OTUD3, and rs2985678 near CDYL respectively (Table 
2.8), and amongst drinkers and non-drinkers: rs6104890 in SDCBP2, rs8090940 near NETO1, 
and rs4500065 near CPA6 respectively (Table 2.9)) as well as rs6943555, which was a third 
ranking SNP in the AUTS2 gene, implicated in brain function. The details of these 7 SNPs are 
shown in Table 2.7. 
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Table 2.6. Inflation factors for analyses of males and females 
Study 
Inflation factor 
Drinkers 
Drinkers/non-
drinkers 
Male Female Male Female 
COLAUS (Switzerland) 1.01 1.01 1.02 1.01 
DESIR (France) 1.01 1.03 1.00 1.01 
EPIC-Norfolk (UK) 1.00 1.01 1.00 1.00 
ERF (The Netherlands) 1.00 1.00 1.00 1.00 
ERGO (The Netherlands) 1.02 1.02 1.02 1.04 
FTC (Finland)  1.01  1.00 
KORA (Germany) 1.00 1.01 1.00 1.00 
LOLIPOP NE-Affy (UK) 1.02 1.03 1.02 1.03 
LOLIPOP NE-Perlegen (UK) 1.01  1.03  
NFBC 1966 (Finland) 1.00 1.01 1.02 1.02 
NTRNESDA (The Netherlands) 1.01 1.00 1.00 1.00 
SSAGA (Australia)  1.05  1.05 
TwinsUK (UK)  1.00  1.01 
Table 2.7. Genomic context, minor allele and minor allele frequency for candidate SNPs 
SNP 
Chr. Nearest gene (bp) Context Minor 
allele 
Frequency of 
minor allele (%) 
rs16823039 1 OTUD3 (24351) Intergenic C 11 
rs26907 5 RASGRF2 (0) Intronic A 17 
rs2985678 6 CDYL (4645) Downstream T 28 
rs6943555 7 AUTS2 (0) Intronic A 24 
rs4500065 8 CPA6 (40136) Intergenic C 12 
rs8090940 18 NETO1 (68467) Intergenic A 29 
rs6104890 20 SDCBP2 (612) Intronic T 16 
Minor allele and frequency of minor allele estimated in four cohorts, COLAUS, ERGO, NFBC, 
and Turin (>4000 samples in each cohort).  
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Figure 2.10. Q-Q plots in drinkers in a) male, c) female, and c) male and female, and Q-Q 
plots in drinkers and non-drinkers in d) male, e) female, and f) male and female. 
2.7.2 Replication stage 
 
For these seven candidate SNPs, we carried out direct genotyping replication in 4 
independent cohorts and in silico replication in 3 independent cohorts of the total size 
21,186.  All results from 7 candidate SNPs were then meta-analysed using an inverse 
variance weighted fixed effect model. Although the SNPs were selected based on their 
results in only one of the 6 models, we test each one using all models at the replication 
stage.  
 
We first set significance level for replication at 7x10-3 following Bonferroni adjustment 
where there are 7 independent tests under the nominal significance threshold of 0.05. 
Among 6 candidate SNPs chosen as the top SNP from each analysis, only rs6943555 which 
was selected from the consecutive ranking regions with the potential biological function 
attained P=6.9x10-6 in males and females combined, among drinkers and P=1.2x10-3 in 
analyses including non-drinkers (Table 2.8 and Table 2.9). In addition, some suggestive 
association signals can be observed in rs26907. Rs26907 which gave P-value of 1x10-7 in 
male drinkers at the discovery stage was attained P-value 0.024 at the replication stage in 
male drinkers only and P=0.02 in analyses including male non-drinkers (Table 2.8 and Table 
2.9).   
 
Results at the candidate SNPs in all 19 studies from GWAS and replication were together 
meta-analysed. Two of the candidate seven SNPs were attained approximate genome-wide 
significance of 5x10-8. For rs6943555, males and females combined, overall P=4.1x10-9 
among drinkers and P=4.2x10-8 in analyses including non-drinkers; for rs26907, overall 
P=5.2x10-8 for male drinkers only (Table 2.8 and Table 2.9).  
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Table 2.8. P-values in discovery GWAS meta-analysis, replication samples and overall, and 
effect sizes (percentage change per minor allele obtained from overall stage) in replication 
cohorts, for analyses among drinkers 
   P-values  
Effect% (95%CI) 
SNP Nearest gene Discovery Replication Overall 
Male      
rs16823039 OTUD 1.3x10
-02 
7.0 x10
-01 
3.4x10
-01 
-0.5
 
(-3.1,2.2) 
rs26907 RASGRF2 1.0x10
-07 
2.4x10
-02 
5.2x10
-08 
-4.6 (-8.5, -0.6) 
rs2985678 CDYL 1.4x10
-03 
9.4x10
-01 
5.9x10
-02 
-0.1(-2.7, 2.5) 
rs6943555 AUTS2 1.0x10
-03 
1.4x10
-01 
7.5x10
-04 
-2.5(-5.7, 0.8) 
rs4500065 CPA6 1.9x10
-02 
4.1x10
-01 
4.5x10
-02 
1.1(-1.5, 3.8) 
rs8090940 NETO1 9.3x10
-01 
5.7x10
-01 
6.2x10
-01 
0.8 (-1.9, 3.4) 
rs6104890 SDCBP2 3.7x10
-02 
9.1x10
-01 
6.3x10
-02 
4.6
 
(-7.5,9.1) 
      
Female      
rs16823039
2 
OTUD 2.3x10
-06 
3.6x10
-01 
2.3x10
-04 
-1.4(-4.5,1.7) 
rs26907 RASGRF2 8.8x10
-01 
9.7x10
-01 
8.9x10
-01 
0.1(-4.2, 4.5) 
rs2985678 CDYL 2.3x10
-04 
4.5x10
-01 
4.9x10
-02 
1.2(-1.8, 4.3) 
rs6943555 AUTS2 2.2x10
-02 
1.5x10
-07 
4.5x10
-07 
-9.2(-12.4, -5.9) 
rs4500065 CPA6 1.1x10
-02 
4.2x10
-01 
2.2x10
-02 
1.3(-1.8, 4.4) 
rs8090940 NETO1 3.1x10
-04 
7.7x10
-01 
3.8x10
-03 
0.5(-2.5, 3.5) 
rs6104890 SDCBP2 4.2x10
-01 
1.3x10
-01 
9.3x10
-01 
-4.7(-10.3,1.3) 
      
Male and Female
 
    
rs16823039 OTUD 5.3x10
-02 
5.1x10
-01 
1.0x10
-01 
-0.7(-2.7,1.4) 
rs26907 RASGRF2 7.4x10
-04 
8.7x10
-02 
2.2x10
-04 
-2.6(-5.5, 0.4) 
rs2985678 CDYL 1.1x10
-06 
5.7x10
-01 
8.4x10
-03 
0.6(-1.4, 2.6) 
rs6943555 AUTS2 1.1x10
-04 
6.9x10
-06 
4.1x10
-09 
-5.5(-7.8, -3.1) 
rs4500065 CPA6 5.3x10
-04 
2.4x10
-01 
2.3x10
-03 
1.2(-0.8, 3.2) 
rs8090940 NETO1 4.6x10
-03 
4.9x10
-01 
1.4x10
-02 
0.7(-1.3, 2.7) 
rs6104890 SDCBP2 5.8x10
-02 
2.2x10
-01 
3.0x10
-01 
-3.1(-7.9,1.9) 
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Table 2.9. P-values in discover GWAS meta-analysis, replication samples and overall, and 
effect size (percentile rank change per minor allele obtained from overall stage) in 
replication samples, for analyses including non-drinkers 
   P-values  Percentile rank change 
(95%CI) SNP Nearest gene Discovery Replication overall 
Male      
rs16823039 OTUD 2.5x10
-02 
5.4x10
-01 
5.2x10
-01 
-0.0032 (-0.0134, 0.0070) 
rs26907 RASGRF2 3.2x10
-05
 2.0x10
-02
 4.1x10
-06
 -0.0178 (-0.0328, -0.0028) 
rs2985678 CDYL 4.8x10
-03
 8.2x10
-01
 1.5x10
-01
 0.0012 (-0.0087, 0.0110) 
rs6943555 AUTS2 1.2x10
-03
 2.1x10
-01
 1.6x10
-03
 -0.0078 (-0.0199, 0.0043) 
rs4500065 CPA6 3.1x10
-04
 7.2x10
-01
 2.1x10
-02
 0.0019 (-0.0081, 0.0119) 
rs8090940 NETO1 7.0x10
-01
 6.5x10
-01
 5.6x10
-01
 0.0022 (-0.0075, 0.0120) 
rs6104890
2
 SDCBP2 5.9x10
-06
 9.9x10
-01
 9.5x10
-05
 0.0002 (-0.0300, 0.0305) 
      
Female      
rs16823039 OTUD 2.0x10
-02 
4.6x10
-01 
4.1x10
-02 
-0.0042 (-0.0150, 0.0067) 
rs26907 RASGRF2 3.2x10
-01
 7.4x10
-01
 5.7x10
-01
 -0.0025 (-0.0171, 0.0122) 
rs2985678 CDYL 6.1x10
-02
 5.4x10
-01
 4.0x10
-01
 0.0033 (-0.0072, 0.0139) 
rs6943555 AUTS2 1.9x10
-03
 4.0x10
-04
 3.4x10
-06
 -0.0215 (-0.0468, 0.0038) 
rs4500065 CPA6 7.5x10
-04
 6.3x10
-01
 9.7x10
-03
 0.0026 (-0.0081, 0.0134) 
rs8090940 NETO1 5.3x10
-07
 6.6x10
-01
 5.9x10
-05
 0.0023 (-0.0080, 0.0126) 
rs6104890 SDCBP2 9.1x10
-01
 4.5x10
-01
 6.5x10
-01
 -0.0085 (-0.0306, 0.0136) 
      
Male and Female     
rs16823039 OTUD 6.9x10
-01 
4.6x10
-01 
4.0x10
-01 
-0.0028 (-0.0103, 0.0046) 
rs26907 RASGRF2 6.4x10
-02
 5.5x10
-02
 7.9x10
-03
 -0.0104 (-0.0209, 0.0002) 
rs2985678 CDYL 1.3x10
-03
 5.0x10
-01
 1.3x10
-01
 0.0025 (-0.0047, 0.0097) 
rs6943555 AUTS2 8.9x10
-06
 1.2x10
-03
 4.2x10
-08
 -0.0126 (-0.0281, 0.0030) 
rs4500065 CPA6 9.9x10
-07
 5.5x10
-01
 5.0x10
-04
 0.0023 (-0.0051, 0.0096) 
rs8090940 NETO1 2.5x10
-05
 4.9x10
-01
 6.2x10
-04
 0.0025 (-0.0046, 0.0096) 
rs6104890 SDCBP2 1.3x10
-02
 5.4x10
-01
 6.0x10
-02
 -0.0058 (-0.0242, 0.0126) 
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2.7.3 Summary of discovery and replication stages 
 
At the discovery stage, we did not observe strong signals that reach the GWAS P-value 
threshold of 5x10-8. As this could due to moderate/low genetic effect which limits 
associated SNPs to achieve the stringent GWAS threshold, we decided to select 7 candidate 
SNPs for replication based on criteria previously stated. These 7 candidate SNPs were 
further investigated in the replication stage where only rs6943555 achieves statistical 
significance after Bonferroni correction. This rs6943555 was later shown to attain genome-
wide significance at the overall stage after combining results from both discovery and 
replication stage. In addition, rs26907 was also attained genome-wide significance at the 
overall stage, however, only some suggestive association signal was observed at the 
replication stage.  
 
To further look into association signals obtained in rs6943555 and rs26907, the association 
plots created from Metamapper in both regions are shown in Figure 2.13. The highlighting 
region of association signals is shown around rs6943555 because rs6943555 lies in a 12 kb 
LD block (Figure 2.11). Nevertheless, the highlighting region of association signals is not 
observed around rs26907 because rs26907 is not in strong LD with other nearby SNPs 
(Figure 2.12). The effect sizes at these 2 SNPs are further shown in the forest plots to 
visualise underlying association signals obtained across cohorts. For rs6943555, most of the 
effects across cohorts is in the same direction (Figure 2.14 and Figure 2.16) therefore this 
gave the stronger signal when consider them together in the male and female combined 
analyses. The effect sizes of rs26907 show almost the same direction only in male drinkers 
under both GWAS and replication therefore this boosts the signal when combining all male 
drinkers results together. (Figure 2.15 and Figure 2.17). Evidence of heterogeneity in effect 
sizes between studies is observed in all combined male and female analyses for the SNPs 
(Figures 2.14-2.16) rs6943555 (including drinkers: p-value of heterogeneity test=0.047, 
including drinkers and non-drinkers: p-value of heterogeneity test=1.9x10-4), and rs26907 
(including drinkers: p-value of heterogeneity test=1.6x10-5, including drinkers and non-
drinkers: p-value of heterogeneity test=1.2x10-8). However, this evidence of heterogeneity 
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was not observed in almost all male only or female only analyses, except for rs6943555 in 
the analysis including drinkers and non-drinkers in females only (p-value=4.5x10-5). This 
implies that there may be an interaction between the SNPs and gender, partly explaining 
the observed heterogeneity. This supports our strategy of performing association testing by 
gender separately, in addition to the combined male and female analysis. 
 
To further investigate these two SNPs, we further check these association signals with 
results from categorical data. By meta-analysed 3 cohorts with categorical data, it did not 
yield any significant findings after Bonferroni correction for rs6943555 (P=0.05 in males and 
female combined, among drinkers and 0.3 in analyses including non-drinkers) and rs26907 
(P=0.4 in male drinkers only). 
 
For the functional study, only rs6943555 in AUTS2 was further investigated, whereas 
rs26907 is dropped off because of its weak association signal at the replication stage and its 
additional cost in functional study. Functional studies were then further pursued in order to 
explore whether AUTS2 plays any role in alcohol intake pathway. With the collaboration 
from Prof Gunter Schumann’s team, the biological function was explored in brain regions 
which are most implicated in reinforcement mechanisms and in Drosophila for alcohol 
sensitivity [Schumann, et al. 2011]. In 94 prefrontal cortex samples from human brain, they 
found decreased expression of AUTS2 in carriers of the minor A allele of rs6943555 (which 
correspond to our analysis that show decreased intake in carrier A allele) compared with T 
allele (p=0.026). They analysed transcriptional expression of AUTS2 in whole brain extracts 
of mice known to differ markedly in voluntary alcohol consumption (p<0.017). In two of the 
three probe sets for AUTS2, they found significant expression differences. To further explore 
AUTS2, there is no knockout mouse model for AUTS2 therefore the Drosophila was used. In 
Drosophila mutants with downregulated AUTS2, we observed decreased alcohol sensitivity 
(p<0.001), which provides further support for the involvement of this gene in alcohol-
related behaviour. These findings suggest that AUTS2 have the role in alcohol-related 
behaviour.  
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Figure 2.11. The pairwise LD between SNPs near rs6943555. The squares coloured bright 
red/blue, shade of red/pink, and white represent the level of LD between a pair of SNPs 
from high to low (blue and white have less confidence in the calculated pairwise LD). 
 
 
 
Figure 2.12. The pairwise LD between SNPs near rs26907. The squares coloured red, pink, 
blue, and white represent the level of LD between a pair of SNPs from high to low (blue and 
white have less confidence in the calculated pairwise LD).  
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Figure 2.13. Regional association plots for rs6943555 in AUTS2 from drinkers/non-drinkers 
in male (a), female (b), and male/female (c), and regional association plots for rs26907 in 
RASGRF2 from drinkers only in male (d), female (e), and male/female (f). SNP location in the 
gene is shown in symbols: right triangle, intronic; left triangle, stop gained or stop lost; 
upside-down triangle, intergenic; horizontal rectangle, upstream or downstream; vertical 
rectangle, 3’-UTR or 5’-UTR. R2 between each SNP and the top signal is colour coded: >0.99, 
blue; 0.8-0.99, red; 0.5-0.8, orange; 0.2-0.5, pink; 0.1-0.2, yellow; 0-0.1, white. 
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Figure 2.14. Forest plot for rs6943555 from analyses including drinkers in male (a), female 
(b), male and females (c). P-values from tests of heterogeneity between studies are 0.24, 
0.054, and 0.047 respectively. 
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Figure 2.15. Forest plot for rs26907 from analyses including drinkers in male (a), female (b), 
male and females (c). P-values from tests of heterogeneity between studies are 0.14, 0.12, 
and 1.6e-5 respectively. 
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Figure 2.16. Forest plot for rs6943555 from analyses including drinkers and non-drinkers in 
male (a), female (b), male and females (c). P-values from tests of heterogeneity between 
studies are 0.2, 4.7e-5, and 1.9e-4 respectively. 
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Figure 2.17. Forest plot for rs26907 from analyses including drinkers and non-drinkers in 
male (a), female (b), male and females (c). P-values from tests of heterogeneity between 
studies are 0.08, 0.07, and 1.2e-8 respectively. 
 
2.7.4 Signals at alcohol-related genes  
 
Gene families previously shown to be associated with alcoholism, i.e. ADH and ALDH, were 
further investigated in our alcohol consumption study. If there is some evidence of 
association which nevertheless does not reach the genome-wide significance threshold, this 
evidence with their prior knowledge of being known genes in alcohol-related phenotype 
could further identify additional candidate genes for the alcohol consumption.  
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Under these two gene families, only interesting association evidence were observed in the 
ALDH1L1 whereas the other genes did not show strong evidence as such, i.e. ADH1, ADH2, 
ADH3, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and ALDH1L2. In ALDH1L1, there is an 
association peak of 52 SNPs with P-values 10-6-10-5 (Figure 2.18). These 51 SNPs are lying in 
two adjacent LD blocks (Figure 2.19, LDblock1: 25kb (46 SNPs) and LDblock2: 11kb (5 SNPs)). 
One of these SNPs is lying in LDblock4 which is approximately 3kb from the LDblock2. 
Among 46 SNPs in LDblock1, 1 SNP is upstream, 1 SNP is downstream and the rest is 
intronic. SNPs in LDblock2 and the other SNPs are intronic. Therefore, based on this 
observation, ALDH1L1 gene should also be attempted to replicate in other data sets of 
alcohol consumption. 
 
 
Figure 2.18. The manhattan plot from meta-analysis in male and female combined drinkers. 
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Figure 2.19. LD plot for ALDH1L1 regions with some evidence of association with alcohol 
intake. 
    
2.8 Discussion 
 
The wealth of data available in the ENGAGE consortium allowed a large-scale GWAS meta-
analysis of alcohol consumption to be initiated. In contrast to alcohol dependence, little is 
known about the underlying genetics of alcohol consumption in the general population, 
although it has been reported that the heritability of alcohol consumption is estimated to be 
approximately 40% [Kaprio, et al. 1987]. As the main analyst for this study, I not only 
performed the analyses using a standard meta-analysis procedure but also investigated 
novel quality control (QC) measures to efficiently minimise the probability of false-positive 
findings without reducing statistical power more than necessary.  
 
We reported rs6943555 in AUTS2 as attaining genome-wide significance in the Alcohol 
consumption meta-analysis GWAS, with supportive evidence from functional studies 
[Schumann, et al. 2011]. In addition, rs26907 in RASGRF also attained genome-wide 
significance from the combined meta-analysis of the discovery and replication stages, but 
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only a suggestive association was observed at the replication stage. Based on the genes 
previously implicated in alcohol-related phenotypes, suggestive associations were observed 
in ALDH1L1. Therefore, apart from the published AUTS2, these two genes should be further 
explored, by, for example, attempting to replicate these associations in other data sets and 
exploring their biological functions in relation to alcohol drinking behaviour. 
 
Our study on alcohol consumption has a number of limitations. In contrast to many other 
phenotypes that can be measured with high accuracy, such as height, weight, or blood 
pressure, the measure of alcohol intake for this study relied on self-reported questionnaires 
rather than a direct observation of alcohol consumption. One source of error in this is the 
human error caused in the reporting of the exact quantity of alcohol intake, because people 
tend to drink in an irregular pattern and amount at different times, as well as consuming 
different types of alcoholic beverages. A second source of error relating to the 
questionnaires is the fact that different cohorts used different questionnaires and so the 
effect estimates may have inconsistent meaning, compromising the fixed effects meta-
analysis model used. Finally, a further limitation comes from the lack of important common 
environmental risk factors available across cohorts, which cannot then be controlled for in 
the analysis, such as lifestyle, social economic status, and education. These limitations 
introduce statistical ‘noise’ into the GWAS analysis, which can lead to a reduction in the 
power to detect causal genetic variants. 
 
In a well-powered study, the high-risk variant is more likely to reach the significance 
threshold compared to the low-risk variant. Extremely high sample sizes are required for 
low-risk variants to reach the GWAS significance threshold. Therefore, since we did not 
observe SNPs exceeding the significance threshold at our discovery stage, we instead 
investigated the top-ranking SNPs exceeding a less stringent, while recognising the higher 
probability of false positives among those SNPs. This included top ranked SNPs across 6 
models, as well as those SNPs at nearby genes with a potential functional role. While AUTS2, 
which was first selected for replication based on a combination of its top association signal 
and its functional role, did not reach genome-wide significance at the discovery stage, it is 
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highly replicated at the replication stage and reaches genome-wide significance in the 
combined meta-analysis. Therefore, this implies that AUTS2 is unlikely to be a false positive. 
In addition, the supportive evidence of functional role of AUT2 is shown in gene expression 
in brain regions and alcohol sensitivity in Drosophila, which further supports the causality of 
AUTS2 in alcohol consumption.  
 
To our knowledge, this is the first and largest GWAS meta-analysis study to investigate the 
genetic determinants of alcohol consumption. Our ﬁndings indicate the potential 
importance of genetic variants inﬂuencing levels of alcohol consumption in the general 
population, which may lead to a better understanding of the mechanisms underlying alcohol 
drinking behaviour. 
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Chapter 3 The effect of transformations on statistical power in GWAS 
 
3.1 Introduction 
 
The main objective of most epidemiological studies is to identify associations between 
exposures to putative risk factors and phenotypes of interest. Linear regression, which 
assumes normally distributed residuals, is generally performed when the phenotype data 
are continuous, and thus non-normal phenotype data are often first transformed to help 
induce normality in the residuals. In genome-wide association studies (GWAS), the most 
commonly applied transformations are standardisation, which linearly shifts and rescales 
the phenotype such that it has mean zero and variance of one, the log transformation (LT), 
which transforms data to a log scale, and the inverse normal transformation (INT), which 
transforms each value to its equivalent percentile point on the standard normal distribution. 
We performed a systematic review of the GWAS literature and found that 41% of studies 
applied no transformation, 23% applied the LT, 19% applied the INT, and 17% applied 
standardisation (Methods). GWAS results are often combined across studies in a meta-
analysis to increase sample size and thus the statistical power to detect variants of small 
effect sizes. The inverse variance (IV) and weighted Z-score (WZ) meta-analysis methods are 
commonly used. 
 
To date there has been little investigation into the effect of different transformations of the 
phenotype on statistical power in the context of GWAS [Beasley and Erickson 2009; Buzkova 
2013]. Furthermore, there appear to be no ‘rules-of-thumb’ in use in the field, indeed 
different transformations have been applied to the same phenotype in different studies: of 
5 publications for height; 1 applied no transformation (NT) [Cho, et al. 2009], 3 applied 
standardisation [Cho, et al. 2009; Gudbjartsson, et al. 2008; Lettre, et al. 2008; Weedon, et 
al. 2008], and 1 applied the INT [Sanna, et al. 2008]. Of 5 publications for body mass index; 3 
applied the INT [Gudbjartsson, et al. 2008; Speliotes, et al. 2010; Thorleifsson, et al. 2009], 1 
the LT [Loos, et al. 2008], and 1 applied different transformations in different cohorts [Cris, 
et al. 2009].  
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Here we test the statistical power to detect genotype-phenotype associations under NT 
(which does not affect the shape of the phenotype distribution and is thus equivalent to 
standardisation in terms of power), LT, and INT using both simulated data as well as re-
analysis of reported associations in the Northern Finland Birth Cohort 1966 (NFBC1966). We 
also test sensitivity of the IV and WZ methods of meta-analysis to the transformations 
performed.  
 
3.2 Methods 
 
3.2.1 Power to detect reported associations in NFBC1966 GWAS data 
 
To further investigate the effect of different transformations of skewed phenotype data on 
the power to detect genotype-phenotype associations, we perform association tests under 
the different transformations on data from the NFBC1966. The phenotypes to study were 
chosen according to being present on the National Human Genome Research (NIH) GWAS 
catalogue [Hindorff, et al. 2009], published in Nature or Nature Genetics with a study of 
sample size greater than 5000, and where the skewness of the phenotype in the NFBC1966 
is greater than 0.5. There were 41 such publications and 448 significant genotype-
phenotype associations reported within (Table 3.1). We perform association tests of these 
448 associations in the NFBC1966 under the different transformations.  
 
We assess how many of the 448 reported genotype-phenotype associations exceed 
different P-value thresholds after analysis in the NFBC1966 under NT, the INT and the LT. To 
estimate their 95% confidence intervals (CIs), we applied a bootstrapping technique. We use 
bootstrap resampling from 448 reported SNPs (in which we sample, with replacement, the 
number of SNPs exceeding each threshold and repeat the analysis 100 times). For example, 
at the p-value threshold 1e-6, 50 true positive SNPs are detected under INT in NFBC data. To 
calculate CI of this detected 50 true positive SNPs, we resample 50 SNPs with replacement 
from the 448 reported SNPs and record how many of them are the same as those 50 SNPs 
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detected in NFBC. By doing this 100 times, we can estimate a 95% CI of the 50 true positive 
SNPs detected under INT in NFBC. Similarly, the same approach is taken to calculate the CI 
for the 45 true positive SNPs detected under LT at the p-value threshold 1e-6. The 
difference between SNP numbers after bootstrapping between INT and LT is then used to 
calculate the 95% CI for the difference between the number of true positive SNPs gained 
under INT (50 SNPs) compared to LT (45 SNPs). 
 
The rank based INT of the phenotype is shown as 
  
     (
    ( )   
      
) 
where    denoting the standard normal quantile function and n is the sample size. Various 
options of c has been shown but c=3/8 is commonly used [Beasley and Erickson 2009; 
Buzkova 2013], therefore we use this value subsequently. 
 
 
3.2.2 Assessing power in the single-study GWAS setting via simulation 
 
We investigated the statistical power to detect genotype-phenotype associations via 
simulation across a range of skewness and coefficient of variation (CV) of the phenotype. 
The data were simulated according to the following model: 
 
iii
ε+βg=q        (1) 
 
where 
i
q  denotes the value of a quantitative phenotype for individual i, 
i
g  denotes the 
genotype of a SNP, where  0,1,2
i
g  corresponds to the count of risk alleles,   is the risk 
allele effect size, and iε  is the error term, which captures all other genetic and 
environmental risk factors.  
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The effect size   is calculated relative to the phenotypic variance explained (VE). To 
calculate   from Equation1, first we derive the variance of phenotype ( 2
q
 ) as a function of 
the variance of error distribution ( 2

 ) and the genotypic variance explained (VE ). Then, 
the calculation of   can be derived as a function of these variances. 
 
Since VE  is the proportion of genotypic variance which explains the phenotypic variance, 
this can be written as 
 
22
*
qg
VE 

 .  
 
From Equation1, we have 
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where pg is the frequency of the minor allele and   
  is the variance of genotype. 
 
In our simulations we consider values of VE = 0.01%, 0.1%, 1%, 10% and vary the sample size 
simulated to maintain approximate power, so that the number of ‘individuals’ simulated are 
N = 200000, 25000, 4000, 300, respectively.  Then N genotypes are chosen from [Begum, et 
al. 2012] assuming a minor allele frequency of 20% and Hardy-Weinberg Equilibrium.  
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As described below, the error term, iε , is modelled both by sampling from NFBC1966 
phenotype data and by drawing from the skew normal and generalised gamma 
distributions.  
 
Since we are investigating the LT, we simulate only positive phenotypes values 
i
q  > 0 by 
setting 0  and 0
i
ε .  
 
This simulation of genotype-phenotype data was repeated 10000 times, and for each 
repetition we used linear regression to calculate the P-value of association under (i) NT, (ii) 
the LT, and (iii) the INT. The proportion of genotype-phenotype associations with P < 5x10-8 
(the genome-wide significance level) was considered the statistical power of the test. 
 
To investigate the behaviour of the tests under the null model of no association in the 
different scenarios of parameter settings we simulated 10000 replicates of genotype-
phenotype data, across a range of VE and skewness, under the null of no genetic effect 
(where β=0). The CV was fixed to be 0.1 since this was the approximate level showing 
greatest differences in statistical power between the transformations, and which may 
therefore be most likely to have inflation or deflation under the null. 
 
3.2.2.1 Single-study simulation with error distribution sampled from NFBC1966 
 
To assess the statistical power to detect associations under the different transformations 
based on levels of coefficient of variation (CV) and skewness observed in real data, we 
sampled the error distribution iε  from observed phenotype distributions in the NFBC1966. 
This should produce phenotype data highly reflective of real data when the casual SNP 
contributes a small proportion of phenotypic variance. We designed a sampling strategy to 
sample 200000 phenotype values from 4700 NFBC1966 samples, which avoided producing 
multiple equal measurements. We first ordered the phenotype values from lowest to 
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highest. Then, instead of choosing a value with random index k for each sample, we chose a 
value drawn from the uniform distribution between the values with index k-1 and k+1. 
 
3.2.2.2 Single-study simulation with error modelled by the skew normal and generalised 
gamma distributions 
 
In our simulations, we control the mean (  ), variance ( 2 ), CV and skewness ( ) of the 
error term, denoted by )*,( 222 CV  . The variance is expressed in terms of the 
mean and CV, where the CV captures the variation of the phenotype relative to the mean. 
Deviation from normality is controlled by the skewness. We apply two different 
parameterisations, the skew normal and generalised gamma distributions. 
 
The skew normal distribution 
For the skew normal distribution, ),,(  SN  where  ,,  represent the location, 
shape, and scale parameters. We next calculate these parameters according to different 
fixed values of skewness (  ) and CV.  
 
Let )( x denote the standard normal probability density function, 
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with the cumulative distribution function given by 
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where erf is the error function. Then the probability density function of the skew-normal 
distribution with location  , scale  , and shape   is given by 
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Under the skew normal distribution applied for   term, at a given skewness (  ),   can be 
solved numerically from 
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Therefore, the skewness is controlled via the shape parameter, , only, with maximum 
skewness equal to 1. 
 
Next, the CV is defined both by the location parameter, , and the scale parameter, . Thus, 
we can vary the CV in two ways. Firstly, we can use a fixed-scale approach, where we fix 
=1, and vary the location parameter  to obtain a pre-defined CV. Secondly, we can also use 
a fixed-location approach, where we fix 2 , and vary the scale parameter, . To derive 
the equations used to calculate  and  , 
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and therefore   can be written as 
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and    can be written as 
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After  ,  , and   parameters are calculated based on the required skewness and CV, the 
random number under the skew normal distribution can be generated using an R function, 
),,,( Nrsn .  
 
Simulated samples are only considered valid if fewer than 5% of values are negative, in 
which case they are truncated at zero to ensure a positive distribution. Using this approach, 
we could simulate in the range )1,0(  and )6.0,0(CV .  
 
The generalised gamma distribution 
The generalised gamma distribution is parameterised as ),,( pdaGG . To derive 
equations used to calculate the skewness and coefficient of variation, we next describe the 
generalised gamma distribution. 
 
For non-negative x, the probability density function of the generalized gamma is 
   
 pd
exap
pdaxf
p
axdd

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1
),,;( , 
where a>0, d>0, p>0 and  denotes the gamma function. 
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 If x has a generalized gamma distribution then )()( rGaxE rr   where 
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The random number from the generalised gamma distribution can be generated using an R 
function, rgengamma(N,scale=1,p,d/p). 
 
Using this approach we can simulate )5,0(  and )3,0(CV  (Figure 3.9). 
 
 
3.2.3 Assessing power in the meta-analysis GWAS setting via simulation 
 
We investigate the use of the different phenotype transformations in conjunction with two 
meta-analysis approaches, in the presence of between-study heterogeneity of skewness or 
CV. We simulated 20 different genotype-phenotype data sets, with a certain proportion 
having high, and the rest low, levels of skewness or CV. Each data set is simulated as 
described above, with a genetic effect of 0.1% of phenotypic variance, the skew-normal 
distribution as the error term, and N=1000 per cohort. Under simulation of CV 
heterogeneity, the skewness was fixed at 1 and the 20 cohorts were assigned to ‘low’ and 
‘high’ CV groups, in which the ‘low’ CV was fixed at 0.2, and the ratio of ‘high’ to ‘low’ CV  
(CVratio) was varied. Under simulation of skew heterogeneity, the CV was fixed at 0.2 and the 
cohorts were assigned to ‘low’ and ‘high’ skewness groups, in which the ‘low’ skew was 
fixed at 0.5, and the ratio of ‘high’ to ‘low’ skew (SKratio) was varied.  The 20 cohorts were 
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assigned to low:high  skew or CV groups in the proportions: 20:0, 16:4, 12:8, 8:12, 4:16 and 
0:20.   
 
These genotype-phenotype simulations were repeated 1000 times, and for each repetition 
we performed a GWAS meta-analysis applying (i) the INT, and (ii) the LT of the phenotype, in 
conjunction with both inverse variance (see section 1.3.6.3) and weighted-Z (see section 
1.3.6.2) meta-analysis methods.  The proportion of phenotype-genotype associations with 
corresponding P < 5e-8 was recorded in each case as the power of the test. 
 
3.3 Results 
 
3.3.1 Performance of different transformations in a single GWAS study setting 
 
We compiled a list of genotype-phenotype associations from 41 meta-analysis publications 
in Nature or Nature Genetics that had sample size greater than 5000 and were present on 
the NIH GWAS catalog [Hindorff, et al. 2009] prior to February 2012. The twenty phenotypes 
from these publications that had skewness in the NFBC1966 greater than 0.5, were selected 
for our study (Table 3.1). We performed association tests across the 20 phenotypes in the 
NFBC1966 under NT, the INT, and the LT, and noted the number of previously reported SNP 
associations that could be detected in these data at various P-value thresholds (Figure 3.1). 
This analysis indicates that the INT is on average marginally more powerful than the LT, and 
at a threshold of 10-6 this difference is statistically significant (P-value = 0.003).  
 
Table 3.1. NFBC1966 phenotypes investigated in this study.  The final column lists the 
number of reported SNP associations that are detectable, at P < 1e-4, after applying either 
NT, the INT or the LT transformation on the NFBC1966 data. 
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Phenotype Symbol CV skew 
Number of 
reported SNP 
associations 
Number of 
reported SNP 
associations 
detectable in 
NFBC1966  
at P < 1e-4 
1.Platelet count PTL 0.22 0.52 36 8 
2.Waist to hip ratio WHR 0.1 0.57 8 0 
3.Systolic blood pressure SYST 0.11 0.57 29 1 
4.Cholesterol CHOL 0.2 0.67 65 13 
5.High-density lipoprotein HDL 0.24 0.68 78 19 
6.Low-density lipoprotein LDL 0.3 0.74 65 21 
7.Phenylalanine Phenyl 0.19 0.97 1 0 
8. High-density lipoprotein-
cholesterol 
HDL_C 0.26 0.97 1 0 
9.Alanine/Tyrosine Ala/Tyr 0.21 1.11 1 0 
10.Alanine/Glutamine Ala/Glu 0.21 1.12 1 0 
11.Phenylalanine/Tyrosine Phenyl/Tyr 0.23 1.41 1 0 
12.Body mass index BMI 0.17 1.48 59 2 
13. ratio of total lipids in 
large HDL to total lipids in 
medium HDL 
L/M_HDL 0.4 1.48 1 0 
14.Homeostatic model 
assessment for b-cell 
function 
HOMA_B 0.29 1.97 10 2 
15.Waist to hip ratio in 
female 
WHR_female 0.1 2.16 8 0 
16.Triglyceride TRIGL 0.62 3.04 61 12 
17.Glucose metabolite mGlucose 0.2 3.48 2 0 
18. Homeostatic model 
assessment for insulin 
resistance 
HOMA_IR 0.5 4.28 2 0 
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19.Insulin level INS 0.51 4.57 2 0 
20.Glucose level Glucose 0.11 5.16 17 4 
Total       448 82 
 
 
 
Figure 3.1. Power to detect skewed phenotype associations in the NFBC1966. a) Number of 
reported SNP associations exceeding different P-value thresholds in the NFBC1966 data 
under the different transformations of the phenotypes. b) The percentage of SNPs 
exceeding the thresholds under the INT compared to the LT in 20 phenotypes. The error 
bars are calculated via bootstrap re-sampling. The increasing size of the error bars, as the P-
value thresholds decrease, is a result of fewer SNP associations passing the smaller 
thresholds. 
 
While this analysis is suggestive of an average greater power of the INT over NT and the LT 
for phenotypes with skewness > 0.5, the relatively low sample size of the NFBC1966 cohort 
(compared to most meta-analysis GWAS) limits the reliability of this finding. Therefore, we 
next simulated a large genotype-phenotype data set, simulating the error term (Eqn. 1) 
using the observed NFBC1966 phenotype distribution (see 3.2 Methods), and considered 
genetic effects with VE = 0.01%, 0.1%, 1% and 10% and corresponding sample sizes N = 
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200000, 25000, 4000, 300. The difference in power between the NT, the INT and the LT for 
each phenotype, applying the genome-wide significance threshold P = 5x10-8, is shown as a 
function of both the skewness and CV (Figure 3.2, Figure 3.3, and Figure 3.4). Both the INT 
and the LT have higher power than the NT in all phenotypes, especially when skewness is 
high. When the genetic effect only explains a small proportion of the phenotypic variance, 
and thus only detectable with more than 25000 samples, the INT shows substantial power 
gains over the LT, particularly at high skew and low CV, as well as for low-skew and high-CV 
phenotypes (Figure 3.2a,b).   The simulations corresponding to Figure 3.2c have a sample 
size approximately equal to that of the NFBC1966 (N = 4000) and show similarly modest 
power gains of the INT over the LT as observed in real data (Figure 3.1).  
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Figure 3.2. Difference in power between the INT and the LT when NFBC1966 phenotype 
distributions are used as error distributions. The sizes of the circles correspond to the 
difference in power between INT and LT. Filled/empty circles correspond to greater power 
under INT/LT respectively. VE (sample size) of a) 0.01% (200000), b) 0.1% (25000), c) 1% 
(4000), and d) 10% (300). 
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Figure 3.3. Difference in power between INT and NT when NFBC1966 phenotype 
distributions are used as error distributions. The sizes of circles correspond to the difference 
in power between INT and LT. Filled/empty circles correspond to greater power under 
INT/LT respectively. VE (sample size) of a) 0.01% (200,000), b) 0.1% (25,000), c) 1% (4,000), 
and d) 10% (300). 
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Figure 3.4. Difference in power between LT and NT when NFBC1966 phenotype distributions 
are used as error distributions. The sizes of circles correspond to the difference in power 
between INT and LT. Filled/empty circles correspond to greater power under INT/LT 
respectively. VE (sample size) of a) 0.01% (200,000), b) 0.1% (25,000), c) 1% (4,000), and d) 
10% (300). 
 
In order to further delineate the relationship between power gain under INT and the 
skewness and CV of the error distribution, we conducted simulations using parametric error 
distributions. First we modelled the error term using a skew normal distribution. CV was 
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varied by fixing the scale and varying the location parameter of the skew normal distribution 
(Equation 4). When VE is small (0.01%, 0.1%, and 1%), INT leads to either similar or 
significantly greater power than LT (Figure 3.5). A dramatic increase in power under INT is 
observed when CV is low (< 0.3) and skewness high (> 0.8), and a moderate increase in 
power is observed at low-skew/high-CV. At low-CV/low-skew, or high-CV/high skew LT 
marginally outperforms INT. At a higher VE of 10%, the advantage of INT in high-skew/low-
CV regions decreases, while INT retains its advantage in the low-skew/high-CV region. We 
also compared the power under transformed data with the raw non-transformed data, 
comparing INT and NT (Figure 3.6) and LT and NT (Figure 3.7). As expected, INT and LT both 
result in higher power than NT in the presence of skew (> 0.2), especially under the small 
variance explained. When there is low level skewness (<0.2), INT and LT give a similar power 
as NT although we would rarely expect transformation to be used in this case. In contrast to 
our study, Buzkova 2013, in general, reported the lack of justification for the use of 
transformations for INT compared to NT in genetic association studies. However, this paper 
mostly focused on the case when there is an existence of heteroscedasticity under the null 
and showed that there could be high inflation of false positives. In contrast to our study 
where the heteroscedascity was not investigated across different levels, our simulated and 
real data show that there is no inflation under the null. This could be because the 
heteroscedasticity levels investigated in Buzcova 2013 may not be realistic. In addition to 
investigation under the null, we performed more thorough power investigations than 
Buzcova 2013, who performed limited investigation on this. In her investigation on the 
power under the non-heteroscedasticity scenario, she reported that there is a slight 
increase in power when INT is applied to data with heavy tails, although the variance 
explained is not reported. We believe that if she investigated different scenarios, including 
various CV levels under the small variance explained, the power increases that we observed 
would have been found. 
 
We also investigate the null by modelling no genotypic effect (  =0 in Eq.1). Type I errors 
are close to the expected values under NT, LT, and INT across the range of skewness 
investigated for CV = 0.1 (Table 3.2). This implies that the type I error is not inflated or 
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deflated by any of the transformations. Similar results were obtained when the skew normal 
distributions were simulated based on a change of scale with fixed location (Equation 5, and 
Figure 3.8). 
  
 
Figure 3.5. Heatmap for the difference in power between INT and LT under the skew normal 
error distribution at VE (sample size) of (a) 0.01% (200000), (b) 0.1% (25000), (c) 1% (4000), 
and (d) 10% (300) respectively. The simulated skew normal distribution has fixed scale (
=1) and variable location parameter. 
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Figure 3.6. Heatmap for the difference in power between INT and NT under the skew 
normal distribution at VE of (a) 0.01% , (b) 0.1%, (c) 1%, and (d) 10% respectively. 
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Figure 3.7. Heatmap for the difference in power between LT and the NT under the skew 
normal distribution at VE of (a) 0.01% , (b) 0.1%, (c) 1%, and (d) 10% respectively. 
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Table 3.2. Type I error rates under the null at different VE and skewness where CV=0.1 
skewness  
Type I error rates 
NT LT INT 
  0.05 0.01 0.05 0.01 0.05 0.01 
variance explain=0.01%             
0 0.048 0.0097 0.0476 0.0105 0.048 0.0098 
0.2 0.0492 0.0095 0.0489 0.0094 0.0484 0.0098 
0.4 0.0485 0.0088 0.0491 0.0083 0.0498 0.0083 
0.6 0.0502 0.0082 0.0505 0.0082 0.0512 0.0084 
1 0.0536 0.0118 0.0526 0.0121 0.0506 0.0119 
variance explain=0.1%             
0 0.0523 0.0106 0.0531 0.0108 0.0519 0.0106 
0.2 0.0528 0.0092 0.053 0.0097 0.0531 0.0097 
0.4 0.0493 0.0095 0.0502 0.0098 0.0491 0.0099 
0.6 0.0498 0.0101 0.0518 0.0105 0.052 0.0107 
1 0.0496 0.0103 0.0482 0.0104 0.0469 0.0098 
variance explain=1%             
0 0.0506 0.01 0.0496 0.0091 0.051 0.0099 
0.2 0.0518 0.0103 0.0521 0.0101 0.0517 0.0104 
0.4 0.0461 0.0084 0.0465 0.0083 0.0462 0.009 
0.6 0.0523 0.0106 0.0516 0.0104 0.052 0.0101 
1 0.0512 0.0104 0.0518 0.01 0.0498 0.0104 
variance explain=10%             
0 0.0496 0.0102 0.0488 0.0099 0.0493 0.0097 
0.2 0.0507 0.0113 0.051 0.0111 0.0522 0.0112 
0.4 0.0512 0.0103 0.0508 0.0106 0.051 0.0097 
0.6 0.0498 0.0091 0.0508 0.0095 0.0508 0.0099 
1 0.0501 0.0095 0.0497 0.0095 0.048 0.01 
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Figure 3.8. Heatmap for the difference in power between INT and LT under the skew normal 
error distribution at VE (sample size) of (a) 0.01% (200,000), (b) 0.1% (25,000), (c) 1% 
(4,000), and (d) 10% (300) respectively. The simulated skew normal distribution has fixed 
location ( ) and variable scale parameter. 
 
We used the generalised gamma distribution to further explore power differences between 
the LT and the INT.  The range of CV and skew accessible to the generalised gamma 
distribution excludes the low-CV/high-skew and high-CV/low-skew regions found to harbour 
2
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greatest differences in power, and in the remaining regions there is no major power 
differences between the transformations, consistent with the results from the skew normal 
simulation in these regions (Figure 3.9).  
 
 
Figure 3.9. The heatmap plots for the difference in power between INT against LT under the 
generalised gamma distribution at VE of (a) 0.01%, (b) 0.1%, (c) 1%, and (d) 10% 
respectively. 
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We investigated whether the above differences in power may be due to deviations of the 
error distribution from normality after the transformations, using Aderson-Darling test 
statistics (A2). Across the range of investigated VE, the phenotype distribution is mainly 
influenced by the error distribution. Therefore, the phenotype distribution is similar to the 
error distribution, especially for small VE, and as a result the INT error distribution is almost 
perfectly normally distributed (Figure 3.10). For small VE, the LT error distribution deviates 
from normality in the high-skew/low-CV as well as low-skew/high-CV regions, for which it 
loses power relative to INT (Figure 3.11). For high VE, there is evidence of deviation from 
normality of the LT error distribution in the low-skew/high-CV region, for which LT also loses 
power relative to INT. The deviation from normality is therefore a possible explanation for 
power reduction in a single study under LT.  
 
The main potential problem for the use of the INT is the loss of information rather than 
deviation from normality. Unlike the LT, which transforms the phenotype relative to its 
original value, the INT transforms the phenotype based on its rank. Therefore, the INT can 
lead to some loss of information, which may result in a loss of power. When the VE is large, 
much of the skewness in the phenotype is attributable to the genotypic effect, and is thus 
informative; however, both the skewness and some of this information is removed by the 
INT. However, when the VE is small the genotype effect has minimal contribution to the 
skewness, and so the main consequence of the INT is to induce normality in the residuals of 
the regression as intended.  
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Figure 3.10. Heatmap of test statistics (A2) under Aderson test for normality of residuals 
under INT at VE of (a) 0.01% , (b) 0.1%, (c) 1%, and (d) 10% respectively. At the test statistics 
A2=0.75, 1.04, 2.26, and 3.49, the corresponding P-values of significance of deviation from 
normality are 0.05, 1e-2, 1e-5, and 1e-8 respectively. 
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Figure 3.11. Heatmap of test statistics (A2) under Anderson test for normality of residuals 
under LT at VE of (a) 0.01%, (b) 0.1%, (c) 1%, and (d) 10% respectively. P-values for deviation 
from normality of 0.05, 10-2, 10-5, and 10-8 correspond to test statistics A2=0.75, 1.04, 2.26, 
and 3.49, respectively. Note that the scale is different in each panel. 
 
Our simulations have shown that the INT is more powerful than the LT for highly skewed 
phenotypes (> 0.8) with a low coefficient of variation (CV < 0.3). Thus we now refer back to 
the association results from the analysis of previously reported SNPs in the NFBC1966 to 
check whether these simulation results are reflected in the real data. As predicted, we find 
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that among the 10 phenotypes from Table 3.1 with skewness > 0.8 and CV < 0.3, the INT 
detects approximately twice as many true positive SNP associations in the NFBC1966 as the 
LT (Figure 3.12a), whereas the INT finds only marginally more in the remaining phenotypes 
(Figure 3.12b).  
 
 
Figure 3.12. Percentage of extra true positive associations identified in the NFBC1966 under 
the INT relative to the LT for a) phenotypes with CV < 0.3 and  skew > 0.8 b) phenotypes 
with CV > 0.3 or skewness < 0.8. 
 
3.3.2 Performance of different transformations in the GWAS meta-analysis 
setting 
 
In the previous section we observed generally higher power for the INT over the LT, 
particularly for low-CV/high-skew phenotypes, in detecting genetic variants that explain the 
small proportion of phenotypic variation usually observed in GWAS.  Such effects usually 
require upwards of 20000 samples to detect, which is beyond the size of most single 
cohorts, though meta-analysis of results across multiple cohorts has been used to achieve 
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these sample numbers. We hypothesise that while the results from the previous section 
apply to a meta-analysis setting provided that the CV and skewness of the phenotype are 
homogenous across cohorts, inter-cohort heterogeneity in CV or skew may result in a loss of 
power for either the LT or the INT in meta-analysis. We investigated this via simulation, in 
which we applied NT, the LT, and the INT in conjunction with two different meta-analysis 
methods, which apply different weightings to the effect size estimates of the different 
cohorts: 1) the inverse variance method (IV, see section 1.3.6.3), and 2) the weighted Z-
score (WZ, see section 1.3.6.2), which has weightings according to cohort sample size.  
 
Simulation of phenotype CV heterogeneity due to variation in the location parameter 
between cohorts (Equation 4), with fixed skewness, demonstrated that when the CV is 
highly variable between cohorts (a ratio of high-to-low CV of above 1.5), there is a dramatic 
loss of power (up to 50%) when using the IV meta-analysis in conjunction with the LT (Figure 
3.13a), while power is maintained under the INT (Figure 3.13b).  However, when CV 
heterogeneity is due to variation in scale, with fixed location (Equation 5), we do not 
observe major power differences (Figure 3.14). Heterogeneity of skewness resulted in 
minimal power differences between IV and WZ meta-analysis, regardless of phenotype 
transformation (Figure 3.15a, b).   
 
The loss of power under IV compared to WZ in conjunction with the LT can be explained by 
the difference in the weighting technique. The weights under WZ are based on the sample 
sizes, so in our simulations, which model equal-sized cohorts, the correct weight is given to 
the test-statistic estimates across both ‘high’ and ‘low’ CV cohorts. However, IV combines 
results by weighting all effect sizes by the inverse variance of the estimate of the effect size 
and so does not necessarily weight the effect estimates from the different cohorts equally. 
In particular, the LT induces greater variance for values closer to zero because of the higher 
gradient of the log function close to zero, which in turn results in a greater variance in the 
estimate of the genetic effect, thus resulting in a smaller relative weight for high CV (small 
location) cohorts, and a larger relative weight for low CV (large location) cohorts. In 
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contrast, when CV heterogeneity is based on the change of scale, we do not observe this 
loss in power, as this heterogeneity does not change the average distance from the origin.  
 
We also investigate the null distribution in the meta-analysis setting by modelling no 
genotypic effect (  =0 in Equation (1)). The type I errors are close to the expected values 
under NT, the LT, and the INT in conjunction with both the IV and the WZ (Table 3.3). 
Although IV has been mainly used in genetic studies compared to WZ (Figure 1.7c) because 
it is likely to be more powerful test when the weight is also accounting for the reliability of 
the effect size in additional to sample size, we reported the special case where IV is less 
powerful than WZ, that is, when the LT is used in conjunction with IV where there is 
heterogeneity of CV between studies. Our results suggest that the INT can be used in 
combination with either of the meta-analysis methods, but that the use of the LT should be 
restricted to applying WZ when there is high variation in phenotypic CV.  
 
 
Figure 3.13. Heatmap of percentage difference in power between WZ and IV meta-analysis 
in the presence of CV heterogeneity, with a range of ratios of high-to-low CV (with low CV 
fixed at 0.2) and a skewness of 1 after a) the LT and b) the INT. The simulated skew normal 
distribution has fixed scale and variable location. 
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Figure 3.14. Heatmap of percentage difference in power between WZ and IV meta-analysis 
after LT in the presence of a) CV heterogeneity, with a range of ratios of high to fixed low CV 
of 0.2, at a common skew of 0.5; and b) skew heterogeneity, with a range of ratios of high to 
a fixed low skew of 0.5, with a common CV of 0.2. The simulated skew normal distribution 
has the fixed location and varied scale. 
 
110 
 
 
Figure 3.15. Heatmap of percentage difference in power between WZ and IV meta-analysis 
in the presence of skew heterogeneity, with a range of ratios of high-to-low skewness (with 
low skewness fixed at 0.5) and a common CV of 0.2 after a) the LT and b) the INT. The 
simulated skew normal distribution has fixed scale and variable location. 
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Table 3.3. Type I error rates under the null in both IV and WZ meta-analyses at CVratio of 3 
and a common skew of 1. 
 Combinations 
of 20 cohorts 
with CV 
heterogeneity 
  
  
  
type I error rates 
  
NT 
 
LT  
  
INT 
  
IV 
  
WZ 
  
IV 
  
WZ 
  
IV 
  
WZ 
  
0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05  0.01  
CV 0.2x20 0.0491 0.01 0.049 0.0103 0.049 0.0101 0.0474 0.0102 0.0479 0.0099 0.0478 0.01 
CV 0.2x16  
CV 0.6x4 0.0474 0.0093 0.0467 0.0092 0.0515 0.0096 0.0486 0.0094 0.047 0.009 0.0465 0.0094 
CV 0.2x12  
CV 0.6x8 0.0537 0.0114 0.0539 0.011 0.0539 0.0106 0.052 0.0106 0.0529 0.0105 0.0523 0.0105 
CV 0.2x8  
CV 0.6x12 0.0531 0.0091 0.0533 0.009 0.0531 0.0081 0.0525 0.0087 0.0526 0.0077 0.053 0.008 
CV 0.2x4  
CV 0.6x16 0.0504 0.0115 0.0501 0.0112 0.05 0.0092 0.0508 0.0111 0.0515 0.0107 0.0514 0.0109 
CV 0.6x20 0.05 0.0098 0.0491 0.0096 0.0495 0.01 0.0494 0.0101 0.0492 0.0102 0.0495 0.0102 
 
3.4 Discussion 
 
In recent years genome-wide association studies have discovered hundreds of genetic 
variants associated with hundreds of phenotypes. Many of the tested continuous 
phenotypes have skewed distributions, and they are transformed prior to performing 
association testing in regression models in order to induce normality in the residuals. 
However, there has been little investigation into the effect of different transformations of 
phenotypes on the statistical power to detect genotype-phenotype associations. Here we 
investigated the effect of the two most commonly used transformations, the LT and the INT. 
We tested the statistical power to detect genotype-phenotype associations using both 
simulated data as well as re-analysing reported associations in the NFBC1966. In addition, 
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we tested the sensitivity of the inverse variance (IV) and weighted-Z (WZ) methods of meta-
analysis to the transformations performed.  
 
Based on our investigations assuming a common risk allele (MAF = 0.2), we find, via 
simulation, that while the LT and the INT have similar statistical power when the risk factor 
being tested has moderate or large effect size, the INT has greater or similar power when 
the effect sizes are small. This is because when the VE is small, the genotype effect has 
minimal contribution to the skewness, and so the main consequence of the INT is to induce 
normality in the residuals of regression as intended. The power gain under INT is particularly 
observed for phenotypes in which the skewness is either markedly greater or less than twice 
the CV. We also find supporting evidence for this by performing association testing in the 
NFBC1966 data set at SNPs associated with low-CV and high-skew phenotypes. In addition, 
we found that although the LT is not always robust to the presence of between-cohort 
heterogeneity of CV when used in conjunction with the inverse variance meta-analysis, the 
INT is robust to this heterogeneity regardless of the meta-analysis method used. Although 
our simulations have been done based on association between quantitative phenotype and 
genetic data, i.e. SNPs, our results should be applicable to any association studies that may 
be likely to identify small effects including studies in epigenetics, metabolomics, eQTL 
analyses, and other -omics. In fact, in [Pickrell, et al. 2010], INT is used as the main 
procedure to ensure that the overall distribution of expression levels for each gene is 
normally distributed before performing linear regression with phenotypes. 
 
 
Our study is currently restricted under the common genetic variants where MAF of 0.2 is 
considered. In addition, the limitation of our study is found in the investigation using real 
data. The relatively small sample size and availability of phenotypes in the NFBC1966 limited 
the reliability of the real data findings, where the INT was shown to have significantly more 
power than the LT (P = 0.003) at a significance threshold of 10-6 and, on average, has 
marginally more powerful at the other thresholds tested. Another limitation is found in the 
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simulation study where our investigation is currently restricted to two main distributions of 
the skew normal and the generalised gamma distributions. 
 
In contrast to the single cohort GWAS setting, where the choice of phenotype 
transformation can be investigated directly, our findings should be a particular benefit to 
the meta-analysis GWAS setting where multiple sets of phenotypes cannot be easily 
assessed consistently. Rather making the choice of transformation on an ‘ad-hoc’ basis, 
study by study, the INT can generally be recommended as a choice of phenotype 
transformation for GWAS across cohorts. 
 
Given the potential for substantial power gains, it may be worth re-evaluating previous 
studies in which the LT was used for highly skewed phenotypes with a low coefficient of 
variation. For example, for phenotypes such as BMI, Insulin, and HOMA-B, particularly when 
used in conjunction with the inverse variance meta-analysis method and for studies where 
the phenotype has large variation in CV between cohorts. While many meta-analyses may 
only have small variation in CV between cohorts (CVratio <1.5), there are known examples of 
phenotypes that have their values measured close to zero that often show high variation in 
CV, such as methylation states, which have a CVratio ~5 *Rakyan, et al. 2011+, and alcohol 
consumption, which has CVratio ~1.7 *Schumann, et al. 2011+.  
 
Thus, while the INT may not be the preferable choice of transformation in many 
epidemiological studies where effect sizes are large, its application to non-normal 
phenotypes in GWAS, where effect sizes are small and the priority is discovery over 
interpretability, may lead to an increase in the discovery of genetic variants affecting 
continuous traits.  
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Chapter 4 Meta-analysis of CNV GWAS 
 
4.1 Introduction 
 
Copy number variation (CNV) is a type of genetic variation that corresponds to an abnormal 
number of copies of one or more sections in the DNA that has been deleted (deletion) or 
duplicated (duplication). In contrast to mutations that give rise to SNPs, which alter one 
single nucleotide base, CNVs have an extended region that ranges from one kilobase to 
several megabases in size. It has been shown that CNVs cover 12% of the genome in total, 
which is larger than the cumulative region covered by SNPs [Redon, et al. 2006]. As a result 
of their substantial size, they can affect a large part of genes which have functional role 
influencing the risk of disease. Compared to rare SNPs, rare CNVs may have larger impact on 
the disease risk due to their extended region, for example, in an extreme case, the whole 
functional gene might be deleted. It has been shown that the deletion of 16p11.2 leads to a 
notably high odds ratio of 30 to the risk of being obese [Walters, et al. 2010]. In additional, 
there are a number of reported rare CNVs associated with human phenotypes and disorders 
[Elia, et al. 2012; Glessner, et al. 2010a; Glessner, et al. 2010b; Glessner, et al. 2009; Wang, 
et al. 2010]. However, due to the challenge of limited statistical power to detect associated 
rare CNVs, a large sample size is required. Thus, similarly for SNP GWAS data, this can be 
achived using meta-analysis. By applying meta-analysis, our motivation is to search for rare 
CNVs with strong effect and as a consequence of applying meta-analysis on genome-wide 
scale, this also provides a search for the common CNVs with moderate effect size. 
Nevertheless, to our knowledge, there is no publication for the CNV meta-analysis on a 
genome-wide scale. In addition, unlike SNP GWAS where the common significance threshold 
of 5x10-8 is always used, the significance threshold of CNV association analysis is not well 
established due to its complex structure.   
 
The aim of this chapter is to develop an approach to enable CNV meta-analyses to proceed 
in a similar way as SNP meta-analyses and to produce a pipeline and software to support 
this proposed CNV meta-analysis. Our pipeline and software, called cnvPipe, was 
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implemented to combine CNV data across studies in the ENGAGE to search for CNV 
associated with height and weight. To our knowledge, this is the largest CNV meta-analysis 
so far which combines CNV data sets across Europe. In addition, a simulation study is 
performed to estimate the significance threshold for CNV GWAS, which is then used to 
identify associated CNVs. 
 
4.2 Background 
 
CNVs can be directly detected using, for example, comparative genomic hybridization and 
tiling oligonucleotide microarrays [Conrad, et al. 2010; Redon, et al. 2006]. However, 
because direct CNV detection comes with high cost, an indirect CNV detection via SNP data 
is commonly performed in practice. Genome-wide SNP data are widely available in many 
epidemiology data sets, so this allows CNVs to be called and association between 
phenotype-CNV to be tested along the genome. The method to call CNVs based on SNP data 
in addition to the PennCNV software are previously described in section 1.4.1. In this 
chapter, we focus on analyses of called CNVs and therefore CNV calls are assumed to be 
known based on PennCNV. This following section first describes definitions of CNV regions 
and then further provides background of association analyses that have been applied tn 
CNV data. 
 
4.2.1 CNV region (CNVR) definitions 
 
Single base pair mutations give rise to SNPs and, at a SNP, an individual either has one or the 
other allele. Therefore every individual can be genotyped at a uniform set of SNP locations. 
In contrast, CNVs are a consequence of DNA segment mutations and there is no uniform set 
of CNVs, that is, different individuals can have different sets of CNV locations. This leads to 
overlapping CNV segments across individuals. In addition, when CNVs are called based on 
SNPs, this results in variability in the CNV boundary from the true CNV boundary. Therefore, 
this inaccuracy of the CNV boundary adds an extra layer of variability in the non-overlap of 
CNV boundaries. To be able to perform association analyses, the same boundaries among 
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individuals are required such that the loss, gain, diploid state of CNV can be coded. These 
boundaries form the newly defined CNV regions called CNVRs. There have been several 
proposed ways of defining CNVRs. 
 
Firstly, a CNVR can be represented as a union of overlapping CNVs (uCNVR).  Across all 
individuals, overlapping CNVs by at least 1 basepair are merged into a CNVR [Redon, et al. 
2006]. This leads to a minimal set of CNVRs with the potential for very long CNVRs because 
of an extending region across overlapping CNVs.  Identified CNVRs with extremely long 
regions can also be detected. This can lead to a CNVR that covers many CNVs, which can 
dilute the association information. To avoid extremely long CNVRs with this approach, two 
main thresholds have been used to trim long CNVRs, which are the CNV frequency threshold 
and the overlapping CNV threshold. By setting a CNV frequency threshold, the areas with 
low CNV frequency contributing to a CNVR are removed. For example, the areas showing 
less than 10% of the total contributing CNVs within a CNVR are to be trimmed [Kim, et al. 
2012]. Alternatively, an overlapping CNV threshold can be used to trim CNVR. This 
overlapping threshold is called the reciprocal overlap (RO) and it is defined as a proportion 
of overlapping length of CNVs to the maximum length of overlapping CNVs in the region 
[Conrad, et al. 2010]. Since RO represents the degree of overlap, it can be set to restrict only 
highly overlapping CNVs to be merged for CNVR. For example, the overlapping CNVs that 
have RO < 50% will be excluded. When two different CNVs are slightly overlapped just 
because of uncertainty in CNV call boundaries, the RO can prevent these two CNVs to be 
presented as one long CNVR.  
 
Secondly, CNVRs can be represented as fragments (fCNVR) after splitting all overlapping 
CNV regions *Sha, et al. 2009+, that is, fCNVR can be defined using the start and end of all 
CNVs. As an example, in Figure 4.1, all CNVs across 4 individuals result in 5 fCNVRs, i.e. the 
first fCNVR on the left side is defined by the start of the CNV in individuals 2 or 3 and the 
start of the CNV in individual 1, the second fCNVR is defined by the start of the CNV in 
individual 1 and the start of the CNV in individual 4, the third fCNVR is defined by the start 
and the end of the CNV in individual 4, the fourth fCNVR is defined by the end of the CNV in 
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individuals 2 or 3 and the end of the CNV in individual 4, and the fifth fCNVR is defined by 
the end of the CNV in individual 4 and the end of the CNV in individual 1. Thus, instead of 
getting the minimal set of CNVR as in the previous described approach, this definition can 
lead to a larger number of CNVRs. If the association analysis strategy is to carry out a test of 
association between genotypes and a phenotype one CNVR at a time across the genome, an 
association analysis based on the definition of fCNVR can take longer processing time 
compared to the other CNVR definitions due its large numbers. 
 
These different CNVR definitions have been applied to identify regions in CNV-phenotype 
association studies. Even though there are differences in definitions, those CNVRs are highly 
overlapping and this is reflected in the similar association results *Kim, et al. 2012+. Finally, 
instead of using CNVR which can be varied in size, the fixed-size region has also been 
applied. This fixed-size region is called a “fixed window” (wCNVR). By sliding the fixed 
window across the genome, CNVs can be assessed on each window at a time [Cooper, et al. 
2011].  
 
 
Figure 4.1. CNVR definitions 
 
4.2.2 CNV association analysis 
 
The association between CNV and phenotype has been widely investigated to further 
explain missing heritability because, so far, SNPs have explained a small proportion of 
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phenotypic variance. Two main approaches have been used to perform association analysis 
in CNV data, which are, burden analysis and association analysis of copy-numbers in CNV. 
 
For the burden analysis, an underlying hypothesis is that the total number of CNVs across a 
region (gene, other region of interest, or entire genome) that an individual carries is 
associated with their risk of disease. CNV burden is investigated under the case-control 
scenario where the number of CNVs is shown to be enriched in cases compared to controls. 
This approach is widely used, especially when there is insufficient power to detect CNVs 
directly due to low frequency of CNVs or small sample size [Cooper, et al. 2011; Elia, et al. 
2012; Glessner, et al. 2010a; Glessner, et al. 2009]. This is because all rare CNVs within a 
region can be analysed together, which allows higher frequency and thus more extreme P-
values can be observed. Chi-squared and Fisher’s exact tests can be used to test for 
association under burden analysis (Figure 4.2).  
 
Instead of burden analysis which focuses on the total of CNVs within a region, the 
association analysis can be performed based on copy-numbers in each CNVR, i.e. for each 
individual, there is zero/one/two copies of a deletion or zero/one/two copies of a 
duplication. In each CNVR, copy-numbers can be tested with the phenotype using logistic or 
linear regression depending on the data type of the phenotype. An associated CNVR can 
later be referred back to the region where the particular CNV resides [Sha, et al. 2009].  
 
A number of software packages have been developed to perform association analysis of 
copy-numbers in CNVs on a genome-wide scale [Forer, et al. 2010; Glessner, et al. 2013; 
Subirana, et al. 2011]. This association analysis has the advantage of directly identifying 
associated CNVs and it allows the analysis to be performed on both case-control and 
quantitative traits. 
 
119 
 
  
Figure 4.2. Contingency table definitions to test CNV frequency difference in cases versus 
controls [Glessner, et al. 2013] where CN=0 (two copies of a deletion), CN=1 (one copy of a 
deletion), CN=3 (one copy of a duplication), and CN=4 (two copies of a duplication). 
 
4.3 Method  
 
4.3.1 CNVR definition for meta-analysis 
 
To define a uniform set of CNV regions across individuals/studies, the CNVR definition is first 
selected. We follow the definition of the fragment CNVR (fCNVR). As explained above, the 
definition of fCNVR leads to a large number of regions, many of which refer to the same 
CNVs. As a consequence, these multiple fCNVRs, which refer to the same CNV, are highly 
correlated. Therefore, similar to the concept of SNPs in LD, these fCNVRs can be viewed as 
highlighting regions of interest and, at the same time, fCNVR should be able to pinpoint the 
causal CNV within the highlighted regions. This highlighted region can also be used to spot if 
there should be any concern with the CNV calling when a single hit is shown rather than 
many in the same region.  
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The other two CNVR definitions, uCNVR and wCNVR, are not used because they might result 
in a reduction in the power to detect CNV-phenotype association. It is likely that uCNVR 
identifies many regions highlighted via fCNVRs, but it is possible that uCNVR might result in 
some long CNVRs that cover too many CNVs and this could dilute information contributing 
to the true underlying association. In addition, compared to uCNVR, which investigate CNVs 
within extended regions, fCNVR can explore CNVs based on smaller regions and this may 
allow the causal CNV to be better pinpointed. Similarly, wCNVR can lead to potential power 
reduction to search for CNV-phenotype association because its rigid boundaries may not 
reflect the true underlying CNV regions and thus the information from the nearby non-
causal CNVs can be included which may dilute the true association information.  
 
4.3.2 CNVR association analysis 
 
A large sample size can be obtained via meta-analysis, in which case we may have high 
power to detect rare CNVs with large effect sizes and common CNVs with moderate-large 
effect sizes. As a consequence of expected adequate power, we aim to pinpoint the causal 
CNVs directly, and thus apply an association analysis based on copy-numbers of CNVs rather 
than apply the burden analysis. 
 
To be able to identify an underlying mechanism of causal CNVs, we investigate deletion and 
duplication separately. For deletions, under each fCNVR, individuals can be classified as 0 
when there is no deletion, 1 when there is one copy of a deletion, and 2 when there are two 
copies of a deletion at a locus. Similarly, for duplications, individuals at each fCNVR take the 
value 0 when there is no duplication, 1 when there is one copy of a duplication, and 2 when 
there are two copies of a duplication at a locus. By assuming additive effects, linear 
regression is applied to test association between copy-numbers of deletions or duplications 
with the phenotype. Note that other types of CNVs are not considered in this Chapter, e.g. 
three and four copies of a duplication, because it is more difficult to distinguish between 
them based on LRR values, which makes them prone to be incorrectly called. For example, 
the difference of LRR between four copies of a duplication (LRR=1.1) and three copies of a 
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duplication (LRR=0.92) is 0.18 whereas the difference of LRR between two copies of a 
duplication (LRR=0.7) and one copy of a duplication (LRR=0.4) is 0.3. 
 
4.3.2 cnvPipe: CNVR Meta-analysis pipeline 
 
To support our approach to enable CNV meta-analyses, the pipeline and software, called 
cnvPipe, was developed. The aim of cnvPipe is to generate the uniform set of fCNVRs across 
cohorts (fCNVRcombine), and perform the phenotype-fCNVRcombine association analysis. After 
CNV calling has been performed on every cohort using PennCNV software. The output files 
can then be directly used as input files for cnvPipe to determine fCNVRcombine. However, 
because of restrictions in data sharing, the co-ordinating centre cannot request all CNV calls 
from collaborators to define fCNVRcombine directly. Therefore, cnvPipe separates the process 
into the three following stages (Figure 4.3). 
 
4.3.2.1 Stage I 
 
The aim of the cnvPipe stage I is to first identify a set of fCNVR within each cohort 
(fCNVRcohort). PennCNV is the recommended software to do CNV calling, though, other 
available software packages for CNV calling can also be used. Quality control is first applied 
at an individual level. To exclude individuals with evidence of low DNA quality, the default 
thresholds are SD(LRR) < 0.3, |WF| < 0.05, and |GCWF| < 0.05. However, as previously 
stated in section 1.4.2, it is advisable that each cohort determines their own appropriate QC 
thresholds. Only individuals that pass quality control thresholds are used to define 
fCNVRcohort. To ensure the reliability of CNV calls, CNVs that contain fewer than 3 SNPs are 
also excluded. 
 
4.3.2.2 Stage II 
 
The aim of the cnvPipe stage II is to identify the uniform set of fCNVRcombine across all 
cohorts. Using the same approach previously used in identifying fCNVRcohort, the information 
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from all fCNVRcohort (chromosome, start and end base-pair) is used to re-generate 
fCNVRcombine by splitting all overlapping fCNVRcohort regions. Therefore, fCNVRcombine has a 
greater number of splitting fragments than fCNVRcohort. This stage is done by the co-
ordinating centre.  
 
4.3.2.3 Stage III 
 
After obtaining the fCNVRcombine, which allows the uniform set of fCNVRs across all cohorts, 
each cohort can re-generate their fCNVRs based on the fCNVRcombine. At this stage, the 
association analysis will be performed. Either logistic or linear regression is used to perform 
association analysis where covariates can also be included. For quantitative phenotypes, 
cnvPipe applies the inverse normal transformation (INT) to induce normality before applying 
regression. As previously shown in Chapter 2, the INT could potentially provide greater or 
similar power when the effect sizes are small because it induces normality in the error term 
under the linear regression model. In addition, INT is robust to the presence of between 
cohort heterogeneity of coefficient of variation (CV) when used in conjunction with inverse 
variance meta-analysis. 
 
After phenotype-fCNVRcombine association results are obtained from all cohorts, the co-
ordinating centre then uses cnvPipe to perform meta-analysis to combine phenotype-
fCNVRcombine association results. The cnvPipe software and its instruction are available on 
the website www.imperial.ac.uk/medicine/peopel/l.coin. 
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Figure 4.3. cnvPipe pipeline 
 
4.4 CNVR investigations 
 
The pipeline and cnvPipe software were implemented to combine CNV data from 7 cohorts 
in the ENGAGE (Table 4.1) with the total size of 17,223. EGCUT and ERF have their SNP 
genotyping performed in multiple data sets.  
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Table 4.1. ENGAGE collaborators in CNV meta-analysis 
Cohort Batch name 
 
The Northern Finnish Birth 
Cohort 1966  
 
NFBC 
The Wellcome Trust Case-
Control Consortium  
 
WTCCC2 
 
The National Blood Service  
 
NBS 
 
 
 
Estonian Genome Project  
 
EGCUT370_1 
EGCUT370_2  
EGCUTOMNI_1 
EGCUTOMNI_2 
EGCUTOMNI_3 
EGCUTOMNI_4 
 
Helsinki Birth Cohort  
 
HBCS 
Dietary, life style, and genetic 
determinants of obesity 
metabolic syndrome  
 
DILGOM 
 
 
 
 
 
The Erasmus Rucphen Family  
ERF_cohort_1 
ERF_cohort_2 
ERF_cohort_3 
ERF_cohort_4 
ERF_cohort_5 
ERF_cohort_6 
ERF_cohort_7 
ERF_cohort_8 
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4.4.1 Overview of CNVRs characteristics 
 
After cnvPipe stage I, where fCNVRcohort was identified, the characteristics of fCNVRcohort in 
each cohort are investigated (Table 4.2). In general, there is low median frequency of both 
deletion fCNVRcohort (0.06%-2.15%) and duplication fCNVRcohort (0.09%-2.6%). The length of 
deletion fCNVRcohort has a range 23-353 kb, except ERF_cohort_8, which contains an outlier 
of lenght 1933 kb, and the length of duplication fCNVRcohort has a range 18-931kb.  
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Table 4.2. The summary of fCNVRcohort and fCNVRcombine 
  N deletion fCNVRcohort duplication fCNVRcohort 
  
 
n Frequency 
 
(median) 
Length 
kb 
(median) 
n Frequency 
 
(median) 
Length  
kb 
(median) 
DILGOM 649 356 0.0015 102 1155 0.0054 41 
EGCUT370_1 1062 373 0.0009 126 9787 0.0014 166 
EGCUT370_2 615 491 0.0024 104 20612 0.0057 82 
EGCUTOMNI_1 888 526 0.0011 119 1015 0.0011 142 
EGCUTOMNI_2 475 441 0.0021 162 4013 0.0011 215 
EGCUTOMNI_3 533 425 0.0019 121 5056 0.0009 211 
EGCUTOMNI_4 794 356 0.0013 120 2181 0.0013 163 
ERF_cohort_1 77 98 0.0130 114 194 0.0260 931 
ERF_cohort_2 50 60 0.0100 133 141 0.0100 134 
ERF_cohort_3 108 101 0.0046 120 103 0.0046 160 
ERF_cohort_4 231 357 0.0065 65 9393 0.0043 169 
ERF_cohort_5 537 874 0.0028 77 8504 0.0019 206 
ERF_cohort_6 116 159 0.0086 106 1844 0.0086 162 
ERF_cohort_7 193 82 0.0026 128 153 0.0052 127 
ERF_cohort_8 93 114 0.0215 1933 135 0.0054 177 
HBCS 1545 687 0.0006 122 78113 0.0091 18 
NBS 1944 4340 0.0013 52 4928 0.0054 21 
NFBC 4799 5323 0.0011 353 4009 0.0038 37 
WTCCC2 2514 7482 0.0032 23 3874 0.0012 94 
fCNVRcombine 17223 20318 0.0015 18 144490 0.0032 12 
 
 
For fCNVRcombine identified from all fCNVRcohort, the histograms of fCNVRcombine length and 
frequency are shown in Figure 4.4. Overall, the median of fCNVRcombine length in deletion 
(18kp) is higher than that in duplication (12kb) and the median of deletion frequency 
(0.0015) is lower than duplication frequency (0.0032).  
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Figure 4.4. Histograms of fCNVRcombine length in a) deletion and b) duplication and 
fCNVRcombine frequency in c) deletion and d) duplication. 
 
In addition to the previous summary of basic characteristics, we further investigate our 
assumption that these characteristics of fCNVR numbers, frequency, and length, may 
directly depend on the total sample size. To assess the relationship between the sample size 
and the other characteristics across data sets, the information from Table 4.2 is plotted in 
Figure 4.5 and Figure 4.6. By assessing this relationship, we can visually observe 
characteristics at the different size across data sets.  In addition, this may allow us to spot 
data sets that have unusual/extreme characteristics compared to the others so that those 
data sets should be carefully investigated and the exclusion should be considered before the 
meta-analysis. 
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Firstly, we observe that the higher the sample size (N_cohort), the higher the number of 
deletion fCNVRcohort (N_fCNVR) (cor=0.83 in Figure 4.5a). This is likely because more 
deletions exist in a bigger cohort, therefore more deletion fCNVRs can be also identified. 
Nevertheless, this is not clearly observed under duplication (cor=0.15 in Figure 4.6a), 
especially when HBCS, which is shown as an outlier, is excluded (cor=0.09). Secondly, we 
observe some evidence of lower frequency of deletion fCNVRcohort and duplication 
fCNVRcohort (cor=-0.41 in Figure 4.5b and cor=-0.23 in Figure 4.6b) with an increase of the 
sample size of the cohort. This is likely for two main reasons; low frequency can only be 
calculated from a large cohort (for example, the lowest fCNVR frequency from 1000 
individuals can be 0.001 whereas the lowest fCNVR frequency from 100 individuals cannot 
go below 0.01) and the larger cohort is more likely to detect (new) rare CNVs that have not 
been found before in smaller cohorts. Based on these two reasons, these can lower overall 
fCNVR frequency. Thirdly, even though the relationship between N_cohort and fCNVRcohort 
length is not first strongly observed (cor=-0.09 in Figure 4.5c and cor=-0.35 in Figure 4.6c), 
this relationship appears to show, after excluding outlier cohorts, some evidence of decrease 
in fCNVRcohort length when N_cohort increases. By excluding the outliers ERF_cohort8 and 
NFBC, the correlation between N_cohort and fCNVRcohort length is shown as -0.599 in 
deletion. By excluding ERF_cohort1, the correlation between N_cohort and fCNVRcohort 
length is shown as -0.595 in duplication. The shorter fCNVRcohort length is likely to be a 
consequence of the high overlap of long CNVs when the sample size is increased while short 
CNVs are less likely to overlap with those previously identified. 
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Figure 4.5. The relationship between cohort sample size and a) the total of deletion 
fCNVRcohort, b) frequency of deletion fCNVRcohort, and c) length of deletion fCNVRcohort 
 
 
 
Figure 4.6. The relationship between cohort sample size and a) the total of duplication 
fCNVRcohort, b) frequency of duplication fCNVRcohort, and c) length of duplication fCNVRcohort 
 
 
We further investigate the structure of fCNVRcohort frequency across all data sets. Our 
assumption is that data sets that have similar sample size or come from same population 
are likely to have similar fCNVRcohort frequency overall. To investigate this assumption, 
principal component analysis (PCA) is applied (see section 2.4.2.1 for more information on 
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PCA). By applying PCA, this might reveal underlying structures across data sets and it may 
show outlier data sets which should later be carefully investigated to determine whether 
they should be excluded before the meta-analysis. 
 
In this investigation, only fCNVRs that have non-zero frequency in all data sets are used to 
investigate the structure under fCNVRcohort frequency. In addition, if there are a large 
number of highly correlated fCNVRs which reflect unusually long stretches of LD, PCA may 
capture this LD structure instead of the structure from overall results that we are interested 
in. Therefore, to minimize the impact of LD, one fCNVR in every 100kb only is used to 
perform PCA. Out of 20,318 original deletion fCNVRs, 916 deletion fCNVRs are used to 
perform PCA. Out of 144,490 original duplication fCNVRs, 14,753 duplication fCNVRs are 
used to perform PCA. Most data sets are clustered together whereas ERF_cohort1, 
ERF_cohort7, and EGCUTOMNI_1 are observed as outliers under deletion, and ERF_cohor1 
and ERF_cohor5 are observed as outliers under duplication (Figure 4.7 and Figure 4.8). 
Based on these outliers, we do not fully understand the reason that makes them different 
from the other data sets. This might be because there are many factors affecting fCNVR 
frequency including sample size, quality of CNV calling, as well as different populations, and 
therefore it is difficult to clearly untangle and pinpoint these underlying factors when 
outliers are observed. Thus, it is difficult to justify whether these outlier data sets are a 
concern. 
 
In summary, the characteristics of fCNVR across data sets show some evidence of being 
directly influenced by the total sample size. At first, we thought that this evidence can be 
strongly observed, however, this is not the case, especially for the relationship between 
N_cohort and N_fCNVR in duplication, which will be further discussed in the next section. In 
addition, we further investigate whether overall fCNVRcohort frequency across data sets can 
distinguish different populations or data sets with different size. However, based on our 
investigation, the underlying structure under fCNVR frequency is not clearly observed. 
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Figure 4.7. A scatter plot with the three first largest components of a PCA based on deletion 
fCNVR frequency  
 
 
 
Figure 4.8. A scatter plot with the three first largest components of a PCA based on 
duplication fCNVR frequency 
 
4.4.2 A significance threshold for CNVR GWAS 
 
The multiple testing in GWAS is first shown in SNP data, where a large number of tests are 
conducted across SNPs. This leads to a high risk of false positive findings, and therefore 
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strict thresholds for statistical significance are needed. To maintain a genome-wide false 
positive rate of 0.05 (FWER=0.05), the per-SNP significance threshold was estimated as  
5x10-8 *Risch and Merikangas 1996+. This can be derived using a Bonferroni correction or 
Sidak correction *Pickrell, et al. 2010+ assuming 1x106 independent SNPs at the 5% FWER. To 
further investigate the multiple testing in GWAS across populations that have different 
genomic structures, the per-SNP significance thresholds are investigated in West African, 
East Asian and European populations using a permutation approach to control FWER 
*Hoggart, et al. 2008+. Without prior knowledge of independent SNPs, a permutation 
procedure can be applied to obtain the correct FWER when the tests are dependent. The 
per-SNP significance thresholds across these 3 continental regions are reported under 
different MAFs and sample sizes. Similar to previously estimated significance threshold of 
5x10-8, the per-SNP significance thresholds are shown to be between 1.5x10-8 and 3x10-8 
across all three populations when MAF>5%. As with SNP data, a large number of fCNVRs 
across the genome leads to the multiple-testing problem and the per-fCNVR significance 
level (P-thresholdfCNVR) needs to be specified. The simplest approach to control FWER in 
multiple testing is the Bonferroni correction or Sidak correction. However, to apply these 
corrections, a number of independent fCNVRs are required. Due to a large number of 
fCNVRs and their complex correlation structure, it is difficult to estimate these independent 
fCNVR numbers. Therefore, as previously applied in SNPs, a permutation procedure is used 
to estimate an appropriate the P-thresholdfCNVR. 
 
The idea of obtaining significance thresholds based on the permutation approach is to 
estimate the distribution of the minimum P-values under the null of no association between 
fCNVRs and phenotype. Once the distribution is estimated, the P-value at the 5th percentile 
corresponds to FWER of 0.05. To simulate the null of no association between fCNVRs and 
phenotype, the phenotype measures across individuals are first randomly shuffled to break 
any association between phenotype and fCNVRs. By performing linear regressions for 
association testing between fCNVRs and the sets of permuted phenotypes, the sets of 
minimum P-values can then be used as an estimate of the distribution of the minimum P-
values under the null. 
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4.4.2.1 Data simulations assessing per-CNVR significant thresholds based on NFBC 
 
To estimate the P-thresholdfCNVR, we generate simulated data based on NFBC1966 which is 
an ‘in-house’ data set available to us. The generated fCNVRs across the genome are based 
on CNV calls from NFBC1966 individuals. The data simulation was performed in two main 
steps. Step 1 is to generate a set of fCNVRs under the fixed N sample size. To do this, N 
individuals are first randomly selected. CNVs called in these individuals are then used to 
identify all fCNVRs across genome. The range of investigated N are N=1000, 2000, 3000, and 
4000, which do not exceed the total sample size of 4,722 in NFBC. Step 2 is to permute their 
phenotype so that there is no association between phenotype and fCNVR. In our simulation, 
weight is used for permutation because there is no missing value across NFBC1966 
individuals. After permuting the weight phenotype, linear regression is performed to assess 
phenotype-fCNVR association at each fCNVR at a time across the genome. The minimum P-
value among all fCNVRs, which pass HWE threshold of 10-4 and selected MAF threshold, is 
then recorded. The range of investigated MAF is 0.1%, 0.5%, 1%, and 2%. 
 
To assess the range of minimum P-values obtained from the different possible sets of 
fCNVRs, step 1 is repeated 10,000 times, and each time, a single iteration of step 2 is 
processed. The 10,000 minimum P-values computed for each iteration of this process are 
recorded. Ideally the fCNVRs would also be permuted so that variation in fCNVRs between 
studies can be modelled, but this approach has minimal computational time. We check that 
the recorded P-values are comparable to the minimum P-values recorded under the more 
appropriate but time-consuming approach, where step 1 is repeated 100 times and each 
time, 100 iterations of step 2 are processed (Figure 4.9). To estimate the P-thresholdfCNVR 
under the 5% FWER, the distribution of recorded P-values is assessed at 5%. Therefore, in 
our case, it is the 500th smallest P-value from the recorded 10,000 minimum P-values. 
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Figure 4.9. Minimum P-values from 10,000 iterations at MAF=0.1%, 0.5%, 1%, and 2% 
(N=1000) which are obtained from two simulation approaches, i.e 1) 100 sets of fCNVRs 
each with 100 times of phenotype permutations in deletion (a), and duplication (c), and 2) 1 
permutation under 10,000 sets of fCNVRs in deletion (b) and duplication (d). The light blue 
dot represents the P-thresholdfCNVR at FWER=0.05 at each MAF. The light blue dot is shown 
at an average log10 of total fCNVR number within each MAF. 
 
 
To investigate the P-thresholdfCNVR, we tested across sample size of N=1000, 2000, 3000, and 
4000 and MAF=0.1%, 0.5%, 1%, and 2%. Under the range of N, this allows the variation of 
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the total number of fCNVRs first identified across all samples, i.e. more fCNVRs can be 
identified at the larger sample size. Under the range of MAF, this allows the variation of the 
total number of fCNVRs which are remained at each MAF threshold, i.e. more fCNVRs are 
excluded under the stricter MAF threshold, or in another word, fewer fCNVRs are included 
to perform regression under the stricter MAF threshold.  
 
At N=1000, in deletion (Figure 4.10a), the average number of fCNVR ranges between 50 and 
1000 (log10(total number of fCNVR)=1.7-3), and the P-thresholdfCNVR roughly ranges 
between 0.0001 and 0.001. The stricter P-thresholdfCNVR can be observed at lower MAF 
which allow higher number of fCNVRs. At N=1000, in duplication (Figure 4.11a), the average 
number of fCNVR ranges between 300 and1600 (log10(total number of fCNVR)=2.5-3.2), 
and the significance threshold roughly ranges between 0.00008 and 0.0003. Similarly, the 
stricter P-thresholdfCNVR can be observed at lower MAF, which allow higher number of 
fCNVRs. By comparing deletion and duplication at each MAF, the number of duplication 
fCNVR is higher and lower variant than the number of deletion fCNVR. This is likely because 
duplication fCNVRs have higher MAF (median=0.32%) than deletion fCNVR (median=0.15%) 
as previously shown in Table 4.2. Therefore, at the same MAF threshold, there are higher 
numbers of duplication fCNVRs that pass the threshold compared to deletion fCNVRs, which 
allow the more accurate estimation of fCNVR numbers under 10,000 iterations of 
resampling procedure. 
 
By increasing sample size (Figure 4.10b,c,d and Figure 4.11b,c,d), the number of fCNVR 
under the same MAF is less varied because there is more chance that the same individuals 
from 4722 NFBC1966 individuals are resampled across 10,000 iterations. In addition, at 
increasing sample size, more CNVs can be called and thus the higher fCNVRs can be 
observed, i.e. an increase in log10(total number of fCNVR) across x-axis when sample size 
increases. Note that, at fixed MAF, only a slight increase in fCNVR number is observed under 
duplication. This may explain why we did not observe a clear correlation between N_cohort 
and N_fCNVR in duplication (Figure 4.6a) because this slight increase in N_fCVNR can be 
easily hidden by other factors across data sets. Compared to the high increase in deletion 
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calling at an increase sample size, the slight increase of N_fCNVR in duplication could be a 
consequence of the limitation in duplication calling based on the small difference in LRR 
values from the diploid state (see Table1.1).  
 
 
Figure 4.10. Minimum P-values from 10,000 iterations at MAF=0.1%, 0.5%, 1%, and 2% 
when a) N=1000, b) N=2000, c) N=3000, and d) N=4000 in deletion.  The light blue dot 
represents the P-thresholdfCNVR at FWER=0.05 at each MAF. The light blue dot is shown at an 
average log10 of total fCNVR number within each MAF. 
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Figure 4.11. Minimum P-values from 10,000 iterations at MAF=0.1%, 0.5%, 1%, and 2% 
when a) N=1000, b) N=2000, c) N=3000, and d) N=4000 in duplication.  The light blue dot 
represents the P-thresholdfCNVR at FWER=0.05 at each MAF. The light blue dot is shown at an 
average log10 of total fCNVR number within each MAF. 
 
Alternatively, P-thresholdsfCNVR which were previously presented across sample sizes (Figure 
4.10 and Figure 4.11) can be presented again, this time across MAF (Figure 4.12 and Figure 
4.13). Under the same MAF, the similar P-thresholdsfCNVR are observed across fCNVR 
numbers. 
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Figure 4.12. Minimum P-values from 10,000 iterations across N=1000, 2000, 3000, and 4000  
at a) MAF=0.1%, b) MAF=0.5%, c) MAF=1%, and d) MAF=2% in deletion.  The light blue dot 
represents the P-thresholdfCNVR at FWER=0.05 at each N. 
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Figure 4.13. Minimum P-values from 10,000 iterations across N=1000, 2000, 3000, and 4000 
at a) MAF=0.1%, b) MAF=0.5%, c) MAF=1%, and d) MAF=2% in duplication.  The light blue 
dot represents the P-thresholdfCNVR at FWER=0.05 at each N. 
 
4.4.2.2 Effective number of CNVRs 
 
To investigate the number of independent fCNVRs (i.e. effective fCNVRs), the estimated P-
thresholdsfCNVR previously obtained from the permutation procedure can be back-calculated 
to obtain the number of effective fCNVR, which are hidden under total fCNVRs because of 
their complex correlation structure. The number of effective fCNVRs can be back calculated 
using the Sidak correction [Hoggart, et al. 2008]. Under Sidak correction,  
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n
)1(1   ,                  (4.1)                       
  
where   is a given FWER,    is an estimated P-thresholdfCNVR obtained from permutation 
procedure, and n is the number of effective fCNVR. At a given N and MAF, this effective 
fCNVR number is presented as a proportion to the total fCNVR number, 
 
.
___
/
fCNVRofnumbertotal
n
TratioE                                (4.2)                      
 
 
For example, at N=1000 and MAF=0.01 (Figure 4.10a), there are 271 fCNVRs that pass the 
MAF threshold. The significance threshold obtained from this simulation is p= 0.00054. 
Using equation 4.1 where 00054.0 and 05.0 , this gives n=95 therefore ratio 
E/T=95/271=0.35. All ratios E/T are shown in Figure 4.14 for deletion and Figure 4.15 for 
duplication. This example of ratio E/T 0.35 is plotted against x-axis of 2.27 (an average of 
log10(total number of fCNVR) across all 10,000 iterations) as the far left dot on Figure 4.14c. 
Under the same MAF, similar ratios E/T are observed across total number of fCNVRs within 
deletion (Figure 4.14). For duplications, similar ratios E/T are observed at MAF=0.001, 0.005, 
however, a range of ratios E/T is observed at MAF=0.01 and MAF=0.02 (Figure 4.15). All 
ratios E/T are shown in Table 4.3 for deletion and Table 4.4 for duplication. 
 
Based on these calculated ratios E/T, the n effective fCNVR from data sets with known 
fCNVR number (Table 4.2) can be calculated from equation 4.2. Using these calculated n 
effective fCNVR while fixing 05.0 , the    P-thresholdsfCNVR under each data set can 
be calculated using equation 4.1. The P-thresholdsfCNVR based on the maximum and 
minimum ratios E/T across data sets are shown in Table 4.5 for deletion and Table 4.6 for 
duplication. Even though small-to-moderate variation of ratios E/T can be observed across 
different MAF and sample size, this only reflects a minor difference in the P-thresholdfCNVR. 
In addition, for fCNVR from meta-analysis, similar P-thresholdfCNVR is shown in deletion 
(min=1x10-5 and max=5.5x10-6) and in duplication (min=9.6x10-7, and max=5.1x10-7). 
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Therefore, we take an average of ratio E/T to calculate underlying effective fCNVRs of 
combined data under meta-analysis (average ratio E/T =0.36 in deletion and average ratio 
E/T =0.53 in duplication). Based on these average numbers, for every increase of 100 
deletion fCNVRs, there is an increase of 36 effective CNVRs on average. For duplication, for 
every increase of 100 duplication fCNVRs, there is an increase of 53 effective fCNVRs. Based 
on these average ratios E/T, the P-thresholdfCNVR under meta-analysis is suggested at 7x10
-6
 
for deletion and 6.7x10-7 for duplication. For the rough but sensible P-value thresholds, 
these are suggested at 1x10-5 for deletion and 1x10-6 for duplication. Nevertheless, these 
thresholds may be further adjusted in the future when more CNV calls at larger sample size 
in various populations are available.  
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Figure 4.14. The ratio of effective CNVR to the total CNVR numbers at FWER=5% across 
N=1000, 2000, 3000, and 4000 at a) MAF=0.1%, b) MAF=0.5%, c) MAF=1%, and d) MAF=2% 
in deletion.   
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Figure 4.15. The ratio of effective CNVR to the total CNVR numbers at FWER=5% across 
N=1000, 2000, 3000, and 4000 at a) MAF=0.1%, b) MAF=0.5%, c) MAF=1%, and d) MAF=2% 
in duplication.   
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Table 4.3. The ratio of effective CNVR to the total CNVR numbers at FWER=5% in deletion 
FWER=0.05 N=1000 N=2000 N=3000 N=4000 average 
Maf=0.1% 0.39 0.30 0.41 0.37 0.37 
Maf=0.5% 0.39 0.30 0.35 0.35 0.35 
Maf=1% 0.35 0.38 0.25 0.31 0.32 
Maf=2% 0.42 0.46 0.34 0.36 0.40 
average 0.39 0.36 0.34 0.35 0.36 
 
Table 4.4. The ratio of effective CNVR to the total CNVR numbers at FWER=5% in duplication 
FWER=0.05 N=1000 N=2000 N=3000 N=4000 average 
Maf=0.1% 0.52 0.59 0.46 0.59 0.54 
Maf=0.5% 0.53 0.59 0.50 0.48 0.52 
Maf=1% 0.69 0.61 0.52 0.47 0.57 
Maf=2% 0.60 0.55 0.39 0.37 0.48 
average 0.59 0.58 0.47 0.48 0.53 
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Table 4.5. P-thresholdsfCNVR for deletion calculated from ratio E/T 
deletion 
N of 
fCNVRcohort 
 
per-fCNVR significance threshold 
  
  
    
min 
ratio=0.25 
max 
ratio=0.46 
average 
ratio=0.36 
DILGOM 356 5.8 x10-4 3.1 x10-4 4.0 x10-4 
EGCUT370_1 373 5.5 x10-4 3.0 x10-4 3.8 x10-4 
EGCUT370_2 491 4.2 x10-4 2.3 x10-4 2.9 x10-4 
EGCUTOMNI_1 526 3.9 x10-4 2.1 x10-4 2.7 x10-4 
EGCUTOMNI_2 441 4.7 x10-4 2.5 x10-4 3.2 x10-4 
EGCUTOMNI_3 425 4.8 x10-4 2.6 x10-4 3.4 x10-4 
EGCUTOMNI_4 356 5.8 x10-4 3.1 x10-4 4.0 x10-4 
ERF_cohort_1 98 2.1 x10-3 1.1 x10-3 1.5 x10-3 
ERF_cohort_2 60 3.4 x10-3 1.9 x10-3 2.4 x10-3 
ERF_cohort_3 101 2.0 x10-3 1.1 x10-3 1.4 x10-3 
ERF_cohort_4 357 5.7 x10-4 3.1 x10-4 4.0 x10-4 
ERF_cohort_5 874 2.3 x10-4 1.3 x10-4 1.6 x10-4 
ERF_cohort_6 159 1.3 x10-3 7.0 x10-4 9.0 x10-4 
ERF_cohort_7 82 2.5 x10-3 1.4 x10-3 1.7 x10-3 
ERF_cohort_8 114 1.8 x10-3 9.8 x10-4 1.2 x10-3 
HBCS 687 3.0 x10-4 1.6 x10-4 2.1 x10-4 
NBS 4340 4.7 x10-5 2.6 x10-5 3.3 x10-5 
NFBC 5323 3.9 x10-5  2.1 x10-5 2.7 x10-5 
WTCCC2 7482 2.7 x10-5 1.5 x10-5 1.9 x10-5 
fCNVRcombine 20318 1.0 x10
-5 5.5 x10-6 7.0 x10-6 
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Table 4.6. P-thresholdsfCNVR for duplication calculated from ratio E/T 
duplication 
N of 
fCNVRcohort 
 
per-fCNVR significance threshold 
 
 
    
min 
ratio=0.37 
max 
ratio=0.69 
average 
ratio=0.53 
DILGOM 1155 1.2 x10-4 6.4 x10-5 8.4 x10-5 
EGCUT370_1 9787 1.4 x10-5 7.6 x10-6 9.9 x10-6 
EGCUT370_2 20612 6.7 x10-6 3.6 x10-6 4.7 x10-6 
EGCUTOMNI_1 1015 1.4 x10-4 7.3 x10-5 9.5 x10-5 
EGCUTOMNI_2 4013 3.5 x10-5 1.9 x10-5 2.4 x10-5 
EGCUTOMNI_3 5056 2.7 x10-5 1.5 x10-5 1.9 x10-5 
EGCUTOMNI_4 2181 6.4 x10-5 3.4 x10-5 4.4 x10-5 
ERF_cohort_1 194 7.1 x10-4 3.8 x10-4 5.0 x10-4 
ERF_cohort_2 141 9.8 x10-4 5.3 x10-4 6.9 x10-4 
ERF_cohort_3 103 1.3 x10-3 7.2 x10-4 9.4 x10-4 
ERF_cohort_4 9393 1.5 x10-5 7.9 x10-6 1.0 x10-5 
ERF_cohort_5 8504 1.6 x10-5 8.7 x10-6 1.1 x10-5 
ERF_cohort_6 1844 7.5 x10-5 4.0 x10-5 5.2 x10-5 
ERF_cohort_7 153 9.1 x10-4 4.9 x10-4 6.3 x10-4 
ERF_cohort_8 135 1.0 x10-3 5.5 x10-4 7.2 x10-4  
HBCS 78113 1.8 x10-6 9.5 x10-7 1.2 x10-6 
NBS 4928 2.8 x10-5 1.5 x10-5 2.0 x10-5 
NFBC 4009 3.5 x10-5 1.9 x10-5 2.4 x10-5 
WTCCC2 3874 3.6 x10-5 1.9 x10-5 2.5 x10-5 
fCNVRcombine 144490 9.6 x10
-7 5.1 x10-7 6.7 x10-7 
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4.5 ENGAGE Meta-Analysis Results 
 
From 7 cohorts, we currently obtain results from NFBC, WTCCC2, HBCS, EGCUT, and DILGOM 
with the total sample size of 13,874 (out of 17,223). Results from ERF and NBS will be 
further included, however, the summarised results presented in this chapter are based on 
the current available cohorts. In this section, we present results from our CNV meta-analysis 
pipeline applied to search for CNVs associated with two phenotypes: height and weight.  
 
4.5.1 CNVR association analysis in a single study 
 
To perform association analysis, linear regression analysis is applied. It has been shown that 
different genotyping batches can affect the frequency of CNV calling [Barnes, et al. 2008]. If 
the proportion of cases and controls is not equally pooled across batches, this can lead to 
false positive findings in CNV-phenotype association. Similarly, for quantitative phenotypes, 
this can cause false positive finding of associated CNVs when the proportion of individuals 
with high and low phenotype measurement is not equally distribute between batches. 
Therefore, phenotype-fCNVRcombine association analyses are performed in each batch 
separately. In addition, as previously shown in Chapter 3, an inverse normal transformation 
(INT) has the potential for substantial power gains compared to log transformation (LT). 
Therefore, INT was applied to both height and weight to induce normality before 
performing linear regression. Note that we observe a strong skewness in NFBC1966 weight 
distribution (skew=0.89). Even though we observe no evidence of skewness in NFBC1966 
height distribution (skew=0.02), different levels of skewness in height may appear in other 
cohorts. INT was previously applied across cohorts in a height GWAS [Sanna, et al. 2008], 
which indicates the possibility of skewness in height. In addition, as previously shown in 
Chapter 2, when there is a weak or zero skewness, INT provides similar power compared to 
no-transformation with no evidence of increase in type I error. Therefore, to ensure the 
normality in all phenotype distributions across cohorts with no power reduction to the 
cohort, INT was applied to both height and weight in our CNV association analysis. Age and 
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gender are adjusted for in the regression model. For QC, MAF of 0.5% and HWE threshold of 
1x10-4 are used. 
 
Association results between fCNVRcombine and height are shown as QQ-plots in Figure 4.16 
(deletion) and Figure 4.17 (duplication). Association results between fCNVRcombine and 
weight are shown as QQ-plots in Figure 4.18 (deletion) and Figure 4.19 (duplication). In 
general, overall P-values follow the null with some minor inflation, except the major 
inflation observed in HBCS duplication. We suspect that this might come from the problem 
of overcalling duplication in at least one individual previously shown as an unexpectedly 
high numbers of fCNVR duplications (duplication N_fCNVR=78,113) compared to the other 
cohorts (duplication N_fCNVR =103-9,393) (Table 4.2). Due to this major inflation, this 
suggested that further QC in HBCS is required prior to association analysis. Although 
NFBC1966 appears to show some inflation, this data set is retained in the meta-analysis to 
optimise power. However, this means that caution should be applied for meta-analysis 
results. 
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Figure 4.16. QQ plots for deletion-height association results (HWE=10-4, MAF=0.5%) 
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Figure 4.17. QQ plots for duplication-height association results (HWE=10-4, MAF=0.5%) 
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Figure 4.18. QQ plots for deletion-weight association results (HWE=10-4, MAF=0.5%) 
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Figure 4.19. QQ plots for duplication-weight association results (HWE=10-4, MAF=0.5%) 
 
4.5.2 CNVR association analysis in combined studies 
 
All association results are further combined using an inverse variance fixed-effect model 
where weighted effect sizes across all studies are combined. To ensure that the meta-
analysis signal at each fCNVRcombine does not come from only single study, fCNVRcombine with 
non-zero frequency in at least 2 cohorts are included in the meta-analysis. HBCS is excluded 
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from meta-analysis in duplication due to the concern of some QC issues observed in the 
previous section. In QQ plots showing meta-analysis results (Figure 4.20), moderate to high 
inflation factors are observed, i.e. 0.8 (deletion in height), 1.6 (deletion in weight), 2.2 
(duplication in height), and 1.7 (duplication in weight). Under our previous proposed P-
thresholdfCNVR of 5% FWER (P-thresholdfCNVR is 1x10
-5
 in deletion and 1x10
-6 in duplication), no 
fCNVR reach the thresholds under the CNV meta-analysis in height and weight. 
Nevertheless, two cohorts with sample size of 3349 will be further added and thus further 
power will be obtained.  
 
Under height meta-analysis in deletion, there are 5 fCNVRs that show moderate association 
signals in Chromosomes 6 and 10 (Table 4.7). While the other cohorts have no deletion 
CNVs at these 5 fCNVRs, the association signals on chromosome 6 are obtained from HBCS 
and Dilgom, and the association signals on chromosome 10 are obtained from NFBC and 
WTCCC (Figure 4.21). Those fCNVRs on chromosome 6 are close to MANEA and those 
fCNVRs on chromosome 10 are in PTPN20A and/or FRMPD2P2. PTPN20A was reported to be 
involved in the process of cell growth and cell differentiation 
(http://datasheets.scbt.com/sc-138557.pdf). In addition, based on the Database of Genomic 
Variants (http://dgvbeta.tcag.ca/dgv/app/home) where deletions are highly detected in this 
PTPN20A region, it ensures that the deletion detected in PTPN20A in our study is genuine. 
As PTPN20A was not previously reported in SNP-height GWAS studies, this deletion at 
PTPN20A may further explain the height variation in addition to what have been found 
based on SNPs. Therefore, CNV is this gene region should be further investigated. 
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Figure 4.20. QQ plots for meta-analysis results in a) deletion-height, b) deletion-weight, c) 
duplication-height and d) duplication-weight (HWE=10-4, MAF=0.5%) where HBCS is 
excluded from duplication meta-analysis. 
 
 
 
 
 
155 
 
Table 4.7. fCNVRs with moderate association signals from height meta-analysis in deletion 
chromosome start end P-value gene 
6 95613585 95616070 6.3 x10-5 Intergenic 
(~0.4mb from MANEA) 
6 95616070 95626746 1.5 x10-5 Intergenic 
(~0.4mb from MANEA) 
6 95626746 95629110 1.5 x10-5 Intergenic 
(~0.4mb from MANEA) 
10 46569123 46580067 3.7 x10-5 PTPN20A 
10 46580067 46684858 8.7 x10-5 PTPN20A, FRMPD2P2 
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Figure 4.21. Forest plots for fCNVRs showing moderate association signals from height 
meta-analysis in deletion 
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4.6 Discussion 
 
Due to the challenge of limited statistical power to detect associated rare CNVs, a large 
sample size is required and thus, similar to what has been done in SNP GWAS, this can be 
achieved by using meta-analysis. Nevertheless, meta-analysis has not been applied in CNV 
GWAS to date because, unlike SNPs, the nature of CNV data does not result in a uniform set 
of CNVs across individuals and hence they cannot be directly combined. Therefore, we 
developed an approach to enable CNV meta-analysis to proceed in a similar way as SNP 
meta-analysis, and we provided a software package, cnvPipe, to support this pipeline. In 
addition, unlike SNP GWAS where the significance threshold of 5x10-8 is well-established, 
the significance thresholds of CNV GWAS based on the production of ‘fragment CNVRs 
(fCNVRs)’ required estimation here. Using these estimated significance thresholds, the 
pipeline was implemented to combine CNV data across 5 studies in the ENGAGE study to 
search for CNVs associated with height and weight.   
 
By applying the definition of fCNVRs to obtain a uniform set of CNV regions across 
individuals, cnvPipe consists of three stages: 1) identify a set of fCNVR within each cohort, 2) 
identify the uniform set of fCNVR across all cohorts, and 3) perform association analyses 
corresponding to these fCNVRs within each cohort on phenotypes of interest. 
 
cnvPipe is first used to investigate underlying CNVs in height and weight across 5 studies. 
Overall, the CNV association results do not reach our proposed per-fCNVR significance 
threshold. Two fCNVRs with moderate association signals are in PTPN20A, which was 
reported to be involved in the process of cell growth and cell differentiation. This gene was 
not previously reported in SNP-height GWAS thus this deletion in PTPN20A may contribute 
to explaining the missing heritability in height variation. However, further investigation is 
required to confirm this association. 
 
Due to an absence of standard QCs for CNV GWAS, where instead individual sample sources 
may be advised to determine their own appropriate QC thresholds, our cnvPipe procedure 
was intended to produce consistency in QC across cohorts. However, the default QC under 
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cnvPipe may not be the most suitable for all data. In addition, the further QCs applied to 
association results, such as a MAF of 0.005 and HWE of 1x10-4, are not well investigated, and 
additional QCs may need to be added. Limitations in the current QCs included in cnvPipe 
may result in inconsistency of quality in CNV calls across cohorts and as a consequence, this 
may produce unreliable results and the inflation that was observed in some results.  
 
The nature of CNVs is more complicated than SNPs, that is, their unknown mutation rates, 
the unknown character of their number of copies, and their unknown correlation structure. 
Therefore, in contrast to SNP data where all possible polymorphisms in human genome can 
be simulated based on different mutation rates in the demographic and evolutionary model 
to approximate the history of populations from different continental regions (Hoggart, et al. 
2008), there is no formal way to simulate CNVs in the human genome. Thus the real CNVs 
called from NFBC1966 data has been used in our investigation instead of simulation. If the 
structures of CNVs in other datasets are reflected by NFBC data, our proposed significance 
threshold is applicable. Nevertheless if the structure of CNVs in the NFBC1966 data is 
different from other data sets, then further investigation may be required to obtain 
appropriate significance threshold estimates in different populations. In addition, if more 
CNVs are detected due to much larger sample sizes or advances in technology, the 
significance thresholds that we suggest should be re-evaluated. 
 
In single marker tests of association, genotyping errors are known to impact the power and 
type I error rate. It was shown that random genotyping errors across all samples results in 
power reduction, whereas non-random genotyping errors which can be found in, for 
example, cases but not in controls, results in an inflation of type I error rate [Mayer-
Jochimsen, et al. 2013]. Similarly, an inaccuracy of CNV detection on SNP arrays 
undoubtedly has an effect on downstream association testing. The error rates of the CNV 
calling algorithm is shown to have a noticeable power reduction, especially in smaller CNVs 
[Wineinger and Tiwari 2012]. This is likely because small CNVs have very low recovery rate, 
i.e. high rate of false negatives [Zhang, et al. 2011]. In addition, duplications are shown to 
have higher power reduction compared to deletions due to their higher rate of calling error. 
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Since fCNVRs are CNV fragments, the impact on fCNVR errors is expected to be similar to 
what have been found based on CNV calling errors, i.e. the power reduction for association 
testing is likely to be observed in fCNVRs, which are called from small CNVs, especially in 
duplication. Nevertheless, as is the main aim of fCNVR meta-analyses, it is expected to 
improve the power. Assuming that CNV calling errors are random across samples, the 
signals at true CNV regions will be less likely to be diluted by incorrectly called CNVs at the 
larger samples and thus should help improve the statistical power to some extent. 
 
 
Our cnvPipe software and pipeline allows meta-analysis to be performed on CNV data. We 
hope that this tool should optimise statistical power to detect associated CNVs, while 
limiting the probability of false positive findings. We expect that causal CNVs may be rare 
but with strong effect sizes, given the large-scale impact that they can have on coding and 
regulatory sequences. Therefore, CNVs may reveal a further part of the missing heritability 
of many phenotypes. To our knowledge, this is the first systematic tool to perform meta-
analysis for CNVs. While the results from the CNV meta-analyses in height and weight that 
we conducted did not reveal strong evidence of CNV associations, further investigations on 
other available phenotypes will be explored under the collaboration in ENGAGE. 
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Chapter5  Summary and Future work  
 
5.1 Summary 
 
In 2003, the Human Genome Project (HGP) was completed, providing for the first time the 
entire sequence of nucleotides comprising a typical human genome. The ‘reference 
genome’ produced by HGP initiated rapid advances in technology for obtaining genetic 
variation data across large samples of individuals, which led to the beginning of the 
‘genome-wide association study (GWAS) era’. The first large-scale GWAS were published in 
2007 and since then hundreds of genetic variants have been discovered that affect a huge 
range of diseases and traits in humans. Advanced statistical methods and software tools 
have been developed in order for GWAS to efficiently and effectively identify the underlying 
genetic variants influencing complex human phenotypes. A major challenge in GWAS is that 
most genetic variants only have a small influence on phenotypes, and therefore one of the 
main objectives in the field has been to attain sufficiently large sample sizes to detect causal 
variants. Given the availability of GWAS data across many different epidemiological cohorts, 
and data sharing issues, this meant that large-scale GWAS could most easily proceed via 
meta-analysis. As meta-analysis became the standard approach in GWAS, the need to have 
standardised procedures, which limit false positive findings while optimising statistical 
power, became acute. Therefore, this thesis investigates ways to develop such procedures 
in the context of both SNP and CNV GWAS and performs real data analyses, allowing their 
robustness to be assessed. 
 
A large-scale GWAS meta-analysis on alcohol consumption initiated in my department as 
part of the ENGAGE consortium provided a first opportunity to become familiar with 
standard procedures in the field and this forms the investigation of Chapter 2. A variety of 
quality control measures, both standard and non-standard, were applied to reduce the 
probability of false positive findings. Careful consideration of the phenotype definition was 
required due to the presence of both non-drinkers and drinkers (with a continuous 
measurement of alcohol intake) in the data. One analysis was performed on drinkers-only, 
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applying a log transformation prior to the linear regression GWAS, while a second applied an 
inverse-normal transformation on the combined drinkers and non-drinkers data. Next, we 
developed a software tool, metaMapper, for performing and visualising the results of meta-
analysis GWAS. This was applied in the alcohol consumption study. The main finding from 
the study was the identification of a genetic variant in the AUTS2 gene, with each risk allele 
associated with 5.5% lower alcohol consumption [Schumann, et al. 2011]. The limitations to 
the study are an inaccuracy of alcohol consumption phenotype due to human error from 
self-reported questionnaires, an inconsistent measurement due to different questionnaires 
across multiple studies, and an absence in adjustment of underlying environmental factors, 
such as lifestyle, social economic status, and education in the models. To our knowledge, 
this is the first and largest GWAS meta-analysis study so far to investigate the genetic 
determinants of alcohol consumption. 
 
The alcohol study applied different phenotype transformations to two groups of data, with 
and without non-drinkers, which led to the question motivating the investigation of Chapter 
3, that is, which phenotype transformation optimises statistical power under skewed 
continuous phenotypes in the context of linear regression performed in GWAS. By 
performing a simulation study and a re-analysis of reported associations in the NFBC1966 
data based on the most commonly used transformations, the INT is shown to have greater 
or similar power when the effect sizes are small, especially for low-CV and high-skew 
phenotypes. This is because when the effect size is small, the genotype effect has minimal 
contribution to the skewness, and so the main consequence of the INT is to induce 
normality in the residuals of regression as intended. The INT results further gains in power 
compared to the LT in the meta-analysis GWAS setting, namely when the phenotype takes 
values close to zero and there is between-cohort heterogeneity of CV when used in 
conjunction with an inverse variance weighted meta-analysis.  Thus, the application of INT 
to non-normal phenotypes in GWAS, where effect sizes are small and the priority is 
discovery over interpretability, may lead to an increase in the discovery of genetic variants 
affecting continuous traits.  
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Finally, knowledge gained regarding meta-analysis GWAS of SNP data was extended to 
developing a novel procedure for performing GWAS meta-analysis of CNV data, for which 
rare genetic variants have been shown to have large effect sizes. Due to the challenge of 
limited statistical power to detect associated rare CNVs, and the greater complexity of 
defining consistent variants across different cohort for CNVs, the importance of a carefully 
considered and reliable procedure for meta-analysis is even greater. Chapter 4 develops 
such a meta-analysis procedure, and accompanying software package cnvPipe, as well as 
performing a simulation study to estimate an appropriate significance threshold for CNV 
meta-analysis GWAS. The pipeline was implemented to combine CNV data across 5 studies 
in the ENGAGE study to search for CNVs associated with height and weight. While the first 
set of results in height and weight do not reveal any statistically significant evidence of CNV 
associations, further investigation in other available phenotypes will be explored under the 
collaboration in ENGAGE. 
 
5.2 Future work 
 
5.2.1 Expanded Alcohol GWAS 
 
The sample size of our meta-analysis GWAS study in alcohol consumption (AlcGen) has been 
extended from the size of 26,316 to 40,000 based on additional genotyped samples within 
the existing cohorts, as well as additional recruited cohorts. AlcGen has also been 
collaborating with the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium (N=30,000). Rather than investigating the genetics underlying alcohol 
consumption in the general population, as in AlcGen, CHARGE have been searching for the 
genetic determinants of extreme drinking behaviour by investigating heavy and light 
drinkers under a dichotomous analysis. Therefore, results across consortia cannot be 
directly combined due the difference in models used.  Under an agreement, CHARGE is 
currently performing a further analysis based on the model used in AlcGen and, likewise, 
AlcGen are performing an analysis based on the model used in CHARGE. In the future, we 
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will also expand the collaboration to include the Gene-Environment Association Studies 
(GENEVA) consortium, which will add a further sample of 25,000 individuals. However, 
genotype imputation is yet to be conducted for some of the GENEVA cohorts. Therefore, the 
total sample size will reach 100,000 and this should provide substantially greater statistical 
power to detect genetic variants associated with alcohol consumption.  
 
5.2.2 Extended transformation investigation 
 
Our investigation of power under different transformations, described in Chapter 3, could 
be extended in a number of ways. The study that we performed was restricted to 
consideration of common genetic variants with MAF of 0.2. Further investigation into the 
effect of transformations under a range of allele frequencies, in particular for rare variants, 
could be carried out. The investigation could also be extended to the CNV GWAS setting, in 
which case the range of allele frequencies considered should include those of very low 
value, such as 0.001. 
 
While the deviation in normality of the residuals appears to explain the behaviour of the 
power gained under the INT in different scenarios reasonably well, further investigations 
could be carried out to provide a more detailed explanation as to why the INT improves the 
power compared to the LT under linear regression for small effect sizes. This could include 
testing the homoscedasticity of the errors, the independence of the errors, and the linearity 
of the relationship between dependent and independent variables.  
 
Our investigations into statistical power under the different transformations based on real 
data did not consider the effect of having phenotype data which  is not truly continuous, 
that is, where different individuals may take the same value due to measurement limitations 
or due to value rounding. In our simulation study, these ‘multiple equal measures’ (MEMs) 
were not possible since only continuous values to an accuracy of 4 decimal places were 
simulated. In the real data analysis, we designed a sampling strategy to sample phenotype 
values from 4700 NFBC1966 individuals such that there were no repeated measurements 
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(see 3.2.2.1 for more details). Therefore, the effect of MEMs on the choice of phenotype 
transformation should be further explored. So far we have performed a preliminary analysis 
to compare the power before and after applying our sampling strategy to avoid MEMs in the 
NFBC1966 phenotypes investigated in Chapter 3. The preliminary results, including the 
proportion of MEMs in the sample for each phenotype, are shown in Table 5.1. When there 
are a small proportion of MEMs, there is little change in power. However, when there is a 
high proportion of MEMs, there is a major increase in power for the INT but not the LT. In 
addition, the false positive rate is not affected (data not shown here). This suggests that the 
INT may have substantially higher power than the LT when applied to phenotype data with 
many equal values, although the reason for this is not clear. Thus, further investigation into 
this issue is required. To do this, the effect of different levels of MEMs from proportions of 0 
to 100% should be assessed. This can be done via simulation at the different levels of MEMs, 
in 10% increments of proportion for example. By doing this, we can estimate the level at 
which INT starts to have significantly increased power over the LT, across different error 
distributions based on real phenotypes. The false positive rates and the four main 
assumptions of linear regression should also be assessed to understand the change in power 
across different proportions of MEMs in the phenotype.  
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Phenotype 
 
% of 
MEM 
Power 
INT LT 
no equal 
value 
with equal 
values 
no equal 
value 
with equal 
values 
high level of MEM      
Glucose 0.989 0.614 1 0.328 0.234 
LDL 0.982 0.72 1 0.238 0.28 
Systolic BP 0.977 0.436 0.998 0.204 0.172 
low level of MEM      
Phenyalanine/Tyrosine 0.219 0.550 0.560 0.370 0.340 
HDL_C 0.053 0.436 0.414 0.302 0.286 
L_HDL_L/M_HDL_L 0.050 0.432 0.408 0.428 0.430 
Table 5.1. Power for the INT and the LT (at P-value < 5x10-8) at low and high percentage of 
MEMs when NFBC1966 phenotype distributions are used as error distributions under a 
variance explained of 0.01% and sample size of 200000. 
 
Finally, while we have described in detail the characteristics of the statistical power to 
detect causal genetic variants after the different transformations of the phenotype, each 
phenotype data set that researchers use will have its own unique features. Therefore, we 
plan to utilise our simulation code to produce a user-friendly software package where users 
can upload their phenotype data as input – either from a single-cohort study or from 
multiple cohorts in a meta-analysis – with an output of the statistical power that is expected 
under NT, the INT, and the LT, for different values of effect size of the potential causal 
variant. This should provide an important contribution to the choice of transformation used 
when performing GWAS on continuous phenotype data. We plan to provide the software 
package free to users, either as an R CRAN package or as a website application. 
 
5.2.3 Extended CNV meta-analysis investigation 
 
Our CNV meta-analysis pipeline and software package cnvPipe, described in Chapter 4, was 
applied to 5 cohorts to search for CNVs associated with height and weight. Due to batch 
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effects that can lead to false positive findings in CNV association studies, the association 
analysis was performed in each batch of each data set separately, and separately for both 
deletions and duplications. Nevertheless, some of the QQ plots of the results indicate an 
inflation of the test statistic. Therefore, further investigations are required to understand 
the causes of the corresponding spurious associations, the findings of which can be used to 
develop a more refined QC procedure. For instance, an individual with an extreme 
phenotype value may have a substantial influence on the effect size under the regression 
model. In addition, if this individual has many incorrectly called CNVs, which is likely to 
result in a large number of corresponding rare fCNVRs, false positive associations may be 
observed at many of those large number of fCNVRs. Therefore, such outlier individuals 
should be excluded from the analysis and this may reduce the spurious association 
previously observed. As a consequence, we plan to add an additional metric for performing 
QC that measures how much each individual contributes to the total association signal 
across fCNVRs showing spurious associations. The association signal gained at each fCNVR 
can be measured based on the absolute value of beta under regression model. At each 
fCNVR, the contribution of individual to this association signal can be measured based on an 
individual’s copy number states (CN). This is due to the additive effect assumption 
previously made which assumes the higher risk contribution from an individual with higher 
CN. Therefore, to measure an individual contribution to the total association signals 
(ICassoc) across n fCNVRs, we will investigate this in  ∑ |  |     
 
     where    is the effect 
size, and     is the copy number states at ith fCNVR. Only fCNVRs which show some 
evidence of association (e.g. P-thresholdfCNVR < 10
-3) could be taken into account to measure 
each individual contribution to the total association signal. This may allow us to find the 
"driver" individuals which have a large impact on overall spurious associations and should 
be excluded. As the preliminary analysis, we applied this proposed method to measure 
ICassoc on CVNR association analyses of height in NFBC which previously showed inflation 
under both deletion (Figure 5.1a) and duplication (Figure 5.1c). After excluding samples with 
high ICassoc, it removes the overall spurious results in both deletion (Figure 5.1b), and 
duplication (Figure 5.1d). Based on this evidence, it showed that individuals with high 
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ICassoc could play the major role in the inflation of association results and thus they should 
be further investigated. 
 
 
Figure 5.1. QQ plots for deletion height association results before (a,c) and after excluding 
NFBC samples with high ICassoc score (b,d) in deletion and duplication 
 
Another potential cause of inflation is from confounding factors, such as population 
structure or systematic variation in the data due to procedures in the lab work. To account 
for such confounding factors, the use of PCA based on LRR or fCNVR genotype values should 
be investigated. If accounting for some number of PCs results in the inflation being almost 
eliminated, then those PCs should be further explored for the underlying confounding 
factors that they control. 
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To provide better data interpretation and to make the process of CNV GWAS more efficient, 
visualisation tools will be integrated into cnvPipe, as in our software package metaMapper, 
to automatically annotate the potential functional effects at associated CNVs, using publicly 
available databases. 
 
In addition to NFBC data, which was used to assess significance threshold of fCNVR, this can 
be done using Hapmap3 CNV genotypes based on populations from West Africa, East Asia 
and Europe, which are available publicly to download (N=856 with approximately 15000 
CNV). Moreover, in contrast to FWER, an alternative approach to assess the significance 
threshold can be performed using a Bayesian approach, i.e. posterior odds for true 
association = prior odds  power/significance threshold. An advantage of the Bayesian 
approach is that it does not concern the number of fCNVRs observed and therefore this 
should allow us to assess the general significance threshold that can be applied with any 
data set, unlike the previously calculated fCNVR significance threshold in section 4.4.2.1 that 
might be specific to NFBC data. Further investigations are needed to estimate required 
parameters in order to address an appropriate significance threshold in the Bayesian 
approach, e.g. we may assume that CNVs are as likely to be causal as SNPs; the plausible 
estimate for prior odds of true association, at any specified locus, is under the ratio 
100,000:1 [WTCCC consortium 2008].  
 
5.2.4 Meta-analysis of multi-phenotype GWAS 
 
In the GWAS conducted in this thesis the phenotypes have been tested independently, 
despite the relationships that exist between many of them. It has been shown that 
considering multiple correlated phenotypes simultaneously in GWAS can increase the 
statistical power to detect causal variants [Begum, et al. 2012]. Therefore, we could extend 
our studies here to investigate multiple phenotypes tested in a multivariate model in GWAS. 
For instance, alcohol consumption could be considered with other addiction related 
phenotypes, such as smoking, since the genetic variants affecting them may be involved in 
similar brain function pathways. In addition, height and weight tested independently in our 
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CNV GWAS meta-analysis could instead be tested in the same model based on their 
connection in metabolic pathways. The appropriate way of combining results across GWAS 
performed in this multivariate way across different phenotypes will also need to be 
considered, which may need to be tailored to the multivariate method used, since so far, to 
our knowledge, no such multivariate GWAS have been performed. 
 
One approach to account for multiple correlated phenotypes in linear regression is a 
reversed regression where genotype is regressed on phenotypes, rather than phenotypes-
on-genotype [Begum, et al. 2012].  Ordinal regression is applied to regress the genotype 
data on multiple phenotypes which are jointly modelled as predictors. In this case of the 
phenotypes acting as predictors, it is not necessary for them to be transformed. Therefore, 
this reverse regression approach could be investigated as a transformation-free alternative 
in the single phenotype as well.  
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Appendix Table 1:   Description of genotyping methods in GWAS samples 
        
 CoLaus DESIR Epic Norfolk ERF FTC ROTTERDAM 
STUDY 
KORA 
Genotyping platform  Affymetrix 500k Illumina HAP300 
array  
Illumina Human 
CNV370 
Affymetrix 500K Illumina 318k,  
Illumina 6k,  
Illumina 370k,  
Affymetrix250K 
Illumina 318 Illumina 550K Affymetrix 
500K  
        
Calling algorithm BRLMM Ilumina protocol BRLMN Beadstudio Ilumina protocol Beadstudio Affymetrix 
birdseed 
Genotype based 
exclusions 
Gender 
discrepancy; 
duplication;  
contamination;   
relatedness  
gender discrepancy;  
duplication;  
contamination;  
relatedness 
heterozygosity 
<23% or >30%; 
>5.0% discordance 
in SNP pairs with 
r2= 1 in HapMap; 
ethnic outliers; 
related individuals 
and duplicates. 
Callrate < 96%, 
heterozygosity > 
75%, XX males, 
XY females, XXY 
individuals 
duplication; 
contamination; 
relatedness 
Callrate < 98%, 
heterozygosity > 
75%, XX males, 
XY females, XXY 
individuals 
gender 
discrepancy 
Filter SNP for 
imputation: 
       
       >1 hit in genome NA NA see Willer et al 
(NG 2009) 
 0  NA 
       Call rate >=0.90 >0.95 >=90% chip specific call 
rate 
90% >0.98 >=0.90 
        HWE (p-value) >10-7 >10-4 >10-6 > 10-6 1e-6 > 10-6 NA 
        Mendel NA NA NA NA 0 NA NA 
        MAF NA NA 0.01 0.01 1% 0.01 NA 
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Appendix Table 1 (cont.).   Description of genotyping methods in GWAS samples 
       
 CoLaus DESIR Epic Norfolk ERF FTC ROTTERDAM 
STUDY 
KORA 
Imputation software 
package 
IMPUTE  IMPUTE IMPUTE MACH MACH MACH MACH 
NCBI reference sequence  35 36 35 36 36 36 35 
HapMap reference  CEU 21A CEU 22 CEU CEU 22 CEU 22 CEU 22 CEU 21A 
Strand + + + + + + + 
Dosage vs best guess  dosage dosage dosage  dosage Best guess dosage dosage 
Genotype-phenotype 
association software 
SNP TEST SNP TEST SNP TEST Prob 
ABEL 
PLINK Prob ABEL MACH2QTL 
 
 
 
 
 
 
 
        
N SNPs for imputation 390,631 300,286 397,438 up to 427,922
†
 316,407 491,875 490,032 
172 
 
Appendix Table1 (cont.).   Description of genotyping methods in GWAS samples  
 
      
 LOLIPOP_A LOLIPOP_P NFBC 1966 NTRNESDA SSAGA Twins UK 
Genotyping 
platform  
Affymetrix 
500K 
Perlegen 
custom array 
Illumina 
370K 
Perlegen 600K Illumina 
HumanHa
p 300 
Illumina 317K 
Calling algorithm NA NA Ilumina 
protocol 
Perlegen 
Proprietary 
Ilumina 
protocol 
Ilumina 
protocol 
Genotype based 
exclusions 
Missing rate Missing rate Gender 
discrepancy;  
duplication;  
contaminatio
n;  
relatedness  
gender 
discrepancy;  
duplication; 
contamination;  
relatedness; 
gender 
discrepanc
y; 
duplication; 
contaminat
ion; 
relatednes
s 
duplication; 
contamination;  
relatedness 
Filter SNP for 
imputation: 
      
 >1 hit in genome NA NA N  n n 
Call rate ≥ 0.90 ≥ 0.90 >0.95 >0.95 NA >0.95 
HWE (p-value) ≥ 10
-06
 ≥ 10
-06
 >10
-4
 NA NA >10
-4
 
Mendel NA NA NA 0.01 NA NA 
MAF ≥ 0.01 ≥ 0.01 0.01 0.01 NA 0.01 
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N SNPs for 
imputation 
374,773 267K 328,007 435,291 312424 2,544,233 
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Appendix Table1 (cont.).   Description of genotyping methods in GWAS samples  
 
      
 LOLIPOP_A LOLIPOP_P NFBC 1966 NTRNESDA SSAGA Twins UK 
Imputation software package MACH MACH IMPUTE IMPUTE MACH IMPUTE 
NCBI reference sequence  Build 35 Build 35 35 35 35 36 
HapMap reference  CEU 21A CEU 21A CEU 21A CEU 21A CEU 21A CEU 22 
Strand + + + + + + 
Dosage vs best guess  dosage dosage dosage dosage best-guess dosage 
Genotype-phenotype association software mach2qtl mach2qtl SNPTEST SNPTEST PLINK SNPTEST, Gen- 
ABEL  
Lambda before genomic control 1.000 1.011 1.01 1.00 1.02 1.003 
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Appendix Table1 (cont.). Description of genotyping methods in replication samples  
a. Replication samples (direct genotypes)    
 ARYA Prospect-EPIC Lille UHP Turin 
Genotyping platform  Na Kbiosciences Taqman na Taqman ABI 
7900 
Calling algorithm Na Kbiosciences na na SDS software 
v2.3 
b. Replication samples (imputed genotypes)  
  EGPUT Fenland Study 
Genotyping platform  Illumina 370K Affymetrix 500K 
Calling algorithm Ilumina protocol  BRLMM 
 
Genotype based 
exclusions 
gender discrepancy;  
duplication;  
contamination;  
relatedness,  
duplication;   
relatedness;  
contamination 
Filter SNP for imputation   
       >1 hit in genome N See Newton-Cheh C et al 
Nature Genetics 2009 
       call rate >0.95 >0.9 
        HWE (p-value) >10-4 > 10-6 
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        Mendel NA NA 
        MAF 0.01 0.01 
N SNPs for imputation 333141 362059 
Imputation software  IMPUTE IMPUTE  
NCBI reference sequence  Build 36 36 
HapMap reference panel CEU 21A CEU 22 
Strand + + 
Dosage vs best guess dosage dosage 
Genotype-phenotype 
association software 
SNPTEST SNPTEST 
Lambda before genomic 
control 
1.04 NA 
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Appendix Table2. Questionnaires used to collect alcohol consumption data 
 
Study Questionnaires 
NFBC How often do you usually drink beer, cider, long drink? 
How often do you usually drink wine? 
How often do you usually drink mild, strong or home-made wine? 
How often do you usually drink spirits? 
1) Never, 2) once a year, 3) a couple of times a year, 4) 3-4 times a year, 5) once in a couple of months,  
       6) once a month, 7) a couple of times a month, 8) once a week, 9) a few times a week, 10) daily 
How much do you usually drink beer, cider, long drink? 
How much do you usually drink wine? 
How much do you usually drink mild, strong or home-made wine? 
How much do you usually drink  spirits? 
1) Half a glass, 2) A glass, 3) A couple of glasses, 4) About half a big bottle, 5) Slightly less than a big bottle,  
       6) About a big bottle, 7) One to two big bottle, 8) More than two big bottles, 9) I don’t drink 
KORA A recall method was applied: For estimation of alcohol consumption, each subject was asked how much beer, wine,  
and spirits he or she had drunk on the previous workday and over the last weekend. Total alcohol intake was  
calculated by multiplying weekday consumption by five and adding this figure to weekend consumption.  
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After conversion (1 litre beer = 40 g, 1 litre light beer = 25 g, 1 litre wine = 100 g, 0.02 litre spirits = 6.2g alcohol) and  
average amount of alcohol intake in grams per day was derived. 
DESIR Quantity of wine per day? Quantity of bier or cider per day? Number of pre-dinner drink or liqueur per week? 
NTRNESDA 
 
How often do you have a drink containing alcohol? 
1) Never, 2) Monthly or less, 3) 2 to 4 times a month, 4) 2 to 3 times a week, 5) 4 or more times a week 
How many drinks of alcohol do you have on a typical day when you are drinking? 
1) 1 or 2, 2) 3 or 4, 3) 5 or 6, 4) 7, 8, or 9 
NTR 
 
Did you ever drink an alcoholic drink? 
1) No, 2) A few times to try out, 3) Yes 
How many glasses of alcohol do you drink on average per week (including weekend)? 
       1) Less than 1 glass a week, 2) 1 - 5 glasses a week, 3) 6 - 10 glasses a week, 4) 11 - 20 glasses a week,  
 5) 21 - 40  glasses a week, 6) More than 40 glasses a week 
The Fenland Study 
 
The EPIC-FFQ comprised a list of 130 foods. Under the “drinks” category, nine responses ranging from never to more than  
six times per day were given for four types of alcoholic drink: half pint of beer, lager or cider, a glass of wine, single unit of  
spirits (whisky, gin, brandy, vodka, etc.) and a glass of sherry, port, vermouth or liqueurs Participants were asked to tick  
each category based on their average alcohol consumption in the previous year. 
Australian 
 
Have you ever had a drink of alcohol? [Yes/No] 
During the past 12 months, how often have you had alcoholic drinks? 
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     A = every day, B = 5-6 days per week, C = 3-4 days per week, D = 2 days per week, E = 1 day per week,  
     F = 2-3 days per month, G = 1 day per month, H = 3-6 days per year, I = less often, J = no alcohol in past 12 months 
Think of the times when you've used alcohol during the past 12 months. How many drinks do you typically drink, on these days  
when you had an alcoholic drink. By a drink, I mean a can or stubbie of beer, a glass of wine, or a nip of spirits. 
[Number of Drinks] 
Lolipop 
 
“In the last week, how much of the following have you had to drink?" 
A. Pints of beer, B. Glasses of wine, C. Measures of spirits   
ARYA alcohol units per day: 0- <1 ; 1-2; 3-5; > 5 
Prospect-EPIC 
 
Alcohol (units/day) 
1) None, 2) < 1 glass, 3) 1-2 glasses, 4) 3-5 glasses, 5) >= 6 glasses 
  Alcohol (days/month) 
1) < 2 days, 2) 3-8 days, 3) 9-14 days, 4) 15-20 days, 5) 21-27 days, 6) >=28 days 
EPIC-Norfolk 
 
How often do you usually drink in weekends (Friday until Sunday) :           
   1) never, 2) less once a month, 3) once a month, 4) 2-3 times a month, 5) Once every weekend,  
   6) Two times every weekend, 7) Three times every weekend                            
How many glasses do you take? How often do you usually drink during the week (Monday until Thursday) :                                             
   1) never, 2) less once a month, 3) once a month, 4) 2-3 times a month, 5) Once every weekend,  
   6) Two times every weekend, 7) Three times every weekend                            
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How many glasses do you take? How often do you usually drink during the week (Monday until Thursday) :                                             
     1) never, 2) less once a month, 3) once a month, 4) 2-3 times a month, 5) Once every weekend,  
   6) Two times every weekend, 7) Three times every weekend                            
How many glasses do you take? Beer, red wine, white wine, wine port, sherry, vermouth, distilled drinks  
(jenever, likeur, congnac etc.) 
Turin At the moment, do you drink wine (beer / spirits)?  
a) Yes, b) No, but I did it in the past, c) No, never                  
When you were 20 years old (30/40/50 years old), how many glass of wine (beer/spirits) did you drink?   
a) never, b) less than 1 a week, c) 1-2 a week, d) 3-6 a week, e) 1 a day, f) 2 a day, g) 3-4 a day, h) 5-6 a day, i) 7 or more a day 
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